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Differences in drug response are heritable. Ever since the introduction of drugs in medicine 
there have been problems with adverse reactions. In the absence of knowledge of the mini-
mum effective dose, the occurrence of adverse events was even used to determine the appro-
priate dose of a drug. Doses were increased until adverse effects occurred. Nowadays, drugs 
are extensively tested in clinical studies to obtain information on the effective and safe dosage 
before they enter the market. Despite all these efforts not every drug is safe and beneficial for 
every patient. Different people may respond differently to the same drugs at the same dose 
in terms of efficacy of the drug, but also in the occurrence of adverse effects. For instance, as 
a rule of thumb, one third of people benefit from antidepressants, one third does not and one 
third does not take them or discontinues them (in part) because of adverse effects. Although 
some differences can be explained by differences in age (and the accompanying changes in 
metabolism), sex, organ function, concomitant therapy, drug-drug interactions and the nature 
of the disease, differences in reaction to drugs are often unpredictable. However, differences 
in efficacy and adverse effects do not occur random. It appears that differences are greater 
among members of a population than within the same person at different times (or between 
monozygotic twins). The existence of large population differences with small intra-patient vari-
ability suggests that inheritance is a determinant of drug response. It is estimated that genet-
ics can account for 20-95% of variability in drug response.1 Once a drug is administered, it is 
absorbed and distributed to its site of action where it interacts with targets (such as receptors 
or enzymes), undergoes metabolism and is then excreted. At each of these processes, ge-
netic variation may influence the drug response.2-4
Single nucleotide polymorphisms (SNPs). In the initial sequencing of the human genome, 
more than 1.4 million single nucleotide polymorphisms (SNPs) were identified with over 
60,000 of them in the coding region of genes.5 Nowadays, it is estimated that 1 in every 300 
nucleotides is polymorphic in a population and 1 in every 1200 base pairs differs between 
two randomly chosen subjects. In total, up to 12-15 million SNPs are present in the human 
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genome. Every SNP represents a common (>1%) variation in the DNA sequence in which 
one base-pair varies between individuals. Since allele frequencies of these SNPs may differ 
largely between populations it is not possible to determine which base-pair represents the 
‘original’ code. Therefore, they are referred to as minor- and major alleles rather than wild type 
and mutant alleles.
Pharmacogenetics and pharmacogenomics. Two main strategies are currently being used 
to identify genes and gene variants that cause individual variations in drug response. Phar-
macogenetics studies the variability in drug responses attributed to hereditary factors, such as 
genetic polymorphisms, in different populations. The concept of pharmacogenetics originated 
from the clinical observation that there were patients with very high or very low plasma or 
urinary drug concentrations leading to adverse drug reactions or lack of efficacy when given 
standard doses of drugs. These observations were followed by the recognition that the bio-
chemical traits leading to this variation were inherited. Only later were the drug-metabolizing 
enzymes identified, and this discovery was followed by the identification of the genes that 
encoded the proteins and the DNA-sequence variation within the genes that were associated 
with the inherited trait.3, 4, 6 Today there is a systematic search to identify functionally significant 
variation in DNA sequences in genes that influence the effects of various drugs. The search 
began with a focus on drug metabolizing enzymes,2, 7 but has extended to membrane trans-
porters that influence drug absorption, distribution and excretion.3, 7, 8 The second strategy is 
pharmacogenomics, the whole genome application of pharmacogenetics. It encompasses a 
genome-wide search for genes and DNA sequence variations that are associated with drug 
response without restriction to known candidates.2, 6 Although both approaches represent dif-
ferent tactics, they share technologies and the terms are commonly used interchangeably. 
With the completion of the Human Genome Project9, 10 and the ongoing annotation of its data, 
the sequences of all genes that catalyze phase I and II drug metabolism are known. The same 
is true for drug transporters, drug receptors and other drug targets. As a result, the traditional 
phenotype-to-genotype pharmacogenetic research paradigm is reversing direction to create a 
complementary genotype-to-phenotype flow of information.2 The recent development of large 
SNP databases,11 genotyping arrays of great accuracy and genome wide coverage of com-
mon variation,12 which allow genotyping of up to 1,000,000 SNPs in a person at once, together 
with analytical methods13 has enabled unbiased surveys of the majority of common variation 
in the human genome. This greatly facilitates pharmacogenomics, allowing genome wide as-
sociation studies (GWA) to search for new candidate variants which influence drug response 
and risk of adverse drug reactions.14, 15
ABCB1. One of the products of classical pharmacogenetics is the discovery of the ATB-bind-
ing cassette family B member 1 (ABCB1) gene. ABCB1 is a 200kb gene on chromosome 
7p21, which encodes for the multi drug resistance 1 protein (MDR1, also known as P-glyco-
protein) a multi-drug efflux transporter. It was first discovered in chemotherapy resistant tumor 
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cells where it was over expressed, but is also widely expressed in normal tissues such as 
the duodenum, kidneys, liver and the blood-brain barrier where it plays a role in the uptake, 
distribution and clearance of many drugs.16-21 Since its first discovery, as many as 647 single 
nucleotide polymorphisms (SNPs) -with an established frequency- have been identified in 
the ABCB1 gene.22 Among the first SNPs to be identified was the C3435T polymorphism, 
which was found to be associated with decreased ABCB1 expression and increased digoxin 
concentration.23 Since then, many more studies on the association between ABCB1 SNPs 
-mostly C1236T, G2677T/A and C3435T- and kinetics of digoxin,24-29 a very old cardiovascular 
drug still in use today, as well as many other drugs30-34 have been performed with varying 
results.35-37 
NOS1AP. The nitric oxide synthase 1 adaptor protein (NOS1AP) gene can be seen as an 
exponent of both pharmacogenomics and classical pharmacogenetics. Common genetic vari-
ants of NOS1AP were recently discovered to be associated with QT-interval prolongation in a 
genome wide association study.38 The electrocardiographic QT interval is a non-invasive mea-
sure of ventricular repolarization. Mendelian congenital long- and short QT syndromes (LQTS, 
SQTS) are both characterized by sudden cardiac death (SCD) from ventricular arrhythmias.39 
Moreover, non-syndromal long40-43 and short44 QT interval are associated with an increased 
risk of SCD in unselected populations. In addition, many drugs are known to prolong QT-inter-
val duration,45, 46 and medication-induced prolonged QT interval and ventricular arrhythmias 
have led to the withdrawal of many non-cardiac medications.47, 48 NOS1AP was not previously 
known to play a role in cardiac repolarization and, so far, not much is known about the mecha-
nism by which NOS1AP influences QT duration. Since QT-altering drugs may interact with 
genetic variants in QT-duration associated genes,39, 49, 50 this makes NOS1AP an interesting 
candidate for pharmacogenetic studies with QT-altering drugs.
Aim and outline of this thesis. In this thesis we explore the effect of interaction of common 
variants in the ABCB1 and NOS1AP genes with drugs on drug response and adverse effects 
of drugs in a number of epidemiological studies. We mainly focus on digoxin and on other car-
diovascular drugs as drugs of interest. In chapter 2 we will quantify the risk of digoxin intoxica-
tion, to give a perspective of the possible impact of these interactions on drug safety. Chapter 
3 will focus on variations in the ABCB1 gene and their interaction with the commonly used 
drugs digoxin and mefloquine. In chapter 4 we study the effect of NOS1AP variants on QT-
duration and their interaction with QT-altering drugs such as digoxin and cardiovascular drugs 
and with anti-diabetic medication. Chapter 5 describes the effect of the interaction of ABCB1 
and NOS1AP genotypes with digoxin on cardiac function as assessed with echocardiography. 
In the general discussion (Chapter 6) the main findings of this thesis are placed in the broader 
context of potential clinical implications of pharmacogenetics and we address methodological 
considerations. Finally, we discuss the direction and methods of future research in the field, 
especially the possibilities of genome wide association studies in pharmacogenomics.
14
Chapter 1
14
References
Kalow W, Endrenyi L, Tang B. Repeat administration of drugs as a means to assess the genetic component in 1. 
pharmacological variability. Pharmacology 1999;58(6):281-4.
Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348(6):529-37.2. 
Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med 3. 
2003;348(6):538-49.
Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356(9242):1667-71.4. 
Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 5. 
million single nucleotide polymorphisms. Nature 2001;409(6822):928-33.
Roses AD. Pharmacogenetics. Hum Mol Genet 2001;10(20):2261-7.6. 
Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234(1):4-7. 
33.
Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact 8. 
in MDR1, MRP1 and MRP2. Pharmacogenomics 2001;2(1):51-64.
Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 9. 
2001;409(6822):860-921.
Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291(5507):1304-51.10. 
A haplotype map of the human genome. Nature 2005;437(7063):1299-320.11. 
de Bakker PI, Yelensky R, Pe’er I, et al. Efficiency and power in genetic association studies. Nat Genet 12. 
2005;37(11):1217-23.
Skol AD, Scott LJ, Abecasis GR, et al. Joint analysis is more efficient than replication-based analysis for two-stage 13. 
genome-wide association studies. Nat Genet 2006;38(2):209-13.
Christensen K, Murray JC. What genome-wide association studies can do for medicine. N Engl J Med 14. 
2007;356(11):1094-7.
Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev 15. 
Genet 2005;6(2):95-108.
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. 16. 
Biochim Biophys Acta 1976;455(1):152-62.
Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full-length cDNA for the human “MDR1” gene confers 17. 
resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987;84(9):3004-8.
Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein 18. 
in normal human tissues. Proc Natl Acad Sci U S A 1987;84(21):7735-8.
Cordon-Cardo C, O’Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothe-19. 
lial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86(2):695-8.
Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant 20. 
gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988;48(7):1926-9.
Klimecki WT, Futscher BW, Grogan TM, et al. P-glycoprotein expression and function in circulating blood cells from 21. 
normal volunteers. Blood 1994;83(9):2451-8.
http://www.ncbi.nlm.nih.gov/SNP/snp. NCBI. (Accessed Juli 11, 2007, at http://www.ncbi.nlm.nih.gov/SNP/snp_ref.22. 
cgi?locusId=5243&chooseRs=het.)
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: 23. 
multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc 
Natl Acad Sci U S A 2000;97(7):3473-8.
Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of 24. 
digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72(2):209-19.
Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J 25. 
Clin Pharmacol 2003;58(12):809-12. Epub 2003 Mar 1.
Comets E, Verstuyft C, Lavielle M, et al. Modelling the influence of MDR1 polymorphism on digoxin pharmacoki-26. 
netic parameters. Eur J Clin Pharmacol 2007;63(5):437-49.
15
General Introduction
15
Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein 27. 
MDR1 gene. Clin Pharmacol Ther 2002;72(5):584-94.
Gerloff T, Schaefer M, Johne A, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 28. 
mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54(6):610-6.
Kurzawski M, Bartnicka L, Florczak M, et al. Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein 29. 
inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol Rep 2007;59(1):107-11.
Babaoglu MO, Bayar B, Aynacioglu AS, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic 30. 
efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 2005;78(6):619-26.
Skarke C, Jarrar M, Schmidt H, et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on dispo-31. 
sition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003;13(11):651-60.
Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and 32. 
more rapid virologic response in HIV-1 infected children. Aids 2005;19(4):371-80.
Op den Buijsch RA, Christiaans MH, Stolk LM, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influ-33. 
ence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam 
Clin Pharmacol 2007;21(4):427-35.
Li D, Zhu JY, Gao J, et al. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 34. 
and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin Chim Acta 
2007;383(1-2):133-9.
Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical 35. 
relevance. Clin Pharmacol Ther 2004;75(1):13-33.
Chowbay B, Li H, David M, et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin phar-36. 
macokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005;60(2):159-71.
Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 2005;20(6):391-37. 
414.
Arking DE, Pfeufer A, Post W, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac 38. 
repolarization. Nat Genet 2006;38(6):644-51.
Newton-Cheh C, Shah R. Genetic determinants of QT interval variation and sudden cardiac death. Curr Opin 39. 
Genet Dev 2007;17(3):213-21.
Schouten EG, Dekker JM, Meppelink P, et al. QT interval prolongation predicts cardiovascular mortality in an ap-40. 
parently healthy population. Circulation 1991;84(4):1516-23.
Siscovick DS, Raghunathan TE, Rautaharju P, et al. Clinically silent electrocardiographic abnormalities and risk of 41. 
primary cardiac arrest among hypertensive patients. Circulation 1996;94(6):1329-33.
Karjalainen J, Reunanen A, Ristola P, et al. QT interval as a cardiac risk factor in a middle aged population. Heart 42. 
1997;77(6):543-8.
Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of 43. 
older adults. J Am Coll Cardiol 2006;47(2):362-7.
Algra A, Tijssen JG, Roelandt JR, et al. QT interval variables from 24 hour electrocardiography and the two year 44. 
risk of sudden death. Br Heart J 1993;70(1):43-8.
Drugs that Prolong the QT Interval and/or Induce Torsades de Pointes Ventricular Arrhythmia. In: The University of 45. 
Arizona Center for Education and Research on Therapeutics, Arizona Health Sciences Center, Tucson, Arizona.
De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce 46. 
torsade de pointes: an overview. Drug Saf 2002;25(4):263-86.
Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89(11):1363-72.47. 
Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-22.48. 
Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. 49. 
Proc Natl Acad Sci U S A 2000;97(19):10613-8.
Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades 50. 
de pointes. Circulation 2002;105(16):1943-8.
16
17
2
Quantifying the risk of adverse drug reactions to 
digoxin
18
19
19
2
Age- and gender specific incidence of hospitalization 
for digoxin intoxication
Abstract 
Background. The safety of digoxin (digitalis) therapy has greatly improved over the past 
three decades, but recent incidence rates for digoxin intoxication-related hospitalization are 
not available. Recent literature suggests that women are at higher risk of digoxin toxicity.
Objective: To provide age- and gender-specific incidence rates for digoxin intoxication-related 
hospitalization and mortality during digoxin intoxication-related hospitalization in The Nether-
lands in the period 2001–2004.
Study design and methods. We conducted a nationwide population-based cohort-study of 
all hospital admissions in the years 2001–2004 using a national computerised hospital admis-
sion registry. All patients with acute admissions were included in the study (n = 2,987,580). 
From these admissions, we selected all hospitalizations that had digoxin intoxication coded as 
either a primary or secondary diagnosis. We obtained data on digoxin prescriptions from the 
Foundation for Pharmaceutical Statistics (Stichting Farmaceutische Kengetallen) pharmacy 
database, which extrapolates drug figures for The Netherlands from prescriptions dispensed 
by 90% of all community pharmacies. We computed age- and gender specific incidence rates 
of digoxin intoxication.
Results. Digoxin intoxication was identified in 0.04% (n = 1286) of acute admissions. The 
incidence rate for digoxin intoxication-related admission was 48.5 ( 95% CI 45.9;51.2) per 100 
000 prescriptions, which corresponds to 1.94 admissions for intoxication per 1000 treatment-
years. Women had a 1.4-fold higher risk of intoxication than men (95% CI 1.3;1.6). The age- 
and gender adjusted relative risk of mortality in patients with digoxin intoxication compared 
with those admitted for other reasons was 0.7 (95% CI 0.5;0.8).
Conclusion. This study shows that digoxin intoxication in patients receiving current therapy is 
presently infrequent and that women are at higher risk of digoxin intoxication than men.
20
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Introduction
The cardiac glycoside digoxin has been successfully used in the treatment of heart disease for 
more than 200 years. Recently, digoxin was formally approved for ventricular response rate 
control in patients with atrial fibrillation and congestive heart failure, based on three clinical 
trials.1-3 However, digoxin has been associated with toxicity problems since its introduction. In 
the past it was associated with a high frequency of intoxications with a high mortality. Studies 
on toxicity for the period 1969 to 1983 showed a frequency of intoxication in users that was as 
high as 11–30%.4-6 One prospective study in 1971 reported a mortality of 41% in patients with 
definite digitalis intoxication6 and in another study 47% of patients with digitalis intoxication 
experienced life threatening arrhythmias.7
Currently, there is widespread knowledge and awareness of digoxin pharmacokinetics and 
of drug interactions of digoxin, as well as a tendency towards a lower dosing regimen and 
more strict therapeutic drug monitoring than had been used in the past. These developments 
in therapy management have resulted in a major reduction of digoxin intoxication and an 
improved prognosis over the last three to four decades. Recent studies showed digoxin intoxi-
cation in 4.8% of inpatients admitted for heart failure who were using digoxin (0.8% definite),8 
1.1% of randomly selected outpatients who were using digoxin,9 and 2% and 1.2% of closely 
monitored outpatients who were using digoxin in trials.1, 9 Furthermore, recent literature sug-
gests that women are at an increased risk of digoxin toxicity.10
Current population estimates of the incidence rate of digoxin intoxication are lacking. In the 
present study, we investigated the incidence rate of digoxin intoxication in the general popula-
tion and the mortality rate during admission. Specifically, we assessed whether women were 
at higher risk of digoxin intoxication than men.
Methods
Population. Data on hospital admissions were retrieved from a nationwide computer da-
tabase for hospital discharge records (National Hospital Registration) in The Netherlands. 
This database contains basic patient characteristics, the dates of admission and discharge, 
the discharge diagnosis, additional diagnoses during or preceding admission, surgical pro-
cedures, the treating medical specialty and special codes indicating drug-related hospitaliza-
tions (E-codes), based on the International Classification of Diseases (9th edition), Clinical 
Modification coding system. All general and university hospitals in The Netherlands partici-
pate in the system. Characteristics of all hospitalizations are registered by medical doctors in 
hospital discharge letters and coded by professional code clerks. Reimbursement of hospital 
and specialist fees does not depend on the way an admission or disease is coded. For every 
admission, one discharge/main diagnosis (mandatory) and up to 9 secondary diagnoses (op-
tional) are registered. All diagnoses are submitted in the same format, mostly electronically.
All patients with an acute (non-planned) admission to a Dutch academic or general hospital 
21
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in the period January 2001–December 2004 were included in the study (n= 2,987,580). A 
digoxin-related admission was defined as a hospitalization with the ICD-code 972.1 as the 
main diagnosis or one of the secondary diagnoses or the code E942.1 as a secondary diag-
nosis (usually diagnosis of the cause leading to main diagnosis).
Digoxin use. Data on the use of digoxin were obtained from the Stichting Farmaceutische 
Kengetallen (SFK)[Foundation for Pharmaceutical Statistics] database, which extrapolates 
drug figures for The Netherlands based on filled prescriptions from 90% of all community 
pharmacies. As community pharmacies deliver 90% of all outpatient prescriptions, this da-
tabase covers more than 80% of such prescriptions in The Netherlands. Due to different 
anonymization procedures in the hospitals as well as in the SFK database, it was not possible 
to link individual prescription data to admission data. Prescription data were only available as 
the number of prescriptions per age group (eight fixed age groups) stratified by gender and by 
year. The range of the age categories was chosen on the basis of distribution of overall drug 
use over age and on the relevance of specific age groups (less drug use in age groups 20-55 
results in wide age-ranges, special interest in children results in smaller age-ranges). This 
resulted in age groups with different age-ranges instead of more conventional age groups with 
equal age range. Since there were no data on drug regimens and digoxin dosages can vary 
greatly among patients, the data did not allow for the calculation of the incidence rate in terms 
of person-years of use.
Analyses. We calculated the proportion of acute admissions that were attributable to digoxin 
intoxication according to the coded discharge diagnoses. Since digoxin prescription rates vary 
across different patient groups, the proportion of admissions may not reflect the actual risk of 
digoxin intoxication. Therefore, we also calculated incidence rates of digoxin intoxication by 
dividing the number of admissions for digoxin intoxication by the number of filled digoxin pre-
scriptions. Using similar methods, we calculated age- and gender-specific incidence rates. 
Descriptive statistical methods were used for subgroup comparisons and consisted of Stu-
dent’s t-tests (unpaired) and Chi-squared tests. The relative mortality risk during admission 
for digoxin intoxication versus other reasons for admission was estimated by using age- and 
gender-adjusted logistic regression analysis. The association between the length of hospital 
stay and admission for digoxin intoxication was studied by using age- and gender-adjusted 
linear regression analysis. All analyses were carried out in SPSS 11.0 for Windows. The age 
adjusted relative risk (RR) of admission with digoxin intoxication per 100,000 prescriptions in 
females versus males, was computed using Mantel-Haenzel methods across the eight age 
strata. 
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Results
Of all 9,729,819 admissions over the years 2001-2004, 30.7% (n= 2,987,580) were acute ad-
missions. The baseline characteristics of the study population are shown in table 1. The mean 
age of acutely admitted patients was 49.1 years and 53.5% were female. The most frequent 
main diagnoses were of a cardiovascular nature including chest pain, myocardial infarction, 
heart failure and stroke (13.5% of all acute admissions). The mean duration of admission was 
8.8 days and 4.9% of all acute admissions ended in death.
Digoxin intoxication was reported in 0.04% (n= 1286) of acute admissions. Patients with 
digoxin intoxication were significantly older (77.4 versus 49.1 years, p< 0.001) and more of-
ten female (68.0% versus 53.5%, p<0.001) than other acutely admitted patients. The mean 
Table 1 Characteristics of all acute admissions (N= 2,987,580)
Characteristic
Mean age (years) 49.1
Age in years (no. of patients)
0-10 380,827
11-20 128,653
21-40 641,91
41-54 383,175
55-64 349,304
65-69 203,664
70-74 242,968
>=75 657,079
Female sex (%) 53.5 %
Top 10 most frequent main diagnoses (% admissions)
Chest pain 5.8
Myocardial infarction 3.0
Heart failure 2.7
Stroke 2.0
Pneumonia 1.9
Atrial fibrillation 1.9
Abdominal pain 1.7
Chronic obstructive pulmonary disease 1.4
Fetal distress 1.3
Acute appendicitis 1.3
Digoxin intoxication (% admissions) 0.04a 
Mean duration of admission (days) 8.8
Died during admission,= (% [No] admissions) 4.9 (147,379)
a N= 1286, mean age 77.4 years
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duration of admissions for digoxin intoxication was 14.2 days. The age and gender adjusted 
difference in duration with other admissions was 2.1 days (95% CI: 1.3; 2.8). Admissions for 
digoxin intoxication ended in death more often than other acute admissions (7.7% [n= 99]of 
admissions for digoxin intoxication versus 4.9% of other acute admissions); however, patients 
who were admitted for digoxin intoxication were older than patients admitted for other causes. 
After adjustment for age and gender, the risk of death during admission appeared to be lower 
for patients admitted with digoxin intoxication than for those admitted for other reasons (RR 
0.7, 95% CI: 0.5;0.8).
There were 2.6 million digoxin prescriptions during the study period, 1.6 million of which 
(61.5%) were prescribed to women. The number of digoxin prescriptions and intoxications 
was stable over the study period. The overall incidence rate of digoxin intoxication was 48.5 
(45.9;51.2) per 100,000 digoxin prescriptions. Assuming an average prescription length of 3 
months (maximum period dispensed per prescription for chronic use in The Netherlands) this 
corresponds to 1.94 intoxications per 1000 person years of digoxin use. The highest rates 
of intoxication were found in very young (0–10 years) users. After the age of 40 years, there 
was a slow increase in risk of intoxication with increasing age (table 2). Women were at a 
higher risk of digoxin intoxication than men, with 55.2 (95%CI 51.6;59.0) versus 38.6 (95%CI 
35.0;42.5) intoxications per 100,000 prescriptions, resulting in an age adjusted relative risk of 
1.4 (95%CI: 1.3;1.6) for women versus men. 
Discussion
In this study, we show that the absolute number of cases of digoxin intoxication requiring hos-
pitalization in The Netherlands between 2001-2004 was rather low (1286 in 4 years, around 
2 per 1000 person years of use). This confirms the observation that current management of 
digoxin treatment has reduced the risk of digoxin toxicity dramatically. At the current time, 
Table 2 Gender specific incidence rates for digoxin intoxication per 100,000 prescriptions, by age 
category (N= 1286)
Males Females
Age Cases Incidence Rate (95% CI) Cases Incidence Rate (95% CI)
0-10 10 229.8 (123.6 – 427.1) 9 251.3 (114.9 – 477.0)
11-20 1 65.0 (1.7 – 362.3) 1 76.8 (1.9 – 427.6)
21-40 7 110.5 (44.4 – 227.7) 6 122.7 (45.0 – 267.1)
41-54 7 17.8 (7.2 – 36.7) 11 52.8 (29.3 – 95.4)
55-64 28 23.0 (15.9 – 33.3) 34 55.2 (39.4 – 77.2)
65-69 34 30.3 (21.7 – 42.4) 43 63.0 (46.7 – 85.0)
70-74 68 40.0 (31.6 – 50.8) 86 64.8 (52.5 – 80.0)
>=75 256 42.1 (37.2 – 47.6) 685 53.0 (49.2 – 57.1)
Total 411 38.6 (35.0 – 42.5) 875 55.2 (51.6 – 59.0)
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digoxin treatment appears to be rather safe, probably due to regimens that employ lower dos-
ages than were used in the past and to increasing awareness of the risk factors for intoxication. 
This improved prognosis is confirmed by the fact that we found a lower risk of in-hospital death 
for patients admitted for digoxin intoxication compared with other acutely admitted patients. 
In the past, mortality from digoxin intoxications used to be as high as 41%.6 By the 1980s, 
all cause mortality for patients with a discharge diagnosis of digoxin intoxication had already 
been reduced to 5%, and only 1.1% of intoxicated patients died as a direct result of the in-
toxication.8 There have been several changes in the therapy of heart disease that explain this 
dramatic reduction in mortality. First, the dosage administered in most digoxin regimens are 
much lower than in the past, leading to less severe intoxication with fewer lethal arrhythmias. 
Second, the patient population receiving digoxin has changed. In the past, many patients re-
ceived digoxin for the treatment of coronary heart disease, but currently the main indications 
for treatment are congestive heart failure and atrial fibrillation. Of the patients with digoxin 
intoxication in 1971, 74% also experienced coronary artery disease. In the 1980s, this was 
reduced to 35%. Old or recent myocardial infarction in intoxicated patients decreased from 
60% to 20%.6, 8 Third, the diagnosis of digoxin intoxication has changed over time, resulting in 
the recognition of less severe cases. In the past, the diagnosis was based on the patient his-
tory and ECGs. Therefore, only more severe cases of intoxication were identified. Presently, 
serum digoxin levels may support the diagnosis in patients with a less severe presentation.11 
Fourth, changes in the treatment of heart disease, especially the introduction of potassium-
sparing diuretics and ACE-inhibitors, has drastically reduced the incidence of hypokalemia 
in patients treated with diuretics. In previous studies, hypokalemia often complicated digoxin 
intoxication giving rise to more serious arrhythmias.7 Finally, patients with severe intoxication 
resulting in lethal arrhythmias might not reach the hospital alive. This might have resulted in 
the selection of cases of intoxication that had relatively good prognoses in this study.
In addition, we found that women were at increased risk of digoxin intoxication. This obser-
vation supports the concerns that were raised earlier in the gender-stratified analysis of the 
Digitalis Investigation Group (DIG) data about a higher risk of digoxin therapy complications in 
women. In a post-hoc analysis of the DIG trial, the group of women treated for heart failure with 
digoxin had a higher mortality rate than the placebo group and than men treated with digoxin. 
Women had slightly higher serum digoxin levels than men after 1 month of use, despite lower 
doses of digoxin per body mass index unit.10 The only other study on the effect of gender on 
outcome of digoxin treatment (the SOLVD trial) showed no difference in survival between men 
and women.12 However, the SOLVD trial included a much lower number of women than the 
DIG study, resulting in lower power to detect a difference. Furthermore, the outcome in both 
studies was death, and as we have shown that the current mortality from digoxin intoxication 
is low, this would make it more difficult to detect a difference in rates between men and women 
in those studies. However, studies on the subject of gender differences in digoxin intoxica-
tion remain scarce since gender-stratified results are not available for most digoxin trials and 
women are traditionally under-represented in trials. One hypothesis about the increased risk 
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of digoxin intoxication in women is the inhibition of P-glycoprotein by hormone replacement 
therapy (HRT), which reduces the excretion of digoxin in the renal tubes.10, 13 However, HRT 
use in The Netherlands is relatively low, making this an unlikely explanation for our findings. 
An alternative hypothesis which seems more likely and also involves P-glycoprotein is the 
suggestion that women have lower P-glycoprotein expression,14 resulting in higher uptake and 
lower excretion of digoxin. It is unlikely that the difference in the incidence of digoxin intoxica-
tion is explained by a difference in renal clearance, since renal function tends to deteriorate 
more with increasing age in men than in women.15 Adjustment for renal function might there-
fore even further increase the RR of digoxin intoxication in women compared with men. On the 
other hand, it remains possible that there were differences in co-medication or co-morbidity 
between men and women that might account for at least part of the difference in incidence that 
was found. In the post-hoc analysis of the DIG trial, for instance, women used diuretics more 
often than men, which might lead to lower potassium levels and hence, higher susceptibility 
to digoxin toxicity.10 However, we were not able to investigate the influence of these factors in 
the current study.
Although we used a nation-wide registry with complete coverage of all hospital admissions 
in The Netherlands, there may be some misclassification in our estimations. In patients with 
severe co-morbidity in addition to digoxin intoxication, the co-morbidity rather than digoxin 
intoxication may have been coded as the main diagnosis. Also, symptoms may not have 
been recognized as digoxin toxicity and instead have been coded as nausea or arrhythmia. 
In addition, digoxin intoxications causing death before reaching the hospital, and patients with 
only mild symptoms of toxicity who were not hospitalized but instead treated by a simple dose 
reduction, will have been missed. These inaccuracies may have led to a slight underestima-
tion of the incidence rate. Furthermore, individual data on dose and duration of digoxin use 
were not available, and we were unable to adjust for co-morbidity or multiple hospitalizations 
per patient.
Conclusion. Despite its limitations we believe that this study provides an accurate quantifica-
tion of digoxin intoxication-related admissions relative to digoxin prescriptions, showing that 
current digoxin treatment is rather safe. Added to the fact that digoxin therapy was proven to 
be effective1 and its use has been recommended in heart failure treatment guidelines, digoxin 
might be used more often in heart failure treatment than it currently is. Furthermore, this study 
supports the previous finding that women are at higher risk of the negative consequences of 
digoxin treatment.
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3.1
Common ABCB1 variants are associated with
increased digoxin serum concentration
Abstract
Background and objective. Digoxin is a known substrate of ATP-Binding Cassette B1 (AB-
CB1/MDR1). However, the results of studies on the association between ABCB1 polymor-
phisms and digoxin kinetics remain contradictory. Almost all studies were small and involved 
only single dose kinetics. The goal of this study was to establish ABCB1 genotype effect on 
digoxin blood concentrations in a large cohort of chronic digoxin users in a general Dutch 
European population.
Methods. Digoxin users were identified in the Rotterdam Study, a prospective population-
based cohort study of individuals aged 55 years and older. Digoxin blood levels were gathered 
from regional hospitals and laboratories. ABCB1 SNPs C1236T, G2677T/A and C3435T were 
assessed on peripheral blood DNA using Taqman assays. We studied the association be-
tween the ABCB1 genotypes and haplotypes and digoxin blood levels using linear regression 
models adjusting for potential confounders.
Results. Digoxin serum levels and DNA were available for 195 subjects (56.4% women, mean 
age 79.4 years). All three ABCB1 variants were significantly associated with serum digoxin 
concentration (0.18 to 0.21 μg/l per additional T-allele). The association was even stronger for 
the 1236-2677-3435 TTT-haplotype allele (0.26 μg/l (95%CI 0.14;0.38)) but absent for other 
haplotypes (CGC-allele considered referent), suggesting an interaction of SNPs in a causal 
haplotype instead of individual SNP effects.
Conclusion. We found that the common ABCB1 C1236T, G2677T and C3435T variants and 
the associated TTT-haplotype were associated with higher digoxin serum concentrations in a 
cohort of elderly European digoxin users in the general population. 
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Introduction
The ATP-Binding Cassette B1 (ABCB1) or Multidrug Resistance 1 (MDR1) gene is a 200kb 
gene on chromosome 7p21. It was first discovered in chemotherapy resistant tumor cells 
but ABCB1 is also widely expressed in normal tissues such as the duodenum, kidneys, liver 
and the blood-brain barrier.1-6 There, ABCB1 is known to play an important role in the uptake, 
distribution and excretion of many drugs.7 Since its first discovery, as many as 647 single 
nucleotide polymorphisms (SNPs) -with an established frequency- have been identified in the 
ABCB1 gene.8
Among the first SNPs to be identified was the C3435T polymorphism, which was found to be 
associated with decreased ABCB1 function, resulting in increased digoxin concentration.9 
Since then, many more studies on the association between ABCB1 SNPs –mostly C1236T, 
G2677T/A and C3435T- and kinetics of digoxin and many other drugs have been performed 
with varying results. In a recent meta-analysis combining all studies of the C3435T SNP and 
digoxin , an association with serum digoxin kinetics could not be confirmed. However, all these 
studies consisted of small groups of healthy volunteers, the largest study encompassing 50 
subjects. Furthermore, all but one of these studies concerned single dose kinetics. In the only 
multiple dose study, subjects received digoxin for no more than five consecutive days.10
The aim of our study was to investigate the association of the ABCB1 SNPs C1236T, G2677T/A 
and C3435T and their haplotypes with digoxin serum concentrations in a large population 
based cohort of digoxin users.
Methods
Setting and study population. A cohort of digoxin users was identified from the Rotter-
dam Study, a prospective population-based cohort study of chronic diseases in the elderly. 
Objectives and methods of the Rotterdam Study have been described in detail elsewhere.11 
The medical ethics committee of the Erasmus Medical Center (Rotterdam, The Netherlands) 
approved the study and all participants provided signed, informed consent for participation, 
retrieval of medical records, use of blood and DNA for scientific purposes and publication of 
obtained results. Baseline examinations took place from March 1990 through July 1993. In 
addition to the follow-up examinations that take place approximately every four years, all drug 
prescriptions dispensed to participants by automated pharmacies are routinely stored in the 
database since January 1, 1991. DNA for genotyping was available for 6571 (82%) partici-
pants from the baseline visit.
For the present study, the study population comprised all subjects from the baseline cohort 
who were dispensed digoxin and who had a digoxin serum concentration assessment at any 
point during the study period. We excluded persons for whom DNA for genotyping was un-
available or information on dose was lacking. Follow-up started on January 1, 1991 or first 
digoxin prescription, whichever was latest, and lasted until the end of the study period on 
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August 30, 2005, digoxin serum concentration assessment, patient death or loss to follow-up, 
whichever came first.
Genotyping. All participants of the Rotterdam Study for whom DNA was available were gen-
otyped for the ABCB1 C1236T, G2677T/A and C3435T polymorphisms.  Genotyping was 
done using Taqman allelic discrimination assays on the ABI Prism 7900 HT Sequence detec-
tion system (Applied Biosystems, Foster City, Ca., USA) on 1 ng of genomic DNA extracted 
from leukocytes, as previously reported.12. The primer and probe sequences, designed by 
Applied Biosystems (Assay-by-Design service) are listed in Table 1. For the tri-allelic variant 
G2677T/A , two separate assays were designed, one detecting G2677T and one detecting 
G2677A. Haplotypes were estimated using the estimation maximization algorithm and soft-
ware as described in the statistical analyses section.
Outcome. All available serum digoxin concentrations of subjects from the study population 
were gathered from 3 hospital laboratories and 1 general practitioner’s laboratory serving the 
area of the Rotterdam Study. To limit the effect of digoxin dose titration, only the first available 
digoxin serum concentration assessment of each subject was used. A potentially toxic digoxin 
concentration was defined as a serum concentration above the upper limit of the therapeutic 
range (i.e., above 2.00 μg/l).
Table 1 Primer sequences.
Assay Primer/probe Sequence
ABCB1 C1236T Forward primer TCTCACTCGTCCTGGTAGATCTTG
Reverse primer CACCGTCTGCCCACTCT
VIC probe TCAGGTTCAGGCCCTT
FAM probe TCAGGTTCAGACCCTT
ABCB1 G2677A Forward primer AATACTTTACTCTACTTAATTAATCAATCAT-
ATTTAGTTTGACTCA
Reverse primer GTCTGGACAAGCACTGAAAGATAAGA
VIC probe TTCCCAGCACCTTC
FAM probe CTTCCCAGTACCTTC
ABCB1 G2677T Forward primer CTTAGAGCATAGTAAGCAGTAGGGAGT
Reverse primer GAAATGAAAATGTTGTCTGGACAAGCA
VIC probe TTCCCAGCACCTTC
FAM probe TTCCCAGAACCTTC
ABCB1 C3435T Forward primer ATGTATGTTGGCCTCCTTTGCT
Reverse primer GCCGGGTGGTGTCACA
VIC probe CCCTCACGATCTCTT
FAM probe CCCTCACAATCTCTT
The positions of the SNPs are underlined
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Co-variables. Covariates were gathered at the baseline examination, and included height (in 
meters), weight (in kilograms) and serum creatinine. Lean body mass (LBM) was computed 
using Devines formula: LBM = (height (cm) -152) x 0.9 + (50 kg (men)) or (45.5 kg (women)). 
Body mass index (BMI) was calculated as: weight (kg) / height (m) squared. Renal clearance 
was estimated using Cockroft and Gault’s formula. Information on daily digoxin dose was 
expressed as the number of defined daily dosages (DDD, 1 DDD is 0.25 mg) as gathered 
from the automated pharmacy records. Dose per unit LBM was calculated dividing the dose 
of digoxin (in DDD) by the LBM. In addition, we identified exposure to inhibitors or inducers of 
ABCB17 within 7 days of blood sampling.
Statistical analyses. Differences in baseline characteristics between men and women were 
tested by using a Chi-square test for binary variables and a t-test for normally distributed 
continuous variables. To ensure comparability of serum digoxin concentration assessments 
across the different laboratories we compared average digoxin concentrations by one-way 
ANOVA. Exact Hardy Weinberg equilibrium p-values were computed for bi-allelic SNPs and 
a simulated p-value for the tri-allelic SNP were computed using the Genetics 1.2.1 (G.Warns 
and F. Leisch) package for R 2.5.0 software (http://www.r-project.org/). Additionally, we com-
pared genotype frequencies with those of the whole Rotterdam Study cohort. D’ was calcu-
lated using the ldmax command from GOLD software.13 All tests for differences in baseline 
characteristics and linear and logistic regression analyses for the individual SNPs were per-
formed using SPSS for windows software, version 11.1 (Chicago, Illinois, USA). Expectation 
maximization and linear and logistic regression analyses for the haplotypes were performed 
with the HaploStats 1.3.0 package for R, using haplo.em and haplo.glm respectively.14, 15 In-
ferred haplotypes with a frequency below 1.5% were pooled into one ‘rare haplotype’ group, 
since estimates become unreliable for rare haplotypes in HaploStats.
Both allelic and general genotype models were tested for the three SNPs and haplotypes, 
although the allelic model was considered primary. In haplotype analyses, the haplotype with 
C-G-C at positions 1236-2677-3435, respectively, was considered the referent, to which the 
other haplotypes were compared. Serum digoxin concentration was tested for association 
with genotype or haplotype as the sole predictor (crude) and adjusted for age, gender, daily 
digoxin dose, LBM and renal clearance (multivariate) in a linear regression model. Addition-
ally, we accounted for the influence of  digoxin dose by repeating the analyses with digoxin 
concentration/digoxin dose (L/D) ratio as the outcome. In the regression analyses, the 2677A 
variant carriers were excluded because the frequency of this variant (1.5%) was too low for a 
reliable effect estimation. To quantify the role of ABCB1 variants in digoxin kinetics, the partial 
r2 was calculated as a measure of the variability of serum digoxin concentrations explained by 
ABCB1 variants, using the formula: partial r = (Tk / √(Tk
2 + (N - K - 1)), in which Tk is the T value 
for the variable of interest, N is the number of subjects and K is the number of variables in the 
model. Finally, two sensitivity analyses were carried out. Because for some of the laborato-
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ries only part of the follow-up period was available, subjects who started digoxin before that 
date might have been titrated already to a lower daily dose by reference to earlier measure-
ments.. Therefore, we restricted these analyses to subjects who had the start date of their first 
prescription after the date the laboratory started contributing data. Second, we excluded all 
subjects using inhibitors or inducers of ABCB1.7
To investigate an association between ABCB1 variants and serum digoxin concentrations 
above 2.0 μg/l, an allelic model was tested using logistic regression analyses, both crude and 
adjusted for age, gender, LBM, digoxin dose and renal clearance. To keep the multivariate 
model stable despite the limited number of cases and some missing values in weight and re-
nal function, LBM, digoxin dose and renal clearance were only kept in the model for toxic con-
centrations if they were tested significant as a risk factor in the overall fully adjusted digoxin 
concentration model at p< 0.1.
Since there are indications that high serum digoxin concentrations are more frequent in wom-
en16, 17 and that ABCB1 expression in women might be lower,18 we performed an additional 
gender stratified analysis. 
Results
Study subjects. During the study period, we identified 1359 (17% of total cohort) digoxin us-
ers in the Rotterdam Study. Digoxin serum concentrations, dose and DNA were available for 
195 (14% of digoxin users) subjects. The average digoxin dose was 0.57 DDD and did not 
differ between men and women, but women received significantly higher doses of digoxin per 
unit LBM (DDD/LBM) (Table 2). We identified 50 subjects using ABCB1 inhibitors: amiodarone 
15-, propafenone 2-, verapamil 9-, atorvastatin 4-, dypiridamole 3-, spironolactone 18-, and 
Table 2 Baseline characteristics of 195 genotyped digoxin users from the Rotterdam Study
Characteristic Total
N= 195
Males
N= 85 (43.6%)
Females
N= 110 (56.4%)
p-value
Age in years 79.4 (7.0) 78.1 (6.1) 80.3 (7.6) 0.03
BMI kg/m2 26.7 (3.6) 26.0 (3.1) 27.3 (3.9) 0.01
LBM 60.9 (10.1) 70.2 (5.8) 53.5 (3.9) <0.001
Renal Clearance ml/min 61.8 (17.4) 67.5 (18.7) 57.5 (15.3) 0.001
Average digoxin dose (DDD) 0.57 (0.26) 0.57 (0.27) 0.56 (0.25) 0.81
Dose per  unit LBM (x1000)a 9.6 (4.4) 8.3 (3.8) 10.6 (4.6) <0.001
Serum digoxin concentration (μg/l) 1.04 (0.73) 1.01 (0.58) 1.07 (0.83) 0.62
Number of serum digoxin concen-
trations >2.00μg/l (%)
12 (6%) 6 (7%) 6 (5%) 0.64
Mean (standard deviation). 
BMI: body mass index, LBM: lean body mass, DDD: defined daily dosage (1 DDD is 0.25mg for digoxin)
a Dose in DDD x 1000 / LBM
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paroxetine 3 users. Of these, 4 subjects used 2 inhibitors simultaneously. None of the partici-
pants used ABCB1 inducers.
Genotyping results. Allele frequencies of the C1236T, G2677T/A and C3435T SNPs are 
shown in Table 3. Genotyping of the study population was successful in 96.9%, 95.9% and 
94.9% respectively and all three SNPs were in Hardy-Weinberg equilibrium, with p-values 
of 0.88, 0.02 and 0.14, respectively. All three SNPs were in strong linkage disequilibrium, 
as previously reported7, 19 with a D’ of 0.93 between C1236T and G2677T/A, 0.87 between 
G2677T/A and C3435T, and 0.81 between C1236T and C3435T. Expectation maximization 
resulted in two major haplotype alleles, the 1236-2677-3435 C-G-C and T-T-T haplotypes, 
both at an allele frequency of 40% and a number of less frequent haplotypes (Table 3). Geno-
type distributions did not differ between the general population and digoxin users with or with-
out a serum concentration assessment. Genotype and haplotype frequencies were consistent 
with other European populations.19-22
Serum digoxin concentrations. There was no significant difference in mean digoxin serum 
concentration or percentage of toxic concentrations between assessments from the four differ-
ent laboratories. There was no association between genotype or haplotype and digoxin dose 
(results not shown). One woman, who was homozygous TT for all three SNPs, was found to 
have an extraordinary high serum digoxin concentration (7.6 μg/l). Even if the sample was tak-
en correctly, and no (un)intentional overdose of digoxin was taken by the patient, such a single 
outlier might excessively influence the effect estimate for the association in such a relatively 
small group and  introduce an erroneous association or mask a true association. Therefore, it 
Table 3 Frequencies of ABCB1 SNP and haplotype alleles in 195 genotyped digoxin users from the 
Rotterdam Study
SNP allele Allele frequency Nr of homozygotes
1236T 0.44 35
2677T 0.43 35
2677A 0.02 1
3435T 0.55 61
Haplotype allele 1236-2677-3435a
C-G-C 0.40 38
T-T-T 0.40 33
C-G-T 0.13 9
T-T-C 0.02 5
T-G-C 0.02 3
C-T-T 0.01 5
C-A-C 0.01 5
a Determined using expectation maximization in Haplostats
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was excluded from further analyses. After adjustment for age and sex, an increase in digoxin 
with 1 DDD was associated with an increase in digoxin serum concentration of 0.93 μg/l (95% 
CI 0.63-1.23) with a partial r2 estimate of 16.7%. The results of the genotypic model were con-
sistent with an allelic model (results not shown). For each of the individual SNPs at positions 
1236, 2677 or 3435, the serum digoxin concentration increased significantly per additional 
T-allele with the strongest association for the 1236-2677-3435 TTT haplotype (Table 4). The 
point estimates for haplotypes with a T variant at just one or two of the positions were around 
zero, but the numbers of these haplotypes  were too low to obtain a statistically robust effect 
estimate (Table 4). Using L/D ratio as the outcome in stead of adjustment for digoxin dose in a 
linear regression model yielded similar results (data not shown). Stratification on sex showed 
similar results for men and women (results not shown). The partial r2 estimate indicated that 
ABCB1 variants explained up to 11.5% of the variability in serum digoxin concentration for 
the TTT haplotype (Table 4). The sensitivity analysis restricted to subjects who started taking 
digoxin after the date the laboratory they were referred to started contributing data (n=100) 
did not substantially change the effect estimates, neither did the analyses excluding subjects 
using ABCB1 inhibitors (data not shown).
Although the number of subjects with a digoxin concentration above 2.0 μg/l (the upper level 
of the therapeutic range) was very low (n=12), a significant association between the T-variants 
Table 5 Risk of serum digoxin concentrations >2.00μg/l per genotype group and odds ratio per vari-
ant allele copy
SNP Cases/total (% within genotype group)
OR by allele
Crude Model 1a Model 2b
C1236T CC
2/59 (3.4%)
CT
4/95 (4.2%)
TT
5/35 (14.3%) 2.4 (1.0-6.1) 2.5 (1.0-6.4) 3.2 (1.2-8.7)
G2677Tc GG
1/55 (1.8%)
GT
5/92 (5.4%)
TT
4/35 (11.4%) 2.5 (1.0-6.6) 2.4 (0.9-6.4) 3.1 (1.1-8.4)
C3435T CC
1/43 (2.3%)
CT
4/81 (4.9%)
TT
5/61 (8.2%) 1.9 (0.7-4.8) 1.8 (0.7-4.7) 2.1 (0.8-5.7)
Haplotype alleled
CGC NA Reference Reference Reference
TTT 3.5 (1.2-10.5) 3.5 (1.2-10.6) 4.3 (1.4-13.4)
CGT 1.5 (0.3-8.0) 1.4 (0.3-7.8) 1.5 (0.2-9.5)
Odds ratios only for allelic models (OR per additional variant allele) due to low numbers of cases per genotype 
group 
a Model 1: Adjusted for gender, age
b Model 2: Adjusted for gender, age, digoxin dose
c A-alleles (GA (n=4) and AA (n=1) genotypes, TA genotype was not found in this population) were excluded 
because of low numbers.
d Because of the limited number of cases, all haplotype alleles with a frequency ≥5% were included in one model 
(haplotypes with frequency <5% were pooled in one ‘rare haplotype’ estimate)
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of the three SNPs and these potentially toxic digoxin concentrations was found. The associa-
tion in the individual SNPs was strongest for the TTT haplotype allele: age sex and digoxin 
dose adjusted OR 4.3 (95% CI 1.4-13.4) per TTT allele (Table 5).
Discussion
To our knowledge, this is the first population based study on the consequences of ABCB1 
polymorphisms in a large population based group of European digoxin users. We demon-
strated a statistically significant association between the common ABCB1 variants C1236T, 
G2677T, C3435T and serum digoxin concentration, which was strongest for the associated 
TTT haplotype allele and explains an important part of the variability in digoxin concentrations 
as determined by the r2 (up to 11.5% by the TTT haplotype). We observed no effect for the 
other haplotype alleles, including the CGT haplotype. This suggests interaction of the three 
SNPs in the TTT haplotype and is consistent with a recent study that demonstrated an effect 
of the silent C3435T SNP only in combination with one or two of the G2677T/A and C1236T 
SNPs. That study suggests an effect on protein folding through rare codon usage, result-
ing in changed substrate specificity.23 Since, in our population, G2677T/A and C1236T best 
predicted the TTT haplotype, it may be sufficient to limit ABCB1 genotype assessment for 
clinical purposes to these two SNPs. The majority of previous studies in Caucasians showed 
similar effects of ABCB1 variants on digoxin kinetics (Table 6), but a meta-analysis could not 
confirm an effect for the C3435T SNP.10 The main difference with our study is that most stud-
ies comprised only single dose kinetics and were underpowered to demonstrate small effects. 
Only one study was performed in actual digoxin using patients.24 and showed no association 
of ABCB1 variants with digoxin kinetics. The used dose was however almost twice that of 
the average daily dose in our study. At these higher dosages, the maximum transport capac-
ity of ABCB1 transport capacity might be saturated by the abundance of digoxin and subtle 
differences in ABCB1 efflux-capacity may no longer contribute substantially to the variability 
in digoxin serum concentration. Studies in Asian populations and with other substrates are 
discussed in more detail elsewhere.10, 25
Although almost all observed serum digoxin concentrations fell within the generally accepted 
therapeutic range (0.5-2.0 μg/l), the observed differences in serum digoxin concentrations be-
tween genotype groups may still be large enough to have immediate clinical consequences. 
An increase of 0.20-0.25 μg/l per variant allele equals the effect of a 0.25DDD dose increase. 
Consequently, subjects with 2 variant alleles have an increase in serum concentration of 0.4-
0.5 μg/l, equal to the effect of a dose increase of 0.5 DDD. Furthermore, even differences 
in serum digoxin concentrations within the accepted therapeutic range might influence the 
efficacy and safety of treatment.26 Finally, this study suggests that T-variant carriers and TTT 
haplotype carriers are also at higher risk of digoxin concentrations that exceed the therapeutic 
range and are generally regarded as toxic. However, to calculate a reliable risk estimate a 
study with more cases of digoxin intoxications is necessary.
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The main strength of our study compared to earlier studies on ABCB1 SNPs and digoxin se-
rum concentrations resides in the large number of digoxin users from a population based co-
hort. Selection bias is unlikely since SNPs were in HWE and the distribution of genotypes did 
not differ between the study population and the whole Rotterdam Study cohort or digoxin us-
ers without a serum concentration assessment. Furthermore, digoxin prescribing and serum 
concentration assessment were blinded for genotype. The influence of confounding, which 
was probably limited, was further minimized by applying a multivariate regression model in-
cluding the most relevant determinants of digoxin serum concentration. One limitation is that 
the present study does not allow an estimation of the influence of ABCB1 SNPs on treat-
ment efficacy. Another limitation involves measurement inaccuracies. Digoxin concentration 
sampling under everyday circumstances is often, incorrectly, performed without regarding the 
time interval since last digoxin dose in clinical practice.27 We could not verify the influence of 
such inaccuracy since the time of the last dose of digoxin and the time of drawing the blood 
sample had not been registered consistently. Any measurement errors (misclassification of 
the outcome) were most likely random and would have led to a conservative estimate of the 
actual effect. We limited the effect of dose titration based on serum concentrations by using 
only the first serum assessment of each subject. Furthermore, the sensitivity analyses, limited 
to subjects who had their first prescription of digoxin after the laboratory they were referred to 
started contributing data, showed similar effect estimates. Finally, this study was performed 
in a European population. The effect of ABCB1 SNPs on serum digoxin concentrations may 
not automatically be valid for other populations since haplotype allele variation might differ 
and variation in expression of other transporter proteins might play a role. For instance, the 
2677A variant is more frequent in certain Asian populations,19, 28 but it was too rare in our study 
population to investigate its effect.
In conclusion, we found that the ABCB1 C1236T, G2677T and C3435T variants were associ-
ated with higher digoxin serum concentrations in a cohort of elderly European digoxin users in 
the general population. The association was strongest for the 1236-2677-3435 TTT haplotype, 
suggesting an interaction of SNPs in a causal haplotype instead of individual SNP effects. The 
findings in this study might provide a starting point for strategies toward improving the efficacy 
and safety of digoxin therapy. As an efflux transporter, ABCB1 influences pharmacokinetics of 
many drugs.7 Therefore, these variants could have important implications for individual varia-
tion in drug concentrations and susceptibility to toxic effects.29-32
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3.2
Common ABCB1 variants increase QTc shortening and 
risk of SCD in digoxin users
Abstract
Background and objective. Digoxin is one of the oldest cardiovascular drugs still in use 
today, but its use has always been associated with the risk of intoxication and life threaten-
ing arrhythmias. Digoxin is a known substrate of ATP-Binding Cassette B1 (ABCB1/MDR1). 
Therefore, we hypothesized that these ABCB1 variants might also increase digoxin toxicity 
associated sudden cardiac death (SCD). In addition, to further evaluate the association with 
cardiac effects of digoxin, we studied the association of ABCB1 variants with QTc interval 
duration in digoxin- and non-digoxin users.
Methods. We used the Rotterdam Study, a population-based, prospective cohort study of 
individuals ≥55 Years of age. ABCB1 SNPs C1236T, G2677T/A and C3435T were assessed 
on peripheral blood DNA using Taqman assays. Hazard ratios (HRs) for time to SCD among 
ABCB1 genotypes with and without digoxin were estimated by Cox proportional hazards mod-
eling with time-dependent exposures. Heart rate corrected QT (QTc) interval duration was 
measured in prospectively collected ECGs and digoxin exposure was determined at the time 
of each ECG.
Results. There were 229 SCD cases, 40 of whom were exposed to digoxin at time of death. 
In digoxin users, homozygotes for 1236 or 2677 T-alleles and TTT-haplotype alleles had a 
two-fold increased risk of SCD (HR homozygous TTT: 2.36, 95%CI 1.02;5.45) in a recessive 
genetic model. No effect of ABCB1 variants on SCD risk was observed within non-digoxin 
users. We included 13,694 ECGs from 5535 individuals (294 ECGs from 222 individuals on 
digoxin). In digoxin users, ABCB1 T-allele or TTT-haplotype allele carriers increased QTc 
shortening compared to subjects homozygous for the reference allele.
Conclusion: ABCB1 C1236T, G2677T/A and C3435T T-alleles and the associated TTT-
haplotype allele increase the risk of SCD to digoxin and show increased QTc shortening to 
digoxin.
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Introduction
Digoxin is one of the oldest cardiovascular drugs still in use today. Although digoxin therapy 
is relatively safe nowadays,1 its use has often been associated in the past with considerable 
risks of intoxication, frequently resulting in of arrhythmias and death.2-4 Toxic concentrations 
may occur at therapeutic doses. Moreover, toxic effects of digoxin can appear within the ac-
cepted therapeutic serum concentration range.5 Digoxin is a known substrate of P-glycopro-
tein, a multi-drug efflux transporter encoded by the ATP-Binding Cassette B1 (ABCB1) also 
known as the Multidrug Resistance 1 (MDR1) gene, a 200kb gene on chromosome 7p21. It 
was first discovered in chemotherapy resistant tumor cells but is also widely expressed in nor-
mal tissues such as the duodenum, kidneys, liver and the blood-brain barrier where it plays a 
role in the uptake and clearance of many drugs.6-11 P-glycoprotein is suggested to play a role 
in digoxin concentration management. 
Many studies on single nucleotide polymorphisms (SNPs) of ABCB1 and digoxin kinetics 
have been performed. However, most studies were small and the results were ambiguous.12 
In a recent study, we showed that common variants in ABCB1 were associated with increased 
serum digoxin concentrations and risk of supra-therapeutic concentrations in a group of 195 
chronic digoxin users from the Rotterdam Study.13 Therefore, we hypothesized that common 
ABCB1 variants might also be involved in digoxin toxicity associated fatal arrhythmia in the 
form of sudden cardiac death (SCD) to digoxin therapy. In addition, to further evaluate the 
association of ABCB1 SNPs with cardiac effects of digoxin, we studied the association of 
ABCB1 variants with QTc interval duration in users and non-users of digoxin.
Methods
Setting and study population. The Rotterdam Study is a prospective population-based co-
hort study of chronic diseases in the elderly. All inhabitants of Ommoord, a Rotterdam suburb, 
aged 55 years and older (10,278), were ascertained from the municipal register and invited to 
participate. Of them, 78% (7983, 58% female and 98% white) took part in the baseline exami-
nation from March 1990 through July 1993. Second and third examinations were conducted 
from September 1993 to August 1996 and from April 1997 to December 1999. Objectives and 
methods of the Rotterdam Study have been described in detail.14, 15 The medical ethics com-
mittee of Erasmus Medical Center (Rotterdam, The Netherlands) approved the study and all 
participants provided signed informed consent for participation, including retrieval of medical 
records, use of blood and DNA for scientific purposes and publication of data. 
Apart from extensive structured interview rounds, clinical characteristics including smoking, 
body mass index (BMI), hypertension, diabetes mellitus, heart failure and myocardial infarc-
tion are ascertained as previously described.16-21 Active surveillance for incident diabetes mel-
litus, heart failure and myocardial infarction is conducted continuously between exams. DNA 
for genotyping is available for 6571 (82%) participants from the baseline visit. Exposure of 
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study participants to medications is gathered on a continuous basis as of January 1st, 1991 
to the present through computerized pharmacy records of the pharmacies in the study area. 
Therefore, the start of the study period for both ECG measures and SCD was January 1st, 
1991.
The study population comprised all participants from the first cohort for whom pharmacy data 
and genotype data were available. Subjects were followed form January 1st, 1991 until death, 
loss to follow-up or end of follow-up, whichever came first.
Genotyping. All participants of the Rotterdam Study for whom DNA was available were geno-
typed for the ABCB1 C1236T, G2677T/A and C3435T polymorphisms.  Genotyping was done 
using Taqman allelic discrimination assays as previously described.13 Haplotypes were esti-
mated using the estimation maximization algorithm and software as described in the statistical 
analyses section.
Adjudication of sudden cardiac death. All genotyped individuals who were alive at the start 
of the study period were included in the SCD analysis. The ascertainment of SCD cases in 
the Rotterdam Study has been described previously.15, 21 SCD was defined operationally as: a 
witnessed natural death attributable to cardiac causes, heralded by abrupt loss of conscious-
ness, within one hour of onset of acute symptoms, or an unwitnessed, unexpected death of 
someone seen in a stable medical condition <24 hours previously with no evidence of a non-
cardiac cause.22, 23 
Assessment of QTc interval and other ECG measurements. ECG measurements gathered 
during the study period were analyzed in all subjects with DNA for genotyping data available. 
The electrocardiographic phenotype studied was the heart rate corrected QT-interval (QTc) in 
msec, using Bazett’s formula (QTc = QT / √RR).24 As in previous studies of QTc in the Rotter-
dam Study21 we used a 10-second resting 12-lead ECG (average of 8 to 10 beats), which was 
recorded on an ACTA electrocardiograph (ESAOTE, Florence, Italy) at a sampling frequency 
of 500 Hz and stored digitally. All ECGs were processed by the Modular ECG Analysis Sys-
tem (MEANS) to obtain ECG measurements.25-27 MEANS determines the QT interval from the 
start of the QRS-complex until the end of the T-wave. MEANS also determines the presence 
of right (RBBB) or left bundle branch block (LBBB) and left ventricular hypertrophy (LVH). To 
study the association between NOS1AP variants and QTc duration, all eligible ECGs from 
subjects with DNA available were used. ECGs with RBBB or LBBB were excluded from the 
analyses. In addition, to minimize confounding by non-genetic influences on QT duration, all 
ECGs taken while the subject was on any QT prolonging drugs were excluded from the analy-
ses. Drugs were considered as possibly QT prolonging if they appeared on any of lists 1-4 at 
www.qtdrugs.org.28 We also excluded ECGs if subjects were on flupenthixol, levomepromaz-
ine, mefloquine, olanzapine or sertindole, which may also prolong QT interval. Finally, ECGs 
taken while digoxin dose >1 defined daily dosage (DDD) or with unknown digoxin dose were 
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excluded. Up to 4 QTc measurements per subject were recorded across the four examination 
cycles 
Digoxin exposure. In order to assess exposure, we calculated the duration of dispensed 
digoxin prescriptions as the number of units dispensed divided by the number of units to be 
taken per day. Digoxin dose was expressed as the defined daily dose (DDD) as determined 
by the WHO (1 DDD is 0.25 mg of digoxin).
Subjects were considered as exposed to digoxin if the index date (date of death) of the case 
fell within a period of digoxin use. Similarly, in each remaining cohort participant, we assessed 
exposure to digoxin in this way on the same index date as the corresponding case of SCD.
For the analyses of QTc-interval duration, a study participant was considered to be exposed 
to digoxin if the ECG was taken on a date which fell within the duration of a dispensed digoxin 
prescription. Because up to 4 ECGs were take per individual, subjects could contribute ECGs 
to both the digoxin and the non-digoxin group. 
Statistical analysis. Exact Hardy Weinberg equilibrium p-values for bi-allelic SNPs and a 
simulated p-value for the tri-allelic SNP (G2677T/A) were computed using the Genetics 1.2.1 
(G.Warns and F. Leisch) package for R 2.5.0 software. Genetic linkage, as expressed by D’ 
was calculated using the ldmax command from GOLD software.29 Expectation maximization 
for the haplotypes was performed with the HaploStats 1.3.0 package for R 2.5.0, using haplo.
em.30, 31 Inferred haplotypes with a posterior probability < 0.95 were excluded from further 
analyses.
Hazard ratios for time to SCD from baseline were estimated using Cox proportional hazards 
models with time dependent variables for digoxin exposure. Based on the outcome from gen-
eral genotype models, either allelic, dominant or recessive models were tested for the three 
polymorphisms and haplotypes. In addition to ABCB1 genotype, known SCD risk factors in-
cluding age, sex, and time dependent incident diabetes mellitus, heart failure and myocardial 
infarction were included as covariates. First, the effect of genotype on SCD risk was tested 
in strata of digoxin use and non-use. Additionally, we created an interaction dummy variable 
with six levels for the three genotypes with and without digoxin use in which non-digoxin users 
homozygous for the major allele were considered as referent. However, because of the vast 
impact of cardiovascular morbidity on SCD –which is much more frequent in digoxin users 
than in non-users- we considered the stratified analyses primary. In the stratified analyses 
we further adjusted for digoxin dose. The main variant haplotype (1236-2677-3435 T-T-T) 
was tested in Cox proportional hazards models similar to the individual SNPs using the 1236-
2677-3435 C-G-C haplotype as the referent. We included the CGT haplotype as a separate 
covariate, and the rare variables as one pooled rare-haplotype covariate. To minimize bias by 
misclassification of SCD, we additionally performed a sub-analysis restricting the case defini-
tion to witnessed deaths only. All Cox proportional hazards analyses were performed using 
SPSS for Windows version 11.0 (Chicago, Illinois, USA).
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Because the QTc in subsequent ECGs of the same subject are correlated, we used repeated 
measures analyses implemented in PROC MIXED (SAS 8.2, Cary, NC). To test for interaction 
of ABCB1 genotypes with digoxin in QTc shortening, we used the same six level interaction 
dummies. Additionally, we compared the effect of digoxin on QTc duration in starters and 
stoppers of digoxin therapy between genotype groups (follow-up design). QTc was tested for 
association with genotype as the sole predictor (crude) and with adjustment for age, sex, heart 
failure, myocardial infarction and diabetes mellitus (multivariable). The main variant haplotype 
1236-2677-3435 T-T-T was compared with the 1236-2677-3435 C-G-C haplotype as the refer-
ent. Other haplotypes were entered in the model similar to the SCD analyses.
Additionally, we studied the effect of digoxin on QTc interval within subjects in a follow-up de-
sign. For this, we determined the difference in QTc duration between two consecutive ECGs 
(one on digoxin and one off) of subjects starting or stopping digoxin therapy and applied 
descriptive statistics.
Differences in digoxin dose between ECGs from different genotype groups were compared 
using repeated measures analyses, because doses at the time of subsequent ECGs of the 
same subject are correlated. Digoxin dose of different genotype groups in SCD cases were 
compared using ANOVA.
Results
Study population and genotyping results. The study population comprised 6541 individu-
als with a mean follow-up time of 10.4 (SD 3.7) years. Of these, 871 subjects used digoxin at 
any time during the study period. SCD cases were older than the overall SCD sample and had 
more cardiovascular risk factors. A total of 13,694 eligible ECGs from 5535 individuals were 
available. Of these, 294 ECGs from 222 individuals were taken while the subject was using 
digoxin. Mean follow-up time was 11.4 (SD 3.7) years. Mean digoxin dose was 0.61 DDD 
(SD 0.27) and did not differ significantly between genotypes in the ECGs taken while using 
digoxin, ever digoxin users in the total SCD sample or SCD cases. Baseline characteristics 
are shown in Table 1.
Successful genotype calls were made in 96.7%, 95.5% and 95.0% for the C1236T, G2677T/A 
and C3435T SNPs. P-values for Hardy-Weinberg equilibrium were p= 0.52, p=0.0001 and 
p=0.20 respectively. The finding that the G2677T/A SNPs slightly deviates from Hardy-Wein-
berg equilibrium is explained by a relative excess of homozygotes for the rare A-allele. All 
three SNPs were in strong linkage disequilibrium, as previously reported32, 33 with a D’ of 0.94 
between C1236T and G2677T/A, 0.84 between G2677T/A and C3435T, and 0.81 between 
C1236T and C3435T. Expectation maximization resulted in two major haplotype alleles, the 
1236-2677-3435 C-G-C and T-T-T haplotypes, both at an allele frequency of 41%, a C-G-T 
haplotype with a frequency of 12% and a number of rare haplotypes. After exclusion of sub-
jects with <0.95 posterior probability haplotype pairs, the mean posterior probability was 0.99. 
Genotype distributions did not differ between the general population and digoxin users. Geno-
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type and haplotype frequencies were consistent with other European populations.32, 34-36
Sudden cardiac death. During the study period, we identified 229 SCD cases 121 of which 
were witnessed, and 40 of which were exposed to digoxin at time of death. Digoxin use re-
sulted in a substantial SCD risk increase (HR 5.1 95%CI 3.7;7.2). However, there may be 
influence of confounding by the cardiac conditions  (especially heart failure) that are the indi-
cation for digoxin. The hazard ratio decreased to 2.9 (95%CI 2.0;4.1) after adjustment for sex, 
smoking and time dependent age, diabetes, myocardial infarction and heart failure.
In digoxin users, both the C1236T and G2677T variants showed a two-fold increased risk of 
SCD according to a recessive model, with a HR of 2.11 (95%CI 1.03-4.31) and 2.20 (95%CI 
1.08-4.50) respectively (Table 2). Unexpectedly, this effect was absent for the C3435T SNP, 
which results even suggested a protected effect for heterozygotes. However, digoxin users 
homozygous for the 1236-2677-3435 T-T-T haplotype allele also had an increased risk of SCD 
2.36 (95%CI 1.02-5.45). We therefore believe that the observed protective effect for 3435CT 
digoxin users is a chance finding introduced by the small number of cases. Other haplotypes 
were too rare to assess their effect on SCD risk. In the stratum of non-digoxin users, no ef-
fect of ABCB1 on SCD was observed. In the sensitivity analyses restricted to witnessed SCD 
cases, similar effects with slightly higher hazard ratios were found (recessive HR (95%CI) for 
C1236T 2.70 (1.06;6.90), G2677T 2.76 (1.09;6.97) and TTT haplotype 2.94 (0.91;9.49)).
Table 3 QTc difference in msec using a four-level ABCB1 genotype-digoxin use interaction dummy 
variable in a dominant genetic model
QTc increase msec (95% CI) by interaction dummyb
Dummies non-digoxin users Dummies digoxin users
Genotype (Na) Genotype (Na)
C1236T CC (1623) CT + TT (3606) CC (67) CT + TT (148)
Crude Reference 0.1 (-1.1;1.4) -4.9 (-10.1;0.2) -12.6 (-16.1;-9.0)
Full modelc Reference 0.2 (-1.0;1.4) -10.7 (-15.8;-5.6) -18.1 (-21.6;-14.6)
G2677T GG (1497) GT + GT (3445) GG (60) GT + GT (140)
Crude Reference 0.1 (-1.2;1.4) -4.1 (-9.5;1.4) -13.1 (-16.7;-9.4)
Full modelc Reference 0.1 (-1.2;1.3) -9.8 (-15.2;-4.4) -18.9 (-22.5;-15.2)
C3435T CC (1116) CT + TT (4022) CC (54) CT + TT (155)
Crude Reference 0.0 (-1.4;1.4) -4.6 (-10.3;1.1) -12.6 (-16.2;-9.1)
Full modelc Reference 0.2 (-1.2;1.6) -10.1 (-15.7;-4.5) -18.1 (-21.6;-14.6)
TTT vs CGCe CGC-CGC (808) TTT carriers (3206) CGC-CGC (40) TTT carriers (131)
Crude Reference -0.1 (-1.4;1.3) -4.5 (-10.4;1.4) -11.6 (-15.9;-7.3)
Full modelc Reference 0.0 (-1.3;1.3) -10.2 (-16.0;-4.4) -17.0 (-21.1;-12.8)
a Number of unique individuals
b QTc difference in msec. Homozygous major allele group without digoxin is the referent.
c Full model: adjusted for: age, sex, heart failure, myocardial infarction and diabetes mellitus at time of ECG
d Homozygous CGC-CGC subjects are the referent, non-TTT haplotype alleles are entered as dummy variables
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QTc interval duration. In the total study population, ECGs taken while subjects were using 
digoxin showed a shorter QTc interval. The average QTc-interval in digoxin users was 9.5 
(95%CI 6.9;12.1) msec shorter than in non-users. After adjustment for age, sex, heart fail-
ure, diabetes mellitus and myocardial infarction it was 15.7 (95%CI 13.0;18.3) msec shorter. 
Within the stratum of digoxin users, the effect of digoxin dose was 11.2 (95%CI 2.7;19.6) msec 
shortening per 0.5 DDD increase. T-variant carriers in the single SNP analyses and TTT hap-
lotype allele carriers showed increased QTc shortening to digoxin. The effect appeared to be 
in accordance with a dominant genetic model (Figure 1 and Table 3).
We identified 80 persons starting on digoxin between ECGs, 24 persons discontinuing digoxin 
between ECGs and 11 subjects who started and later stopped digoxin therapy during the 
study period. On average, the QTc interval shortening to digoxin in starters and stoppers 
was larger among ABCB1 T-allele and TTT-haplotype allele carriers in a in an allele-dose de-
pendent way (1236 TT –24.9 msec versus CC 0.6 msec p-trend= 0.02, 2677 TT –25.5 msec 
versus GG –1.2 msec p-trend= 0.03, 3435 TT –22.0 versus CC –2.3 msec p-trend= 0.03 and 
TTT-TTT –22.0 msec versus –7.7 msec p-trend =0.17).
Figure 1 QTc change by ABCB1 genotype and digoxin use
QTc change in msec using six-level ABCB1 genotype-digoxin interaction dummy variables. For each SNP, digoxin us-
ers homozygous for the major allele are the referent. For the TTT haplotype, digoxin users homozygous for the CGC 
haplotype are the referent. Black squares indicate non-digoxin users, open squares indicate non-digoxin users. Vertical 
bars indicate 95% confidence intervals.
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Discussion
In the present study, we found a more than two fold increased risk of SCD in digoxin users 
homozygous for the variant alleles of ABCB1 C1236T and G2677T SNPs and the associated 
1236-2677-3435 T-T-T haplotype allele. No increase of SCD risk was seen for digoxin users 
with the ABCB1 C3435T variant nor in non- users of digoxin with ABCB1 variant alleles. The 
interaction of ABCB1 and digoxin was further confirmed by its influence on the QTc shortening 
properties of digoxin on ECG.
Digoxin is a known substrate of ABCB1.However, most studies on the effect of ABCB1 SNPs 
on digoxin kinetics were small and the results were not unequivocal.12. As we previously dem-
onstrated, ABCB1 variants are associated with increased serum digoxin concentrations, as 
well as with an increased risk of concentrations exceeding the therapeutic range in chronic 
users in the Rotterdam Study.13 In addition, some studies suggest that even higher digoxin 
serum concentrations that are still within the generally accepted therapeutic range may in-
crease mortality.5 ABCB1 variant allele carriers might therefore be more susceptible to digoxin 
intoxication and to its pro-arrhythmogenic effects, explaining the observed interaction of AB-
CB1 variants on SCD risk in digoxin users. The fact that we do not see a clear effect for the 
C3435T variant can be explained both by lack of power and our previous observation that 
(at least in our population) this variant showed the weakest association with digoxin serum 
concentration.13 Also, because of its higher minor allele frequency, the C3435T variant oc-
curs more often in haplotypes lacking the other two SNPs and a previous study shows that 
the C3435T variant only results in altered ABCB1 function in combination with one of the 
other two variants.37 Since we previously observed an additive effect of ABCB1 T-alleles on 
digoxin concentration, it is striking that the effect of ABCB1 on SCD appears to fit a recessive 
genetic model, whereas the effect on QTc follows a dominant pattern. A possible explana-
tion is that different threshold digoxin concentrations may be needed for the different digoxin 
effects. Digoxin induced SCD may occur beyond a certain threshold concentration which is 
only reached in homozygous subjects resulting in an apparent recessive model. The effect of 
digoxin concentration on QTc shortening may already occur at a lower serum concentration 
and be limited to a maximum effect size resulting in an apparent dominant effect.
One major advantage in our study was the availability of up to four ECGs per subject at regu-
lar intervals during follow-up, resulting in more precise and unbiased long-term ECG mea-
sures. Furthermore, the use of digital ECG recordings all measured using the MEANS system 
likely reduced differential misinterpretation of the QTc interval. In addition, the intersection of 
the Rotterdam Study with detailed pharmacy exposure data allowed us not only to determine 
digoxin use at time of ECG or death, but also to exclude ECGs recorded in individuals on QT 
prolonging drugs, which could have attenuated the power to detect the association. Although 
no information on short QT syndrome cases was available, this is a rare condition and the 
number of relatives in the Rotterdam Study is low, the cohort is of older age and these syn-
dromes are not known to be linked to ABCB1 variants, which makes this an unlikely explana-
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tion for our results. Another advantage of the Rotterdam Study is the prospective ascertain-
ment of risk factors and the active surveillance for SCD events over a relatively long period of 
follow-up. Thus, extensive information surrounding SCD events was available, including the 
time between start of symptoms and death, enabling rigorous adjudication of SCD events.
The prospective design of the Rotterdam Study limits chances of selection or information bias 
and the multivariate models show that confounding is probably limited. However, although we 
stratified on digoxin use and so far ABCB1 is not known to be associated with atrial fibrillation, 
cardiovascular disease or heart failure, we cannot fully exclude confounding by the underlying 
disease. However, the results from the ECG analyses make an effect of the underlying dis-
ease less likely as heart disease is associated with increased QTc duration while we observe 
more QTc shortening to digoxin in ABCB1 variant carriers. One limitation of the study resides 
in the small number of exposed SCD cases. However, despite the limited power we still find a 
more than two-fold increase of SCD in subjects homozygous for the ABCB1 variants in digoxin 
users. Another limitation lies in the variety of competing causes of abrupt death at increasing 
age, which may have led to misclassification of SCD events, especially in cases where death 
was unwitnessed. Since SCD coding was blinded to ABCB1 genotype, this would likely have 
biased our study toward the null hypothesis that no effect exists. The stronger effect on SCD 
in analyses restricted to witnessed SCD lends some support to this hypothesis.
In conclusion, we found a two fold increased risk of SCD in digoxin users homozygous for the 
ABCB1 C1236T, G2677T SNPs and the 1236-2677-3435 T-T-T haplotype allele. In addition, 
T-allele or TTT-haplotype allele variant carriers showed increased QTc shortening to digoxin. 
This is consistent with our previous finding that these common variants are associated with 
increased digoxin serum concentrations.13 If this association can be reliably replicated, testing 
for ABCB1 variants might further increase safe use of digoxin.
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3.3
ABCB1 (MDR1) gene polymorphisms are associated 
with neuropsychiatric adverse effects of mefloquine
Abstract
Background. Mefloquine, a drug used for treatment and prophylaxis of malaria, is known for 
its neuropsychiatric adverse effects. We hypothesized that neuropsychiatric adverse effects 
of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for 
the efflux pump P-glycoprotein.
Methods. The association between MDR1 C1236T, G2677T and C3435T single nucleotide 
polymorphisms (SNPs) and the occurrence of neuropsychiatric adverse effects were exam-
ined in a prospective cohort study of 89 healthy white travellers taking mefloquine. 
Results. Of the subjects, 27 (28%) reported neuropsychiatric adverse effects, women sig-
nificantly more frequently than men. Allele frequencies of the C1236T, G2677T and C3435T 
polymorphisms were similar to those found in other white populations and there was no signifi-
cant association between any of the individual polymorphisms and neuropsychiatric adverse 
effects. However, 1236TT, 2677TT and 3435TT women had a higher risk of neuropsychiatric 
adverse effects than the reference groups of women with heterozygous and homozygous CC 
or GG genotypes with odds ratios of 6.3 (95% CI 1.1;36.9), 10.5 (95% CI 1.1;100.6) and 5.4 
(95% CI 1.1;30.0), respectively. The association for women homozygous for the 1236-2677-
3435 TTT haplotype was even stronger (p= 0.004) than the effect of any of the individual 
polymorphisms. No associations with mefloquine blood levels were observed.
Conclusion. In this study, the MDR1 1236TT, 2677TT and 3435TT genotypes along with 
the 1236-2677-3435 TTT haplotype were associated with neuropsychiatric adverse effects of 
mefloquine in women. MDR1 polymorphisms may play an important role in predicting the oc-
currence of neuropsychiatric adverse effects of mefloquine, particularly in female travellers.
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Introduction
The quinolone derivative mefloquine is widely used in the treatment and prophylaxis of malar-
ia in travellers to areas with chloroquine-resistant falciparum malaria. It has gained popularity 
because of its weekly dosing regimen. In the past decade, however, a number of case reports 
and studies on severe neuropsychiatric adverse effects of mefloquine have been reported.1-3 
Two main classes of neuropsychiatric adverse effects have been attributed to mefloquine: 
type I effects, consisting of mild neuropsychiatric events such as dizziness, dysphoria, light-
headedness and concentration problems occurring within 6 hours after intake and usually 
resolving quickly in the following days; and type II effects, including severe neuropsychiatric 
disorders such as acute psychosis with agitation or depression.1, 3 Risk factors identified so 
far include history of seizures or psychiatric disorders, female gender and low body mass 
index (BMI).4, 5 It has been suggested that the distribution volume or blood concentration of 
mefloquine plays a role, although no clear association between mefloquine blood level and 
neuropsychiatric adverse effects could be demonstrated.5, 6
P-glycoprotein (P-gp) is a product of the Multi Drug Resistance 1 gene/ATP-binding cassette 
B1 (MDR1/ABCB1), located on chromosome 7p21, and plays a role in the uptake and distribu-
tion of mefloquine. P-gp is an efflux pump for various toxins and drugs and is expressed in the 
intestine (regulating uptake into the systemic circulation) and the blood-brain barrier (affecting 
exposure to the brain).7, 8 Mefloquine is a substrate for P-gp, but it is also an inhibitor of P-gp 
function.9 A number of single nucleotide polymorphisms (SNPs) have been found to be associ-
ated with decreased P-gp expression and function,7, 8, 10, 11 the most intensively studied SNPs 
being C1236T, G2677T/A and C3435T.
We examined the association between the MDR1 SNPs C1236T, G2677T and C3435T and 
neuropsychiatric adverse effects in a subgroup of a cohort of mefloquine users previously 
studied to assess neuropsychiatric effects of mefloquine to determine whether MDR1 geno-
type is associated with adverse effects.
Patients and methods
Study population. We performed a genetic re-analysis in a subgroup from a prospective 
cohort of mefloquine users previously studied to assess the neuropsychiatric effects of meflo-
quine.2, 4 In brief, during a 1-year study period, we recruited subjects who received a prescrip-
tion for mefloquine (baseline) for malaria prophylaxis at the Travel Clinic at the Institute for 
Tropical Diseases in the Harbour hospital, in the Rotterdam area in the Netherlands. Subjects 
with one or more contraindications for mefloquine or subjects who used mefloquine in the 
preceding two months or who had risk factors for concentration impairment (e.g. use of opi-
oids, hypnotics or tranquilizers during the two weeks before testing or use of alcohol 4 hours 
before testing) were not included in the study. For the genetic analyses we further excluded 
subjects who refused to undergo blood sampling or who did not take 3 tablets of mefloquine 
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between baseline and follow-up. Subjects were followed from the time of prescription until the 
follow-up visit at 3-4 weeks (i.e. after 3 doses of mefloquine), but always before departure to 
the travel destination. All subjects received mefloquine in a dosage of 250 mg once a week. 
After consent was obtained to perform neuropsychiatric testing, report adverse events and 
provide blood, all personal identification was deleted from the data. Therefore, it was not pos-
sible to obtain further consent for this specific analysis, which was not foreseen at the time 
of sampling. The medical ethical committee gave permission for the genetic reanalysis of de 
de-identified data from the previously approved study. 
Genotyping. Genomic DNA was isolated from whole EDTA blood by use of a total nucleic 
acid extraction kit (Roche, Basel, Switzerland) on a MagnaPure LC (Roche) according to 
the manufacturer’s recommendations. Polymerase chain reaction (PCR)-restriction fragment 
length polymorphism (RFLP) assays were performed by use of 5 ng of genomic DNA in a PCR 
volume of 25 µl containing 1x buffer (10 mmol/l Tris-HCl, pH 8.3; 1.5 mmol/l MgCl2; 50 mmol/l 
KCl, and 0.001% [wt/vol] gelatin [Perkin-Elmer, Wellesley, Mass]), 0.2 mol/l each of the de-
oxynucleotide triphosphates (Roche), 1.25 U of AmpliTaq Gold (Perkin-Elmer), and 40 pmol of 
each forward and reverse primer. For the C1236T polymorphism, forward primer 5’-CCT GAC 
TCA CCA CAC CAA TG-3’ and reverse primer 5’-TAT CCT GTG TCT GTG AAT TGC C-3’ were 
used. PCR conditions were 7 min at 940C, followed by 35 cycles of 1 min at 940C, 1 min at 
550C, and 1 min at 720C, and a final incubation of 7 min at 720C. The 370 bp PCR product was 
digested with HaeIII. For the G2677T polymorphism, forward primer 5’-TAG TTT GAC TCA 
CCT TCC CGG-3’ and reverse primer 5’-GGC TAT AGG TTC CAG GCT TG-3’ were used (the 
underlined and in bold nucleotide is a mismatch with the MDR1 sequence, creating a restric-
tion site in the PCR product). PCR conditions were 7 min at 940C, followed by 35 cycles of 1 
min at 940C, 1 min at 570C, 1 min at 720C; and a final incubation of 7 min at 720C. The 218 bp 
PCR product was digested with BanI (New England Biolabs). For the C3435T polymorphism 
we used primers and PCR conditions and digestion as described previously.12 All PCR diges-
tion products were analyzed on agarose/Trisborate-EDTA gels with ethidium bromide.
Outcome assessment. The primary outcome was neuropsychiatric adverse effects using 
a broad definition that included type I complaints such as dizziness, nausea and sleeping 
problems.1, 3 Subjects were asked to report the occurrence of adverse effects on the diary 
sheet used in previous studies.2, 4 The diary sheet contained one question on adverse effects, 
with an open-ended follow-up question: ‘Did you experience any adverse event(s) while us-
ing mefloquine? If yes what kind of adverse event(s)?’ The answer to the question was only 
filled out if the subject had symptoms. Not returning the diary sheet or questionnaires was an 
exclusion criterion. Two independent physician-assessors classified reported adverse events 
as being neuropsychiatric or not. All classification was performed with blinding to genotype. 
We recorded neuropsychiatric side effects as present (‘yes’) or absent (‘no’) regardless of the 
number or severity of reported events.
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In addition to the diary sheets, neuropsychiatric testing was performed at baseline and at the 
end of follow-up. We measured the intra-individual change in score of the Total Mood Dis-
turbance (TMD), based on the validated Dutch shortened Profile Of Mood States (POMS).13 
The POMS is a standardised questionnaire, used to measure subjective mood. It contains 
32 questions on 5 domains of feelings: tension, anger, depression, fatigue and vigor. The 
answers are graded on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The TMD 
is an overall score, calculated by summing the raw scores and subtracting the score for vigor. 
The calculated TMD ranges from –20 to 108. An increase in TMD reflects an impaired mood 
state.
We measured the intra-individual change in hand-eye coordination, coding speed and sus-
tained attention (Continuous Performance Test (CPT)), which are domains of the validated 
Neurobehavioral Evaluation System (NES). The NES is a series of computerized tests to pro-
vide quantitative neurobehavioural outcomes.14, 15 A negative value in CPT, hand-eye coordi-
nation or coding speed indicates an increase in reaction time between the two measurements. 
Neuropsychiatric tests were not always performed at the same time of day and subjects were 
not restricted from smoking or drinking tea or coffee before testing.
Finally, we measured the serum concentration of mefloquine and its main carboxylic acid 
metabolite in blood samples collected at the end of follow-up. Fresh blood samples were cen-
trifuged for 10 minutes (3000 rpm) within 30 minutes after collection. Serum was separated 
and stored at -200C until analysis. Concentrations were measured by a standardized HPLC 
method. The method used reversed-phase chromatography on a Xterra RP C18 column (5 
µm; Waters, Milford, Mass). The mobile phase consisted of 40% acetonitrile in 50 mmol/l so-
diumphosphate buffer pH 3.1. Quantification was accomplished with 2,8-bis(trifluoromethyl)-
4-quinolinemethanol as the internal standard.16 Calibration was done by calculating weighted 
linear regression from peak height ratios versus nominal concentration. Mefloquine and me-
tabolite quality-control serum specimens were analyzed at concentrations of 50, 100, 200, 
500, 1000 and 3000 ng/ml. The lower limits of quantification of mefloquine and metabolite 
were 50 ng/ml.
Covariates. All data on demographics, weight, height, previous use of mefloquine and long-
term co-morbidity were gathered by use of a questionnaire at baseline. In addition, the time 
interval between last mefloquine dosing and follow-up visit was recorded. Body Mass Index 
(BMI) was calculated by dividing weight (in kg) by height (in squared meters).
Statistical analysis. Statistical analyses were carried out by use of SPSS for Windows, ver-
sion 11 (SPSS, Chicago, Ill). We used standard descriptive statistics to describe population 
characteristics and outcome data. Comparisons between men and women were conducted 
by means of Student’s t-tests or Chi square tests. Genotype frequency was tested against the 
Hardy-Weinberg equilibrium.
After crude odds ratios (ORs) for neuropsychiatric effects in the different genotype groups of 
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the SNPs were calculated, we decided on the genetic model (recessive, dominant or dose-
effect) based on the results. Multivariate analysis was performed using a binary logistic re-
gression model. Logistic regression analysis was chosen because time played no role in this 
study. Confounders were defined as covariates associated with neuropsychiatric effects at a 
p-value of 0.1 and changing the point estimate by 10% or more. Mefloquine concentration was 
tested as an intermediate by including it into the model as a covariate. In a second step, we 
identified effect modification by age, gender, BMI and previous mefloquine use by introducing 
interaction terms and stratified on these factors when statistically significant. Because the co-
hort size is limited and the outcome is frequent, in contrast to traditional case-control studies, 
ORs cannot be interpreted as relative risks.
Linear regression analysis was used to study the associations of the changes in scores on 
the neuropsychiatric tests and mefloquine concentrations with the genotypes, haplotypes and 
covariates. Time since last mefloquine dose was included in the model. Testing of confound-
ers was similar to that for the logistic regression model. A trend test for an allele dose-effect 
relation of the SNP variants was obtained with the number of variant alleles entered as an 
ordered categorical variable. 
Haplotypes were constructed using the program PHASE version 2.0.17, 18 Linkage disequilib-
rium was computed using the Haploview software version 3.11.19
Results
Of the 151 subjects available,4 89 subjects (48 males and 41 females) with a mean age of 40 
years, had blood samples available. The other 62 subjects refused to give a blood sample. All 
subjects included in the final cohort were white persons of European origin. General charac-
teristics of the study population are presented in Table 1. Women had a significantly lower BMI 
compared with men (p= 0.02). Of all subjects, 37% had previously used mefloquine (Table 1). 
The concomitant use of drugs was higher in women than in men but this difference was mainly 
explained by 9 women who only used an oral contraceptive. One subject used a known P-gp 
inducer (acitretin, a synthetic retinoic acid analog) and one used a known P-gp inhibitor (ator-
vastatin). The prevalence of comorbidity was low (n=13) and included, among others, skin 
problems (n=2) and hypertension and other cardiovascular disease (n=5). The time interval 
since administration of the last mefloquine dose to follow-up ranged from 0 days (i.e., same 
day) to 7 days (i.e., just before fourth dose), with a median of 2 days.
Prevalence of SNPs. Frequencies of all three SNPs were consistent with other studies in 
Caucasian populations. For the C1236T the frequencies were CC 29.8%, CT 50.0% and 
TT 20.2%, for the G2677T they were GG 31.8%, GT 51.1%, TT 17.0% and for the C3435T 
polymorphism CC 22.6%, CT 51.2%, TT 26.2%.7, 20, 21 Genotyping failed in 5 subjects(5.6%), 1 
subject (1.1%) and 5 subjects (5.6%) respectively. All SNPs were in Hardy-Weinberg equilib-
rium with p= 0.8 for C3435T, p= 0.7 for G2677T and p= 0.9 for C1236T. The C1236T, G2677T 
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and C3435T SNPs were found to be in linkage disequilibrium. D’ for C3435T-G2677T was 
0.87, for C3435T-C1236T and G2677T-C1236T it was 0.83 and 0.95 respectively. Construc-
tion of haplotypes, via estimation maximization, resulted in two frequent (1236-2677-3435 
CGC and TTT) and four minor haplotypes; the other two theoretically possible haplotypes 
were not found in this population. Frequencies of the different haplotypes were: 1236-2677-
3435 CGC 45.5%, TTT 38.6%, TTC 2.8%, CGT 9.1%, TGT 2.8% and CTT 1.1%.
Neuropsychiatric adverse effects. During the study period, 16 women (39.0%) and 9 men 
(18.8%) reported neuropsychiatric complaints. The most frequently reported adverse effects 
were insomnia or abnormal dreams (or both) (n= 10), fatigue (n= 8), headache (n= 8), dizzi-
ness (n= 5) and agitation, emotional instability or depression (n= 5). Women reported signifi-
cantly more neuropsychiatric complaints then men (p = 0.03) and a higher change in TMD 
score (p =0.03) (Table 1).
SNPs and neuropsychiatric adverse effects. On the basis of the genotype-specific results 
we decided to use a recessive model for further analyses. There was no significant associa-
tion between any of the SNPs and neuropsychiatric adverse effects in the combined analyses. 
In the gender-stratified analyses, women homozygous for the TT-variant of any of the three 
SNPs had a significantly higher risk of adverse effects from mefloquine than the reference 
groups (i.e., the combined groups of CT and CC [for C1236T and C3435T] or GT and GG 
[for G2677T]), with ORs of 6.3, 10.5 and 5.4 for C1236T, G2677T and C3435T, respectively 
(Table 2). In men, no significant association with these SNPs was seen. Although the interac-
tion term for previous use was not significant, we stratified on previous use to explore potential 
Table 1 General characteristics of the study population and comparisons between males and females
Characteristic Males (n=48) Females (n=41)
Age (years) mean, range 41.0 (21 – 68) 38.2 (18 – 59)
BMI (kg/m2)ab 24.7 (19.0 - 33.0) 23.1 (18.3 - 31.3)
≤ 25 28 (59.6 %) 31 (75.6 %)
> 25 19 (40.4 %) 10 (24.4%)
Smokers 13 (27.1 %) 13 (31.7 %)
Concomitant drug 7 (14.6 %) 15 (36.6 %)
Previous mefloquine users 21 (43.8 %) 12 (29.3%)
Neuropsychiatric adverse events 9 (18.8 %) 16 (39.0 %)
Delta TMDb -0.4 (-13 – 21) 5.3 (-16 – 48)
Delta hand-eye coordination (log RMSE)b -0.19 (-0.64 – 1.04) -0.23 (-0.69 – 0.55)
Mefloquine blood level (μg/ml)b 0.59 (0.31 - 1.14) 0.75 (0.37 - 1.51)
Statistically significant differences between males and females are printed in bold (p ≤ 0.05), BMI: Body Mass Index, 
TMD: Total Mood Disturbance
a Numbers do not add up due to missing data on weight and height.
b Mean, range
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confounding by contraindication. This revealed that the higher risks for adverse effects in the 
TT genotypes for the three SNPs was predominant in new users of mefloquine (results not 
shown). There was no effect modification by age or BMI. In multivariate analyses, no signifi-
cant confounders were identified. Forcing age or BMI into the model resulted in only minor 
changes of the estimates. When mefloquine concentration was tested in the model as an 
intermediate this did not diminish the genotype effect.
Haplotypes and neuropsychiatric adverse effects. In the haplotype-based analyses, the 
homozygous 1236-2677-3435 TTT genotype showed a higher risk of neuropsychiatric ad-
verse effects (OR 4.5, 95% CI 1.3;16.0) than was found in the reference group containing all 
other combinations of haplotypes (Table 3). This risk was higher than in any of the individual 
SNPs. Further stratification for gender resulted in a significantly higher risk for 1236-2677-
3435 TTT-TTT women (p= 0.004; OR could not be calculated as all women homozygous for 
the TTT-variant had neuropsychiatric adverse effects). Again, we did not find a significant as-
sociation in men. Being infinite, the OR for the TTT-TTT genotype in women was also higher 
than the OR for any of the individual SNPs.
SNPs and neuropsychiatric tests. We found no significant association between any of the 
neuropsychiatric tests and individual SNPs or haplotypes. However, increases in TMD values 
tended to be higher in subjects with TT-genotypes and those with homozygous TTT hap-
lotypes than in the reference groups. This was most distinct for the C1236T and C3435T 
SNPs, with scores of 1.6 in the 1236CC/CT group, 6.0 in the 1236TT group (p= 0.18), 1.0 in 
the 3435CC/CT group and 5.1 in the 3435TT group (p= 0.17). On the hand eye coordination 
test, subjects with TT-genotypes and those with homozygous TTT haplotypes showed less 
improvement (i.e. less learning effect) than the reference groups. Again this effect was most 
obvious in the C1236T and C3435T SNPs (p= 0.16 and p= 0.09, respectively).
Forcing in age and BMI in the multivariate model did not significantly alter the results. No dif-
ferences in coding speed and continuous performance were observed between the T-variants 
and other variants of the three SNPs.
Given the SDs of the tests and the frequencies of the SNPs and haplotypes, the smallest dif-
ference (irrespective of the direction of the difference) between groups that we were able to 
detect with 90% power was 9.7 for change in TMD (largest true difference, 4.4). For change in 
hand-eye-coordination it was 0.239sec (largest true difference, 0.122sec).
SNPs and mefloquine serum concentrations. Serum concentrations of mefloquine and its 
carboxylic metabolite were on average 0.67 μg/ml and 1.35 μg/ml. Women had significantly 
higher concentrations of the unchanged form (p=0.001). There was no association between 
serum concentrations of mefloquine or its metabolite and any of the investigated MDR1 SNPs 
(Table 4). In addition we did not observe an association of serum levels with neuropsychiatric 
adverse effects.
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For the largest observed difference in mefloquine concentration, found in women homozy-
gous for the TTT haplotype (0.171 μg/ml), the minimal difference (irrespective of the direction) 
to be identified with 90% power was 0.359 μg/ml.
Discussion
In this study, the C1236T, G2677T and C3435T MDR1 polymorphisms were identified as risk 
factors for neuropsychiatric adverse effects in female mefloquine users. A haplotype-based 
analysis showed even more pronounced results. 
Mefloquine is a substrate for the MDR1 multidrug transporter and is expressed in the gut 
where it may play a role in the uptake of the drug, as well as in the liver where it is involved in 
the excretion of mefloquine in the bile.8 Although our data on serum concentration should be 
cautiously interpreted because of differences in sampling time, we were not able to demon-
strate an association of the three MDR1 SNPs with mefloquine or metabolite concentrations 
and, as in literature reports, found no association between adverse effects of mefloquine and 
serum concentration.5, 6
Given that mefloquine, unlike its carboxylic acid metabolite, is able to cross the blood-brain 
barrier22 and P-gp is expressed in the blood-brain barrier,8 MDR1 expression could modify the 
local mefloquine brain tissue concentration. Our finding that mefloquine serum concentration 
was not an intermediate in the association between genotype-haplotype and neuropsychiat-
ric effects may further support this hypothesis. This might explain the association we found 
between the T-variants of the MDR1 polymorphisms and the occurrence of neuropsychiatric 
Table 4 Mefloquine serum concentrations (μg/ml) by gender and genotype
Males Females
Genotype μg/ml t-test p-value μg/ml t-test p-value
C1236T
CC/CT 0.611 0.229 0.728 0.076
TT 0.518 0.889
G2677T
GG/GT 0.608 0.260 0.736 0.115
TT 0.523 0.894
C3435T
CC/CT 0.597 0.678 0.731 0.166
TT 0.568 0.846
Haplotype
non TTT-TTT 0.604 0.314 0.739 0.114
TTT-TTT 0.520 0.910
Interpretation of mefloquine serum concentrations is complicated by differences in sampling time on the pharmacoki-
netic curve, resulting in non-steady state measurements
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adverse effects of mefloquine: a lower expression of P-gp will result in lower mefloquine ef-
flux from the brain, thus exposing it to higher tissue concentrations. Similar effects of MDR1 
polymorphisms have recently been shown for other drugs.23, 24
The effect of MDR1 SNPs on neuropsychiatric functioning was almost exclusively found in 
women. We cannot exclude that this difference is explained by a greater awareness of dis-
turbances in neuropsychiatric functioning by women. The fact that a greater vulnerability to 
neuropsychiatric effects in women than in men when taking mefloquine is genuine was dem-
onstrated in a double-blind placebo-controlled trial comparing atovaquone plus chloroguanide 
(INN, proguanil) with mefloquine.25 Possibly, a higher serum concentration (Table 1) of meflo-
quine in combination with a lower basal expression of MDR126 makes women more suscep-
tible to the subtle effects of MDR1 polymorphisms on its expression and functioning.
In line with several other studies, strong associations were found for the C3435T SNP,7, 11, 
23, 24, 27-29 although some other studies suggested an opposite or absent effect of this poly-
morphism.10, 30-33 C3435T and the C1236T are synonymous SNPs, which do not result in an 
amino acid change in P-gp. A recent study showed that the C3435T T-variant affects mRNA 
stability,34 which might result in lower P-gp expression. This might explain the association of 
the C3435T as a causal SNP for neuropsychiatric adverse effects. However, we found that 
the association of the 2677TT genotype with neuropsychiatric adverse effects was the stron-
gest of the three individual SNPs, suggesting also a causal role for this amino acid changing 
(Ala893Ser) SNP. Furthermore, the association of the TTT-TTT haplotype with adverse effects 
was even stronger than with the 2677TT genotype alone. This could be a result of an addi-
tive effect of the G2677T and the C3435T SNPs. In addition, it cannot be excluded that other, 
unknown causal SNPs associated with the 1236-2677-3435 TTT haplotype might play a role 
in the association with neuropsychiatric adverse effects.
A possible limitation of the study is the limited number of subjects. Especially after stratifica-
tion, the numbers in the different genotype groups became small which increases the risk of 
a false-positive result. The small number of subjects, in combination with large SDs, also re-
sulted in low power, which might explain why no significant association with neuropsychiatric 
tests or mefloquine concentration was found. A second limitation may reside in the subjective 
reporting of our main endpoint. However, because the reporters were unaware of their geno-
type, this could not have biased our results. The fact that the objective neuropsychiatric tests 
were not very strongly correlated with the adverse effects might be because the tests are 
restricted to specific domains of brain function, whereas adverse effects are not. Furthermore, 
in our previous study using the larger cohort a significant association of adverse effects with 
TMD was seen.2 In addition, results from the neuropsychiatric tests suggested impairment 
during mefloquine use and endorse the observed association with neuropsychiatric adverse 
effects. Because the MDR1 C1236T, G2677T and C3435T polymorphisms are randomly dis-
tributed among the population at birth and are not known to be associated with the outcomes 
or covariates, no strong confounding effects or selection bias is expected to affect the as-
sociation. However, the theoretical possibility of an association between MDR1 variants and 
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neuropsychiatric events independent of mefloquine use cannot be entirely excluded in our 
study of mefloquine users. Finally, in different ethnic groups other SNPs may be linked with 
the 1236-2677-3435 haplotypes and frequencies of the different SNPs and haplotypes may 
differ. It is therefore unknown whether the results from this study can be generalized to other 
ethnic groups.
In conclusion, we found that the MDR1 C1236T, G2677T and C3435T SNPs, along with the 
C1236T-G2677T-C3435T TTT haplotype, were associated with neuropsychiatric adverse ef-
fects to mefloquine in women. MDR1 polymorphisms may therefore play an important role in 
predicting the occurrence of neuropsychiatric adverse effects of mefloquine, particularly in 
female subjects.
70
Chapter 3.3
70
References
van Riemsdijk MM, van der Klauw MM, Pepplinkhuizen L, et al. Spontaneous reports of psychiatric adverse effects 1. 
to mefloquine in the Netherlands. Br J Clin Pharmacol 1997;44(1):105-6.
van Riemsdijk MM, Ditters JM, Sturkenboom MC, et al. Neuropsychiatric events during prophylactic use of meflo-2. 
quine before travelling. Eur J Clin Pharmacol 2002;58(6):441-5. Epub 2002 Jul 27.
Barrett PJ, Emmins PD, Clarke PD, et al. Comparison of adverse events associated with use of mefloquine and 3. 
combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. 
Bmj 1996;313(7056):525-8.
van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Low body mass index is associated with an increased risk 4. 
of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 
2004;57(4):506-12.
Schwartz E, Potasman I, Rotenberg M, et al. Serious adverse events of mefloquine in relation to blood level and 5. 
gender. Am J Trop Med Hyg 2001;65(3):189-92.
Schlagenhauf P, Steffen R, Lobel H, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event 6. 
assessments, stereochemistry and compliance. Trop Med Int Health 1996;1(4):485-94.
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: 7. 
multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc 
Natl Acad Sci U S A 2000;97(7):3473-8.
Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical 8. 
relevance. Clin Pharmacol Ther 2004;75(1):13-33.
Riffkin CD, Chung R, Wall DM, et al. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial 9. 
drug mefloquine. Biochem Pharmacol 1996;52(10):1545-52.
Morita Y, Sakaeda T, Horinouchi M, et al. MDR1 genotype-related duodenal absorption rate of digoxin in healthy 10. 
Japanese subjects. Pharm Res 2003;20(4):552-6.
Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of 11. 
digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72(2):209-19.
Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and 12. 
MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 
2003;74(3):245-54.
Wald fdm, Mellenbergh gj. De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS). 13. 
Nederlands Tijdschrift voor de Psychologie 1990;45:86-90.
Baker EL, Letz R, Fidler A. A computer-administered neurobehavioral evaluation system for occupational and envi-14. 
ronmental epidemiology. Rationale, methodology, and pilot study results. J Occup Med 1985;27(3):206-12.
Letz R. Use of computerized test batteries for quantifying neurobehavioral outcomes. Environ Health Perspect 15. 
1991;90:195-8.
Green MD, Bergqvist Y, Mount DL, et al. Improved validated assay for the determination of mefloquine and its 16. 
carboxy metabolite in plasma, serum and whole blood using solid-phase extraction and high-performance liquid 
chromatography. J Chromatogr B Biomed Sci Appl 1999;727(1-2):159-65.
Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am 17. 
J Hum Genet 2001;68(4):978-89.
Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population geno-18. 
type data. Am J Hum Genet 2003;73(5):1162-9.
Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 19. 
2005;21(2):263-5.
Gerloff T, Schaefer M, Johne A, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 20. 
mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54(6):610-6.
Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 21. 
(MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13(8):481-94.
Baudry S, Pham YT, Baune B, et al. Stereoselective passage of mefloquine through the blood-brain barrier in the 22. 
71
ABCB1 (MDR1) gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine
71
rat. J Pharm Pharmacol 1997;49(11):1086-90.
Babaoglu MO, Bayar B, Aynacioglu AS, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic 23. 
efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 2005;78(6):619-26.
Skarke C, Jarrar M, Schmidt H, et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on dispo-24. 
sition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003;13(11):651-60.
van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Atovaquone plus chloroguanide versus mefloquine for 25. 
malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 2002;72(3):294-301.
Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human 26. 
liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995;275(2):1011-8.
Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and 27. 
more rapid virologic response in HIV-1 infected children. Aids 2005;19(4):371-80.
Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein 28. 
MDR1 gene. Clin Pharmacol Ther 2002;72(5):584-94.
Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J 29. 
Clin Pharmacol 2003;58(12):809-12. Epub 2003 Mar 1.
Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 30. 
transport activities. Biochem Pharmacol 2003;65(11):1843-52.
Siegmund W, Ludwig K, Giessmann T, et al. The effects of the human MDR1 genotype on the expression of duode-31. 
nal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002;72(5):572-83.
Pauli-Magnus C, Feiner J, Brett C, et al. No effect of MDR1 C3435T variant on loperamide disposition and central 32. 
nervous system effects. Clin Pharmacol Ther 2003;74(5):487-98.
Chowbay B, Li H, David M, et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin phar-33. 
macokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005;60(2):159-71.
Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects 34. 
mRNA stability. Pharmacogenet Genomics 2005;15(10):693-704.
72
73
4
Common variants in the NOS1AP gene
74
75
75
4.1
Common NOS1AP variants are associated with a
prolonged QTc interval in the Rotterdam Study
Abstract 
Background. QT prolongation is an important risk factor for sudden cardiac death (SCD). 
About 35% of QT interval variation is heritable. In a recent genome-wide association study, 
a common variant (rs10494366) in the Nitric Oxide Synthase 1 Adaptor Protein (NOS1AP) 
gene was found to be associated with QT-interval variation. We tested for association of two 
NOS1AP variants with QT duration and SCD.
Methods. The Rotterdam Study is a population based, prospective cohort study of individuals 
≥ 55 years of age. The NOS1AP variants rs10494366 T>G and rs10918594 C>G were geno-
typed in 6571 individuals. Heart rate corrected QT interval (QTc) was determined with ECG 
analysis software on up to three digital ECGs per individual (total 11,108 ECGs from 5374 
individuals). The association with QTc duration was estimated with repeated-measures analy-
ses and the association with SCD was estimated by Cox proportional-hazards analyses.
Results. The rs10494366 G-allele (36% frequency) was associated with a 3.8 msec (95%CI 
3.0;4.6, p= 7.8x10-20) increase in QTc-interval duration for each additional allele copy, and the 
rs10918594 G-allele (31% frequency) with 3.6 msec (95%CI 2.7;4.4, p= 6.9x10-17) increase 
per additional allele copy. None of the inferred NOS1AP haplotypes showed a stronger effect 
than the individual SNPs. There were 233 sudden cardiac deaths over 11.9 years median 
follow-up. No significant association was observed with SCD risk.
Conclusions. Common variants in NOS1AP are strongly associated with QT-interval duration 
in an elderly population. Larger sample sizes are needed to confirm or exclude an effect on 
SCD risk.
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Introduction
Sudden cardiac death (SCD) claims 300,000 lives annually in the US.1 While certain high-risk 
groups have been identified,2 most SCD occurs in individuals unrecognized to be at risk.3
Familial aggregation of SCD suggests a substantial contribution of genetic variation to SCD 
risk,4-7 but Mendelian mutations identified to date individually explain little of the population 
burden of SCD.8, 9 Until recently the search for sequence variants contributing to SCD risk has 
been restricted to candidate genes known for their role in arrhythmogenesis.10 The recent de-
velopment of large SNP databases,11 genotyping arrays of great accuracy and genome wide 
coverage of common variation,12 together with analytical methods,13 has enabled unbiased 
surveys of most of the common variation in the human genome. Still, the relatively small size 
of existing SCD collections and etiologic heterogeneity limit the statistical power to detect 
causal variants; therefore, initial attention has focused on quantitative SCD risk factors in 
large cohorts.
The electrocardiographic QT interval is a non-invasive measure of ventricular repolarization. 
About 35% of the variation in QT interval duration in unselected community-based samples 
is heritable.14, 15 Mendelian congenital long- and short QT syndromes (LQTS, SQTS) are both 
characterized by SCD from ventricular arrhythmias. Moreover, non-syndromal long QT in-
terval16-19 and short QT interval20 impart increased risk of SCD in unselected populations. In 
addition, medication-induced prolonged QT interval and ventricular arrhythmias have led to 
the withdrawal of many non-cardiac medications,21 making the QT interval an important phe-
notype to study.
Previously, we identified a locus on chromosome 3 with suggestive evidence of linkage to 
QT interval duration, but the genomic interval was large and the finding remains to be con-
firmed.15 More recently, Arking et. al.22 reported the finding from a genome-wide association 
study that a common variant (rs10494366, minor allele frequency 38%) in the NOS1AP gene 
was reproducible associated with QT interval variation in several large population samples. 
The NOS1AP gene, encoding the Nitric Oxide Synthase 1 Adaptor protein, has been found to 
regulate neuronal nitric oxide synthase (NOS1) activation23 and to enhance Dexras1 activa-
tion by NOS1 through a ternary complex.24 NOS1 knockout mice have been found to have 
altered cardiac contractility suggesting a role for NOS1AP in cardiac depolarization.25-27 Fur-
thermore, NOS1AP is capable of interaction with ion channels through its PDZ domain.28-30 
Nevertheless, the involvement of NOS1AP in myocardial repolarization was not known until 
the initial report of the association.
The impact of NOS1AP variants on QT-interval duration in older populations, in whom non-
genetic factors might play a stronger role than heritable factors, is unknown.
The goal of the present study was to test for association of the NOS1AP variant with QT dura-
tion and to test for its association with SCD in the Rotterdam Study.
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Methods
Study population. The Rotterdam Study is a prospective population-based cohort study of 
chronic diseases in the elderly. All inhabitants of Ommoord, a Rotterdam suburb, aged 55 
years and older (10,278), were ascertained from the municipal register and invited to partici-
pate. Of them, 78% (7983, 58% female and 98% white) took part in the baseline examination 
from March 1990 through July 1993. Second and third examinations were conducted from 
September 1993 to August 1996 and from April 1997 to December 1999, respectively. Objec-
tives and methods of the Rotterdam Study have been described in detail.31 The medical ethics 
committee of Erasmus Medical Center (Rotterdam, The Netherlands) approved the study and 
all participants provided signed informed consent for participation, including retrieval of medi-
cal records, use of blood and DNA for scientific purposes, and publication of data. DNA for 
genotyping is available for 6571 (82%) participants from the baseline visit.
Clinical characteristics including smoking, body mass index (BMI), hypertension, diabetes 
mellitus, heart failure and myocardial infarction were ascertained as previously described.19, 
32-36 Active surveillance for incident diabetes mellitus, heart failure and myocardial infarction is 
conducted continuously between exams. In addition, exposure of study participants to medi-
cations has been gathered continuously from January 1st, 1991 to the present through com-
puterized pharmacy records of the pharmacies in the study area.
Genotyping. All participants were genotyped for the NOS1AP SNP SNP rs10494366 T>G, 
previously shown to be associated with QT interval in 3 independent samples.22 The cor-
related SNP rs10918594 C>G, which had evidence of association with QT interval in one of 
the original samples,22 was also genotyped (Figure 1). Both were genotyped using Taqman 
assays C_1777074_10 and C_1777009_10 (Applied Biosystems, Foster City, Calif., USA) in 
1 ng of genomic DNA extracted from leukocytes, as previously reported.37
Figure 1 NOS1AP and location of rs10494366 and rs10918594
The ruler indicates the physical position on chromosome 1. Thick horizontal lines indicate genes in the region with 
NOS1AP exons as thick vertical lines, the arrows indicate direction of transcription. Thick vertical lines on the ruler 
indicate the positions of rs10918594 and rs10494366, approximately 55kb apart. The two SNPs were in linkage disequi-
librium with an r2 of 0.63 and D’ of 0.89.
160,200kb 160,300kb 160,400kb 160,500kb 160,600kb
OLFML2B NOS1AP
rs10494366rs10918594
Chr. 1q23
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Assessment of QTc interval and other ECG measurements. The electrocardiography 
(ECG) phenotype studied was the heart rate corrected QT-interval (QTc) in milliseconds, using 
Bazett’s formula (QTc = QT / √RR).38 As in previous studies of QTc in the Rotterdam Study19 we 
used a 10-second resting 12-lead ECG (average of 8 to 10 beats), which was recorded on an 
ACTA electrocardiograph (ESAOTE, Florence, Italy) at a sampling frequency of 500 Hz and 
stored digitally. All ECGs were processed by the Modular ECG Analysis System (MEANS) to 
obtain ECG measurements.39-41 MEANS determines the QT interval from the start of the QRS-
complex until the end of the T-wave. MEANS also determines the presence of right- (RBBB) 
or left bundle-branch block (LBBB) and left ventricular hypertrophy. To study the association 
between NOS1AP variants and QTc duration, all eligible ECGs from subjects with DNA avail-
able were used. ECGs with RBBB or LBBB were excluded from the analyses. In addition, to 
minimize confounding by non-genetic influences on QT duration, all ECGs taken while the 
subject was on any QT altering drugs were excluded from analyses. Drugs were considered 
possibly QT prolonging if they appeared on any of lists 1 through 4 at www.qtdrugs.org.42 We 
also excluded ECGs if subjects were on flupenthixol, levomepromazine, mefloquine, olanzap-
ine or sertindole, which may prolong QT interval, or on digoxin, which shortens the QT interval. 
Up to 3 QTc measurements were recorded across the three examination cycles.
Finally, in additional analyses, the mean QTc interval per individual was divided into three gen-
der-specific categories as previously described. For women, the cut points were ≤ 450 msec 
(normal), 451 to 470 msec (borderline) and >470 msec (prolonged); for men, the cut points 
were ≤ 430 msec (normal), 431 to 450 msec (borderline) and >450 msec (prolonged).19, 43
Adjudication of sudden cardiac death. For the SCD analyses, all genotyped subjects were 
included. The ascertainment of SCD cases in the Rotterdam Study has been described previ-
ously.19 SCDs were defined operationally as a witnessed natural death attributable to cardiac 
causes, heralded by abrupt loss of consciousness, within one hour of onset of acute symp-
toms, or as an unwitnessed, unexpected death of someone seen in a stable medical condition 
<24 hours previously with no evidence of a non-cardiac cause.44, 45 
Statistical analysis. Genotype frequencies were tested for Hardy-Weinberg equilibrium with 
a Chi-square test. 
Because the QTc in subsequent ECGs of the same subject are correlated, we used repeat-
ed-measures analyses implemented in PROC MIXED (SAS 8.2, SAS Institute, Cary, NC). 
Both allelic and general genotype models were tested for the two polymorphisms, although 
the allelic model was considered primary because of the previously reported rs10494366-
QT relationship.22 Haplotypes were estimated using the estimation-maximization algorithm 
implemented in PHASE 2.0 (University of Washington, Seattle, USA),46, 47 and only individuals 
with successful genotyping for both SNPs and a posterior probability of >0.95 for assigned 
haplotypes were included in haplotype analyses. In total we identified 2245 double heterozy-
gotes, all of which were phased as heterozygous haplotype TC-GG because these are the 
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major haplotypes, with posterior probabilities in excess of 0.95. In haplotype analyses, the 
haplotype with major alleles for both SNPs was considered the reference, to which the three 
other haplotypes were compared individually. QTc was tested for association with genotype as 
the sole predictor (crude) and with adjustment for age and gender (multivariable). To compare 
the outcomes of haplotype analysis with individual SNP analysis, the latter analyses were 
also performed restricting the analysis to subjects in whom genotyping was successful for 
both SNPs. Finally a sensitivity analysis was carried out excluding ECGs with an abnormally 
prolonged QTc, using gender-specific cutoff points of >450 msec for men and >470msec for 
women. Jonckheere-Terpstra tests were used to test whether individuals carrying NOS1AP 
minor alleles had an increased frequency of borderline and abnormal mean QTc.
Hazard ratios for time to SCD from baseline were estimated using Cox proportional-hazards 
models. Again, both allelic and general genotype models were tested for the two polymor-
phisms. In addition to NOS1AP genotype, known SCD risk factors -including age, gender, 
BMI, smoking, hypertension, diabetes mellitus, heart failure and myocardial infarction at base-
line and time dependent incident diabetes mellitus, heart failure and myocardial infarction- 
were included as predictors. To minimize misclassification of SCD, we additionally performed 
a sub-analysis restricting the case definition to witnessed deaths only. As we have previously 
shown, the risk of SCD for increasing QTc is stronger in the younger than in the older age 
group,19 so we determined the hazard ratios for time to SCD separately in groups stratified by 
age above and below the median age at baseline. Finally, we performed a sensitivity analysis 
excluding subjects with a history of myocardial infarction at baseline from the analysis. All Cox 
proportional-hazards analyses were performed using SPSS for Windows version 11.0 (SPSS 
Inc, Chicago, Ill, USA).
Results
Study subjects. Baseline characteristics for the total study population, consisting of all geno-
typed subjects from the Rotterdam Study (n=6571), are summarized in Table 1. Within the 
study population, 12,967 ECGs were available from 6052 subjects across up to 3 examination 
cycles. After exclusion of ECGs with RBBB or LBBB (n= 640) and those performed in indi-
viduals taking QT prolonging or -shortening drugs (n= 1334) or both, a total number of 11,108 
ECGs from 5374 subjects remained (on average, 2.1 ECGs per individual). The 5374 subjects 
included in the QTc analyses were 1.3 years younger at baseline, reflecting exclusions among 
older participants (Table 1). Women had an 8.9 msec longer age-adjusted QTc interval (431.4 
msec vs. msec 422.5, p<0.0001) as has been previously shown,38, 48 and were 2.2 years older 
than men (70.4 vs. 68.2 years at baseline, p<0.0001). The numbers of abnormally prolonged 
QTc in men and women of our study population were slightly higher than expected based 
on numbers from reference populations.48, 49 However, our study population was on average 
already considerably older at baseline (69.5 years vs 53 years and 61 years respectively) and 
this mean further increased when follow-up ECGs were taken.
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Genotyping. The G-allele (minor) frequency of rs10494366 T>G was 36.4% and of rs10918594 
C>G was 31.4%. Successful genotype calls were made in 95.8% and 95.9% of subjects, re-
spectively. Both SNPs were in Hardy-Weinberg equilibrium (p= 0.32 for rs10494366 and p= 
0.89 for rs10918594). The two SNPs were in linkage disequilibrium with an r2 of 0.63 and D’ 
of 0.89. Upon phasing, we observed two common two-SNP haplotypes: TC (61.4%) and GG 
(29.1%), consisting of the two major and two minor alleles, respectively, and two remain-
ing haplotypes containing one major and one minor allele each: GC (7.2%) and TG (2.3%). 
Genotype distributions did not differ between men and women and between quartiles of age 
at baseline.
NOS1AP polymorphisms and QTc. Minor alleles of both NOS1AP SNPs were significantly 
associated with an increase in QTc duration. SNP rs10494366 T>G was associated with a 3.8 
msec increase in multivariable-adjusted QTc interval for each additional G-allele, and SNP 
rs10918594 C>G was associated with a 3.6 msec increase per additional G-allele (Table 2). 
Additional adjustment for electrocardiographic left ventricular hypertrophy did not alter the 
results (data not shown). We observed no difference in effect of the SNPs between men 
and women. A sensitivity analysis excluding ECGs with an abnormally prolonged QTc (using 
gender-specific cut points) resulted in slightly lower estimates (2.9 and 2.7 msec for the allelic 
models); however the association of NOS1AP genotypes with QTc duration remained highly 
significant (all p<10-11).
All three haplotypes containing one (GC and TG) or two (GG) minor alleles for the two SNPs 
were associated with increased QTc compared with the homozygous TC reference haplotype. 
The GG haplotype was associated with a 4.1msec longer multivariable-adjusted QTc per ad-
Table 3 Number of individuals with normal, borderline and abnormal mean QTc per genotype group 
using gender specific cutpoints
Number of individuals (% within genotype)
Genotype Normal Borderline Abnormal Test for trend
rs10494366 P < 0.0001
TT 1679 (80.0%) 329 (15.7%) 92 (4.4%)
TG 1715 (73.5%) 447 (19.2%) 172 (7.4%)
GG 498 (70.7%) 144 (20.5%) 62 (8.8%)
rs10918594 P < 0.0001
CC 1945 (79.2%) 390 (15.9%) 121 (4.9%)
CG 1609 (72.6%) 448 (20.2%) 160(7.2%)
GG 385 (72.6%) 96 (18.1%) 49 (9.2%)
QTc interval divided into three gender specific categories. For women, the cutpoints were ≤450 msec (normal), 451 
to 470 msec (borderline) and >470 msec (prolonged), and for men ≤430 msec (normal), 431 to 450 msec (borderline) 
and >450 msec (prolonged).19, 43
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ditional GG haplotype copy (p=2.0x10-18) using the TC haplotype as reference. The GC and 
TG haplotypes were associated with a 3.2 msec longer (p= 7.0x10-4) and 4.1 msec longer (p= 
0.01) multivariable-adjusted QT interval per additional copy, respectively. None of the haplo-
types had a more significant effect than the individual SNPs.
Furthermore, rs10494366 and rs10918594 were associated with a larger proportion of bor-
derline and prolonged QTc intervals using gender-specific cutpoints19 (test for trend both: p 
< 0.0001; Table 3).
NOS1AP polymorphisms and sudden cardiac death. Within the study population (n=6571), 
we identified 233 sudden cardiac deaths, 121 of which were witnessed. Baseline characteris-
tics of all adjudicated SCD cases are shown in Table 1. After adjustment for known risk factors, 
the NOS1AP polymorphisms rs10494366 T>G and rs10918594 C>G showed non-significant 
trends in the direction of increased hazard of SCD with hazard ratios per additional minor al-
lele for time to SCD of 1.09 (0.90;1.33) and 1.10 (0.90;1.34), respectively. In the subset of 121 
adjudicated SCD cases that were witnessed, a similar non-significant trend towards increased 
SCD risk was found (Table 4). Stratification for baseline age above and below the median 
showed no difference between age groups (data not shown). Finally, a sensitivity analysis 
excluding 767 subjects with a history of myocardial infarction at baseline did not result in a 
substantial change of the effect estimates or confidence intervals (data not shown).
Discussion
We observed strong replication in the Rotterdam Study, a large well-phenotyped cohort of 
European ancestry, of the finding from a prior genome-wide association study22 that common 
NOS1AP variants are associated with increased age-, gender- and heart-rate-adjusted QT-
interval duration. None of the haplotypes showed a more significant effect than the individual 
SNPs, which were not specifically selected to characterize haplotype variation at the locus. 
The two SNPs, which are 55kb apart, are not known to be functional, nor are they highly corre-
lated with any known functional SNP. These results support the existence of a causal untyped 
SNP that is correlated with both rs10494366 and rs10918594.
The association with SCD was not statistically significant. Although we cannot fully exclude 
survival bias because of the older age of our study population, we did not find that the geno-
type distribution differed between different age groups at baseline, making this less likely. The 
modest QTc prolongation associated with NOS1AP variation, despite the strong effect of pro-
longed QTc on SCD risk suggests that a much larger study is needed to definitively confirm or 
rule out an increased risk of SCD by NOS1AP variants. At least 510 cases would be needed 
to detect an odds ratio of 1.2 per minor allele with 80% power. Even if no association with SCD 
is ultimately identified, the 7.2 msec increase in QTc interval in minor homozygotes compared 
with major homozygotes approximates the effect of medications which delay myocardial repo-
larization and increase liability to ventricular arrhythmias.
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The mechanism by which common variation in NOS1AP affects QTc interval duration is un-
known at present. However, the statistical evidence supporting the association with QTc inter-
val of rs10494366 (p<10-19) and rs10918594 (p<10-16) in 5374 individuals confirms that this is a 
genuine association, consistent with evidence from four independent cohorts totaling >13,000 
individuals of European ancestry. Our study examined the relationship of genetic variation, 
present at birth, in an elderly cohort in whom one might assume that genetic factors play a 
smaller role than in younger cohorts. However, these results demonstrate that genetic factors 
continue to play a role even at older age.
One major advantage in our study was the availability of up to three ECGs per subject at 
regular intervals during follow-up, resulting in more precise long-term ECG measures. Fur-
thermore, the use of digital ECG recordings all measured with the MEANS system likely re-
duced systematic differences in assessment of the QTc interval. In addition, the intersection 
of the Rotterdam Study with detailed pharmacy exposure data allowed us to exclude ECGs 
recorded in individuals on QT prolonging or -shortening drugs, which could have attenuated 
the power to detect the association. Although no information on LQTS cases was available, 
the number of relatives in the Rotterdam Study is low and the sensitivity analysis excluding 
abnormally prolonged QTc further minimized influence of potential familial LQTS cases. An-
other advantage of the Rotterdam Study is the prospective ascertainment of risk factors and 
the active surveillance for SCD events over a relatively long period of follow-up. Thus, exten-
sive information surrounding SCD events was available, including the time between start of 
symptoms and death, enabling rigorous adjudication of SCD events.
One limitation of the study resides in the variety of competing causes of abrupt death at in-
creasing age, which may have led to misclassification, especially in cases where death was 
unwitnessed. Because SCD coding was blinded to NOS1AP genotype, this would likely have 
biased our study to detect no effect. This might explain our finding of a slightly increased, 
but still non-significant, hazard ratio when the analyses were restricted to witnessed sudden 
cardiac deaths. Our results and those of the prior study by Arking et al. were restricted to 
population samples of European ancestry. Further testing in samples of African and Asian an-
cestry is needed to establish the role of genetic variation at the NOS1AP locus in myocardial 
repolarization in these population groups. Moreover, substantial frequency differences are 
observed among European, African and Asian HapMap samples, which raises the possibility 
of natural selection in the region (www.hapmap.org accessed November 6, 2006). Attempts 
to validate the NOS1AP association in recently admixed populations, such as African Ameri-
cans, will need to account for global and local chromosomal differences in ancestry because 
of the strong association with continental ancestry and the risk of population stratification.
In conclusion, we have strongly confirmed the association of NOS1AP variants with QT in-
terval duration. With the limited number of SCD cases in our cohort, it was not possible to 
demonstrate that this association translates into an influence on risk of SCD, although the 
point estimates suggest that such a risk increase may truly exist. Additional larger studies will 
be required to determine whether NOS1AP genotype is associated with SCD.
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4.2
Common NOS1AP variants potentiate digoxin induced 
QT-shortening and risk of sudden cardiac death
Abstract
Background. Digoxin, widely used in the treatment of heart failure and atrial fibrillation, is as-
sociated with increased risk of life-threatening arrhythmias. Common variants of the NOS1AP 
gene were recently shown to be associated with QT-prolongation. We analyzed the combined 
effect of NOS1AP genotype and digoxin on QTc-interval duration and the risk of sudden car-
diac death (SCD) to digoxin. 
Methods. We studied the Rotterdam Study, a population-based, prospective cohort study of 
individuals ≥55 years of age. Heart rate corrected QT (QTc) interval duration was measured 
in prospectively collected ECGs. Digoxin exposure was determined at the time of each ECG. 
Hazard ratios (HRs) for time to SCD among NOS1AP genotypes with and without digoxin 
were estimated by Cox proportional hazards modeling with time-dependent exposures.
Results. We included 16,595 ECGs from 7771 individuals (315 ECGs from 243 individuals on 
digoxin). In digoxin users, NOS1AP minor alleles were associated with increased QTc short-
ening of 4.3 msec per additional allele compared to subjects homozygous for the reference 
allele. There were 229 SCD cases, 40 of whom were exposed to digoxin at time of death. In 
digoxin users, NOS1AP minor alleles were associated with an increased risk of SCD of 1.78 
(95%CI 1.13;2.81) per additional allele, resulting in a 3-fold increased SCD risk for homozy-
gous minor allele carriers. NOS1AP variants did not increase SCD risk in non-digoxin users.
Conclusions. Minor allele carriers of a common NOS1AP variant using digoxin have exag-
gerated QTc shortening and an increased risk of SCD.
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Introduction
Digoxin (digitalis) has been used in the treatment of heart disease for over 200 years. More 
recently, digoxin was demonstrated to reduce the number of admissions for heart failure and 
to worsen heart failure on its withdrawal, without clear mortality advantage.1-3 Digoxin is now 
widely used for treatment of atrial fibrillation and heart failure. Digoxin exerts its action, in part, 
by increasing intracellular Ca++ concentration ([Ca++]i), leading to higher contractile force and 
QT-shortening.4 Digoxin has a narrow therapeutic window, and ever since its introduction, it 
has been associated with toxicity and, in the past, high risk of life-threatening arrhythmias and 
mortality.
Common variants of the nitric oxide synthase 1 adaptor protein (NOS1AP) gene were re-
cently discovered to be associated with QT-interval prolongation in a genome wide associa-
tion study.5 We replicated this finding in the Rotterdam Study, a large population based cohort 
of persons 55 years and older.6 NOS1AP was not previously known to play a role in cardiac 
repolarization. So far, not much is known about the mechanism by which NOS1AP influences 
QT duration. NOS1AP activates neuronal nitric oxide synthase (NOS1). NOS1 deficiency in-
creases [Ca++]i and causes QT prolongation.
7-10 
We hypothesized that subjects carrying the minor variants of two NOS1AP SNPs known to 
prolong the QT interval might be less sensitive to the QT shortening effects of digoxin. If so, 
they might also be less sensitive to its pro-arrhythmogenic effects.11-13 In the present study, 
we tested for interaction of NOS1AP variants with digoxin use on QTc interval duration in a 
population based cohort study comprising both digoxin users and non-users. In addition, we 
studied whether these NOS1AP variants were associated with a reduced risk of sudden car-
diac death (SCD) in digoxin users.
Methods
Study population. The Rotterdam Study is a prospective population-based cohort study of 
chronic diseases in the elderly. Starting from March 1990, 7983 inhabitants of Ommoord, a 
Rotterdam suburb, aged 55 years and older took part in the baseline examination. In 2000, 
a second cohort of 3011 inhabitants of Ommoord, aged 55 years and older at that time, 
was added. Follow-up examinations took place at 4 year intervals (Figure 1). Objectives and 
methods of the Rotterdam Study have been described in detail.14, 15 ECGs are taken at every 
follow-up round. Clinical characteristics including smoking, body mass index (BMI), hyperten-
sion, diabetes mellitus, heart failure and myocardial infarction were ascertained as previously 
described.16-21 Active surveillance for incident diabetes mellitus, heart failure and myocardial 
infarction is conducted continuously between follow-up examinations. In addition, exposure of 
study participants to medications has been gathered on a continuous basis since January 1st, 
1991 through computerized pharmacy records from the study area covering >99% of prescrip-
tions to the study population.
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The medical ethics committee of the Erasmus Medical Center (Rotterdam, The Netherlands) 
approved the study. All participants provided signed informed consent for participation, includ-
ing retrieval of medical records and use of blood and DNA for scientific purposes. Baseline 
visit DNA for genotyping is available for 6571 (82%) participants of the first cohort and 2607 
(87%) participants of the second inception cohort. Our study population comprised all indi-
viduals from the Rotterdam Study for whom genotyping and pharmacy data were available.
Figure 1 Flowdiagram of the Rotterdam study
ECGs were taken at every research round.
Baseline cohort First extended cohort
Rotterdam Study
7983 subjects participating in the first 
research round
6315 subjects participating in the second 
research round
4797 subjects participating in the third 
research round
3550 subjects participating in the fourth 
research round
1049 participants died 
6 were lost to follow-up or 
were not invited 
463 did not participate in the 
third research round
504 participants died 
11 were lost to follow-up or 
were not invited 
1153 did not participate in 
the second research round
765 participants died 
35 were lost to follow-up or 
were not invited
447 did not participate in the 
fourth research round
137 participants died 
144 were lost to follow-up or 
were not invited 
341 did not participate in the 
second research round
3011 subjects participating in the first 
research round
2389 subjects participating in the second 
research round
1990
1993
1993
1995
1997
1999
2000
2001
2002
2004
2004
2005
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Genotyping. All participants were genotyped for the NOS1AP SNP rs10494366 T>G and the 
correlated SNP rs10918594 C>G, which were both previously shown to be associated with 
QT interval duration,5, 6 as previously described.6, 22 Because SNP rs10494366 showed stron-
ger evidence of association with QTc in the Rotterdam Study and both SNPs are in linkage 
disequilibrium,5, 6 we considered it primary in the analyses. 
Digoxin exposure. In order to assess exposure we calculated the duration of dispensed 
digoxin prescriptions as the number of units dispensed divided by the number of units to be 
taken per day. Digoxin dose was expressed as the defined daily dose (DDD) as determined 
by the WHO (1 DDD is 0.25mg of digoxin).
Subjects were classified as exposed to digoxin if the date of the ECG or the date of SCD (or 
the index date for the remainder of the cohort) fell within the duration of a dispensed digoxin 
prescription.
Assessment of QTc interval and other ECG measurements. All ECGs from subjects with 
DNA available taken between January 1st, 1991 (first date drug exposure available) and the 
end of the last follow-up round (March 1st, 2005) were checked for eligibility criteria. Heart 
rate corrected QT-interval (QTc) in msec, was calculated using Bazett’s formula (QTc = QT / 
√RR).23 ECG measures were determined using digital ECGs analyzed with the Modular ECG 
Analysis System (MEANS)24-26 as in previous studies of QTc in the Rotterdam Study.6, 21 ECGs 
with right or left bundle branch block were excluded from the analyses. In addition, all ECGs 
taken while the subject was on any QT-prolonging drugs were excluded from the analyses. 
The following drugs were considered to be QT-prolonging: drugs appearing on any of lists 1-4 
at www.qtdrugs.org,27 flupenthixol, levomepromazine, mefloquine, olanzapine or sertindole. 
Finally, ECGs taken while digoxin dose >1 DDD (to reduce influence of extreme dose effects) 
or with unknown digoxin dose were excluded. Up to 4 QTc measurements per subject were 
recorded across the four examination cycles.
Adjudication of sudden cardiac death. For the SCD analyses, we excluded subjects from 
the inception cohort since follow-up of this cohort was incomplete with respect to assessment 
of the causes of death. The end of the study period was January 1st,  2005, the last date for 
which follow-up has been completed for the baseline cohort. Since the inception cohort is a 
younger cohort with shorter follow-up, this did probably not result in loss of many SCD cases. 
The ascertainment of SCD cases in the Rotterdam Study has been described previously.6, 21, 
28, 29 SCD was defined as a witnessed natural death attributable to cardiac causes, heralded by 
abrupt loss of consciousness, within one hour of onset of acute symptoms, or an unwitnessed, 
unexpected death of someone seen in a stable medical condition <24 hours previously with 
no evidence of a non-cardiac cause.28, 29
Statistical analysis. Genotype frequencies were tested for Hardy-Weinberg equilibrium us-
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ing a Chi-square test. 
QTc interval was primarily studied, comparing all ECGs without digoxin exposure to those 
with digoxin exposure. Because measurements in ECGs of the same subject are correlated, 
we used repeated measures analyses with PROC MIXED (SAS 8.2, Cary, NC). To estimate 
the combined effect size of NOS1AP variants and digoxin use in one model, we created an 
interaction dummy variable with six levels (genotypes with and without digoxin) in which non-
digoxin users homozygous for the major allele were considered as referent. Furthermore, 
multiplicative interaction terms (genotype (categorical) x digoxin use and genotype (additive) 
x digoxin use) were used to test for multiplicative interaction. Associations were tested in 
univariate models and in models adjusted for sex and age, heart failure, myocardial infarction 
and diabetes mellitus at the time of the ECG. The effect of genotype on QTc duration was also 
tested stratified on digoxin use to allow further adjustment for digoxin dose. Additionally, we 
studied the effect of digoxin on QTc interval within subjects in a follow-up design. For this, we 
determined the difference in QTc duration between two consecutive ECGs (one on digoxin 
and one off) of subjects starting or stopping digoxin therapy. 
Hazard ratios for time to SCD from baseline were estimated using Cox proportional hazards 
models with time dependent digoxin exposure. Because of the strong impact of prevalent 
cardiovascular morbidity –which is much more frequent in digoxin users- NOS1AP genotype 
effect on SCD risk was tested stratified on digoxin use. First, the association was tested in uni-
variate analyses and subsequently in multivariate models including known SCD risk factors as 
predictors: sex and smoking at baseline and time dependent age, diabetes mellitus, heart fail-
ure and myocardial infarction. In the stratum of digoxin users we further adjusted for digoxin 
dose. To test for interaction, we used multiplicative interaction terms similar to the QTc analy-
ses. To exclude confounding by the underlying heart disease (confounding by indication), we 
also tested the effect of NOS1AP variants on SCD in participants with prevalent myocardial 
infarction or heart failure without digoxin use and in digoxin users without prevalent heart 
disease. To minimize bias by misclassification of SCD, we additionally performed a sensitivity 
analysis restricting the case definition to witnessed deaths only. All Cox proportional hazards 
analyses were performed using SPSS for Windows version 11.0 (Chicago, Illinois, USA).
Differences in digoxin dose between ECGs from different genotype groups were also com-
pared using repeated measures analyses. Digoxin dose between different genotype groups in 
SCD cases were compared using ANOVA.
Results
Study population. For the QTc assesment, a total of 16,595 ECGs from 7771 individuals 
were included. Of these, 315 ECGs from 243 individuals were taken while the subject was 
using digoxin. Mean follow-up time was 9.2 (SD 4.6) years, slightly lower than in the SCD 
population due to inclusion of the second inception cohort which entered the Rotterdam Study 
later. The study population for SCD assessment comprised 6541 individuals with a mean 
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follow-up time of 10.4 (SD 3.7) years. Of these, 871 subjects used digoxin at any time during 
the study period. Baseline characteristics of the QTc and  SCD study populations and of SCD 
cases are shown in Table 1.
Genotypes and digoxin exposure. Genotype assessment of rs10494366 T>G and 
rs10918594 C>G was successful in 96.4% and 97.6%, minor allele frequencies were 
36.5% and 31.4% respectively. Both SNPs were in Hardy-Weinberg equilibrium (p= 0.53 for 
rs10494366 and p=0.78  for rs10918594). Genotype frequencies in digoxin users did not sig-
nificantly differ from non-users (p= 0.93 and p= 0.71 respectively).
Mean digoxin dose was 0.61 DDD (SD 0.27) and did not significantly differ between genotype 
groups of ECGs taken while using digoxin, of those ever using digoxin in the total SCD sample 
or of SCD cases using digoxin on the index date.
Figure 2 QTc difference in msec using by NOS1AP genotype and digoxin use
QTc change in msec compared to persons with rs10494366 TT genotype without digoxin use (reference) adjusted for: 
age, sex, heart failure, myocardial infarction and diabetes mellitus at time of ECG (repeated measures analyses). Age, 
sex, heart failure, myocardial infarction and diabetes mellitus adjusted mean QTc for the reference group is 426msec. 
Vertical bars indicate 95% confidence intervals.
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QTc interval. In the total study population, ECGs taken while subjects were using digoxin 
showed QTc interval shortening of 9.5 (95%CI 6.9;12.1) msec compared to non-users. After 
adjustment for sex and time dependent age, heart failure, diabetes mellitus and myocardial 
infarction digoxin use was associated with 15.7 (95%CI 13.0;18.3) msec shortening. Within 
the stratum of digoxin users, the effect of digoxin dose was 11.1 (95%CI 3.2;18.9) msec short-
ening per 0.5 DDD increase. In non-digoxin users, QTc interval increased with approximately 
3.5 msec per additional variant allele, similar to previous studies.5, 6, 30
Digoxin users with TT genotypes for rs10494366 had a 11.4 (95%CI 7.5;15.3) msec shorter 
QTc interval than TT subjects not using digoxin (reference group), whereas digoxin users 
homozygous for the G-allele showed 23.0 (95%CI 14.4;31.5) msec QTc shortening compared 
to the reference group (Figure 2). The interaction between digoxin exposure and NOS1AP 
genotypes in their effect on QTc interval exceeded multiplicative scale. Within the digoxin use 
stratum, the genotype effect on QTc interval was similar to that shown in Figure 2 and was not 
substantially changed by additional adjustment for digoxin dose (Table 2).
We identified 80 persons starting on digoxin between ECGs, 24 persons discontinuing digoxin 
Table 2 NOS1AP genotype effect on QTc stratified on digoxin users
QTc change in msec (95% CI) by genotypeb
Genotype Na Crude Adjustedc Adjusted + dosed
No digoxin
Allelic modele 7342 3.6 (2.9;4.3) 3.6 (2.9;4.3) NA
Genotypic model
TT 2973 Reference Reference NA
TG 3379 3.4 (2.4;4.5) 3.5 (2.5;4.5) NA
GG 990 7.3 (5.8;8.8) 7.3 (5.8;8.7) NA
Digoxin
Allelic modele 233 -3.4 (-10.2;3.3) -4.5 (-11.1;2.2) -4.3 (-10.8;2.3)
Genotypic model
TT 107 Reference Reference Reference
TG 102 -1.7 (-11.1;7.6) -1.5 (-10.8;7.8) -1.8 (-11.0;7.3)
GG 24 -8.8 (-24.2;6.5) -12.4 (-27.6;2.8) -11.3 (-26.4;3.8)
P-value for multiplicative interaction
Allelic modele 8.8*10-4 8.7*10-5 NA
Genotypic model 0.0033 2.1*10-4 NA
Results for rs10494366 genotypes; NA= not applicable
a Number of unique individuals
b QTc change in msec with 95% confidence interval. Homozygous major allele group is the referent.
c Adjusted for known QT-prolonging factors: age, sex, heart failure, myocardial infarction and diabetes mellitus at 
time of ECG.
d (Users only) Additionally adjusted for digoxin dose at time of ECG
e Additive genetic model, QTc change per additional minor allele
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between ECGs and 11 subjects who started and later stopped digoxin therapy during the 
study period. On average, the QTc interval shortening within individuals (i.e. QTc interval with-
out digoxin minus QTc interval with digoxin) was larger among NOS1AP minor allele carriers 
(35.2 msec shortening in GG vs 11.8 msec shortening in TT subjects, p-trend =0.37) but did 
not reach statistical significance. 
Results of identical analyses for the partially correlated rs10918594 SNP were similar (results 
not shown).
Sudden cardiac death. During the study period, we identified 229 SCD cases 121 of which 
were witnessed, and 40 of which were exposed to digoxin at time of death. Digoxin use re-
sulted in a substantial SCD risk increase (HR 5.1 95%CI 3.7;7.2). The HR decreased to 2.9 
(95%CI 2.0;4.1) after adjustment for sex, smoking and time dependent age, diabetes, myo-
cardial infarction and heart failure.
After stratification for digoxin use, we found no effect of NOS1AP genotypes on SCD risk in 
those not using digoxin (HR allelic model 1.00, 95%CI 0.81;1.24). However, in the stratum 
Table 3 NOS1AP Genotype effect on SCD risk, stratified on digoxin use at the index date
HR (95% CI)a
Genotype SCD cases Crude Adjustedb Adjusted + dosec
No digoxin
Allelic modeld 180 0.95 (0.77;1.18) 1.00(0.81;1.24) NA
Genotypic model
TT 80 Reference Reference NA
TG 73 0.81 (0.59;1.11) 0.86 (0.62;1.18) NA
GG 27 1.01 (0.65;1.57) 1.11 (0.72;1.72) NA
Digoxin
Allelic modeld 37 1.70 (1.09;2.66) 1.78 (1.13;2.81) 1.78 (1.13;2.81)
Genotypic model
TT 10 Reference Reference Reference
TG 18 1.76 (0.81;3.83) 1.86 (0.85;4.10) 1.86 (0.85;4.11)
GG 9 2.89 (1.17;7.14) 3.17 (1.26;7.96) 3.16 (1.26;7.96)
P-value for multiplicative interaction
Allelic modeld 0.013 0.035 NA
Genotypic model 0.055 0.125 NA
Results for rs10494366 genotypes; NA = not applicable
a Hazard ratio and 95% confidence interval per genotype group, stratified by digoxin use. Homozygous major allele 
groups are the referent. 
b Adjusted for known risk factors of SCD: sex, time dependent age, diabetes mellitus, heart failure, myocardial 
infarction, baseline smoking (past, present, never)
c (Users only) Additionally adjusted for digoxin dose at index date
d Additive genetic model , hazard ratio per additional minor allele
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of digoxin users we found an increased risk of SCD in minor allele carriers (HR 1.78 per ad-
ditional minor allele, 95%CI 1.13;2.81). Multiplicative interaction significantly exceeded mul-
tiplicative scale (Table 3). The sensitivity analyses restricting the outcome to witnessed SCD 
cases only, resulted in a slightly higher point estimate of SCD risk for minor allele carriers 
using digoxin (HR fully adjusted allelic model 1.92, 95%CI 1.06-3.49). In participants with 
prior myocardial infarction or heart failure not using digoxin, no effect of NOS1AP genotype 
on SCD was observed (HR allelic model 1.01, 95%CI 0.68;1.50) and in digoxin users without 
previous myocardial infarction or heart failure, the effect estimate of NOS1AP was even larger 
(HR allelic model 2.01, 95%CI 0.84;4.85) making a strong effect of confounding by indication 
unlikely. 
Results for the minor variant of rs10918594 were similar (results not shown).
Discussion
In the present study, we surprisingly found that digoxin users carrying the NOS1AP minor al-
lele had significantly more pronounced QT shortening than major allele homozygous users, in 
contrast to the effect observed in non-users. Apparently, the QTc-shortening effect of digoxin 
is significantly worsened in those with the minor allele. Furthermore, minor allele carriers had 
an up to three-fold increased risk of SCD to digoxin. No genotype effect on SCD risk was 
observed in non-users of digoxin. Although the mechanism by which NOS1AP influences QT 
interval duration and interacts with digoxin is not known, it may involve calcium handling in the 
cardiomyocyte.7-10 Digoxin is capable of increasing intracellular Na+ by inhibition of the Na/K 
ATP-ase, resulting in an increased intracellular Ca++ concentration ([Ca++]i).
31, 32 In addition, 
the increased peak [Ca++]i results in faster kinetics of [Ca
++]i decay,
4 thus leading to a faster 
repolarization and QT shortening. NOS1AP has been found to activate NOS1.33 NOS1 knock-
out cardiomyocytes have increased contractility through increased [Ca++]i as well as a slower 
time to relaxation and a prolonged time-course of decay of the [Ca++]i transient.
7-10, 34 Further-
more, NOS1 seems to be able to interact with the L-type Ca++ channel,35 which is known to 
be associated with both Short- and Long QT Syndrome and SCD.36, 37 This suggests a model 
in which both digoxin and NOS1AP minor alleles increase [Ca++]i, resulting in excess [Ca
++]
i. Calcium overload can result in spontaneous cycles of Ca
++ release and reuptake, resulting 
in after-depolarizations and increased risk of ventricular arrhythmias.31 This would explain 
the increased risk of SCD in digoxin users with the variant NOS1AP alleles. If digoxin coun-
teracted the slower decay of the [Ca++]i transient caused by lower NOS1 activity, the excess 
[Ca++]i would also result in faster [Ca
++]i decline,
4 explaining the increased QTc-shortening in 
NOS1AP variants. In turn, short QT in itself, both as a congenital syndrome and in the general 
population, is a risk factor of SCD.11-13, 36, 38 
A strength of our study was the extensive information surrounding SCD events, including the 
time between start of symptoms and death, enabling rigorous adjudication of SCD events. 
Furthermore, precise long-term ECG measures were available in up to four ECGs per subject. 
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The availability of detailed pharmacy exposure data allowed us to determine digoxin use at 
time of ECG or death, and to exclude ECGs recorded in individuals on QT prolonging drugs. 
The prospective design of the Rotterdam Study limits the risk of selection or information bias 
and the multivariate models show that confounding is limited. We cannot fully exclude con-
founding by (severity of) the underlying cardiovascular disease. However, this is unlikely to 
explain the results, since adjusting for concomitant heart disease slightly increased the effect 
estimates for NOS1AP minor alleles. Furthermore, in participants with prior myocardial infarc-
tion or heart failure not using digoxin no effect of NOS1AP minor alleles on SCD was ob-
served, whereas a stronger genotype effect was observed in digoxin users without prevalent 
heart disease. Finally, the results from the ECG analyses show increased QTc-shortening to 
digoxin in NOS1AP minor allele carriers. Heart disease usually increases QTc duration, which 
further argues against an effect of the underlying disease.
One limitation of the study resides in the small number of SCD cases. However, despite the 
limited power we found a statistically significant, three-fold increased risk of SCD to digoxin 
in subjects homozygous for the NOS1AP minor allele. Another limitation lies in the variety of 
competing causes of abrupt death at increasing age, which may have led to misclassification 
of SCD events, especially in cases where death was unwitnessed. Since SCD coding was 
blinded to NOS1AP genotype, this would likely have biased our study toward the null hypoth-
esis that no effect exists. The stronger effect on SCD in analyses restricted to witnessed SCD 
lends some support to this hypothesis.
In conclusion, we have found that common NOS1AP variants interact with digoxin, result-
ing in an increased QTc-shortening and an up to three-fold increased risk of SCD in digoxin 
users with NOS1AP minor alleles. These findings raise the possibility of testing for common 
NOS1AP variants with the goal of improving patient safety in digoxin therapy.
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4.3
Cardiovascular drugs, NOS1AP and QTc prolongation
Abstract
Aim. To study whether NOS1AP variant alleles rs10494366 T>G and rs 10918594 C>G modify the effect 
of cardiovascular drugs which may prolong the QTc interval and to study whether this combination was 
associated with a higher risk of sudden cardiac death.
Methods. This study was conducted as part of the prospective population-based Rotterdam Study, and 
included 16,603 ECGs from 7565 participants aged 55 years and older, after exclusion of ECGs from 
patients with left ventricular hypertrophy, left and right bundle branch block as well as carriers of pacemak-
ers. The primary endpoint of the study was the length of the QTc interval of users with the minor alleles 
compared to non-users with the major alleles. The secondary endpoint was the risk of sudden cardiac 
death (SCD) of users with the minor alleles compared to non-users with the major alleles. Associations 
were examined by repeated measurement analyses and Cox proportional-hazards models, adjusted for 
age, gender, diabetes mellitus, hypertension, myocardial infarction, heart failure and use of other QTc 
prolonging drugs. 
Results. Overall, 1061 participants developed QTc prolongation during follow-up. The G-allele (minor) 
frequency of rs10494366 T>G was 36.5% and of rs10918594 C>G was 31.4%. Users of triamterene and 
verapamil with the rs10494366 GG genotype showed significantly more QTc-prolongation than users with 
the TT haplotype. SNP rs10918594 C>G showed similar results. Although the numbers of SCD cases ex-
posed to QT-prolonging drugs at time of death was very low, point estimates for amiodarone (15 exposed 
SCD cases) and verapamil (8 exposed cases) suggest that NOS1AP minor variant carriers might be at 
increased risk of SCD in users of these drugs.
Conclusions. We demonstrated that the minor alleles of both NOS1AP SNPs potentiated the QTc pro-
longing effect of several cardiovascular drugs, mainly in users of triamterene and verapamil. We also 
found indications that amiodarone, and verapamil in combination with NOS1AP minor alleles increase the 
risk of sudden cardiac death, which endorses the clinical importance of this gene-drug interaction.
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Introduction
In the past decade, one of the most frequent causes of withdrawal or restriction of marketed drugs has 
been the prolongation of the heart-rate corrected QT (QTc) interval in combination with case-reports of 
sudden cardiac death. The QTc interval is the traditional measurement for assessing the duration of ven-
tricular repolarization which may result in early after depolarizations (EAD) and re-entry, and thereby pro-
voke Torsade de Pointes and fatal ventricular arrhythmias.1-5 Previously, we have demonstrated that QTc 
prolongation is associated with an increased risk of sudden cardiac death.6 An increasing number of drugs 
has been recognized to delay cardiac repolarization and to induce Torsade de Pointes.4 The QTc interval 
is influenced by factors such as gender, age and use of certain drugs. However, it is mostly unknown 
which other underlying risk factors modify the risk of drug-induced QTc-prolongation. As the QT interval is 
a genetically quantitative trait with ~30% heritability,7-9 it is likely that such genetic effect modifiers exist.
Recently, we reported the finding from a genome-wide association study that a common variant 
(rs10494366, minor allele frequency 38%) in the NOS1AP gene was associated with QT interval variation 
in several large population samples.10,11 The NOS1AP gene encodes the nitric oxide synthase 1 activating 
protein.10 The mechanism by which common variation in NOS1AP affects the QTc interval is presently 
unknown. NOS1AP is a regulator of neuronal nitric oxide synthase effected by forming a ternary complex 
with PSD95 (membrane-associated guanylate kinase)11 and Dexras 1 (member of the Ras family of small 
monomeric G proteins).12 NOS1 has been shown to have a role in cardiac contractibility.13, 14 It is hypoth-
esized that nitric oxide signaling may be involved in cardiac repolarization. 
We conducted a population-based prospective cohort study to investigate whether NOS1AP variant al-
leles rs10494366 T>G and rs10918594 C>G modify the effect of cardiovascular drugs which may prolong 
the QTc interval and to study whether this combination was associated with a higher risk of sudden car-
diac death.
Methods
Setting and study design. The Rotterdam study is a prospective population-based cohort study, which 
started with a baseline visit between 1990 and 1993. The Medical Ethics Committee of the Erasmus 
Medical Center, Rotterdam, the Netherlands, approved the study. All inhabitants of Ommoord, a suburb 
of Rotterdam, aged 55 years and over, were invited to participate (n=10,275). Of them, 7983 (78%) gave 
their written informed consent and took part in the baseline examination. Objectives and methods of the 
Rotterdam Study have been described in detail elsewhere.15 At baseline, all participants were visited at 
home for a standardized questionnaire, and 7151 were subsequently examined at the research center. 
Since the start of the study, follow-up visits took place in the period 1993 through 1996 for the second 
visit, in the period between 1997 through 1999 for the third visit and in the period between 2002 through 
2004 for the fourth visit. Furthermore, in 2000 a second cohort (first extended cohort) was enrolled.16 This 
included all inhabitants of Ommoord, at that time aged 55 years and over, who were invited to participate 
(n = 4504). Of them, 3011 (67%) entered the study and took part in the baseline examination. The second 
visit of the first extended cohort took place in the period between 2004 and 2005.  In addition to follow-up 
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examinations, the total cohort is continuously being monitored for major morbidity and mortality through 
linkage of general practitioner and municipality records. Furthermore, all drug prescriptions dispensed to 
participants by automated pharmacies are routinely stored in the database since January 1, 1991. 
Study population. Two study populations were used, one for the QTc analysis and one for the sudden 
cardiac death analysis.
All cohort members of the Rotterdam Study and the first extended cohort, who had at least one ECG 
and was genotyped, were enrolled in the study population for the QTc analysis. Participants could con-
tribute up to four ECGs to the analyses. Overall, 20,596 ECGs were available, 8586 in men and 12,010 
in women. Digitally stored ECGs were available for 5397 participants at the time of the first visit (75% of 
7151 participants visiting the research center), of 4798 participants at the time of the second visit (76% 
of 6315 participants visiting the research center), of 3818 participants at the time of the third visit (91% of 
4215 participants visiting the research center), and of 3118 participants at the time of the fourth visit (99% 
of 3145 participants visiting the research center). There were 2273 ECGs available of the participants of 
the first extended cohort at the time of the first visit (84% of 2722 participants who visited the research 
center), and of 1190 at the time of the second visit (53% of 2249 participants who visited the research cen-
ter). Missing ECGs were mainly due to temporary technical problems with ECG recording. Participants left 
the cohort mainly due to mortality while a minority was lost to follow-up (Figure 1). For the present study, 
the visit during which the first ECG was made was defined as baseline. ECGs of participants who used 
digoxin, which is a QTc shortening agent at the index date were excluded. In addition the ECGs were 
excluded of persons with a pacemaker, as well as of persons with evidence of left ventricular hypertrophy, 
left and right bundle branch block, since these conditions are associated with a prolonged QTc interval.17, 
18 Consequently, 6205 participants (3599 women and 2606 men) were included in the QTc interval study 
population.
For the sudden cardiac death study population, all cohort members of the Rotterdam Study who were 
genotyped, were enrolled. Since drug prescriptions dispensed to participants by automated pharmacies 
are routinely stored in the database since January 1, 1991, the follow-up lasted from January 1, 1991 until 
reaching one of the censoring dates (death or transferring out) or the end of the study period (January 
1, 2006). Overall, 6214 participants (3705 women and 2509 men) were included in the sudden cardiac 
death study population.. 
ECG. The primary endpoint of the study was the length of the QTc interval in msec. A 12-lead resting ECG 
was recorded with an ACTA electrocardiograph (ESAOTE, Florence, Italy) at a sampling frequency of 500 
Hz and stored digitally. All ECGs were processed by the Modular ECG Analysis System (MEANS) to obtain 
ECG measurements, the MEANS program has been evaluated extensively and has been validated.19-22 
MEANS determines common onsets and offsets for all 12 leads together on one representative averaged 
beat, with the use of template matching techniques.20 The MEANS program determines the QT interval 
from the start of the QRS complex until the end of the T-wave. To adjust for heart rate, Bazett’s formula 
(QTc=QT/√RR) was used.23 European regulatory guidelines were used to categorize QTc prolongation 
into 3 categories. For men, the cut-off points were less than 430 ms (normal), 430-450 ms (borderline) and 
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more than 450 ms (prolonged), and for women less than 450 ms (normal), 450-470 ms (borderline), and 
more than 470 ms (prolonged).24 Additionally, the MEANS program determines left ventricular hypertrophy 
and left and right bundle branch block.
Sudden cardiac death. The ascertainment of sudden cardiac death cases in the Rotterdam Study has 
been described previously.6 In short, information on vital status is obtained from municipal health authori-
ties in Rotterdam and general practitioners. In case of a fatal event, general practitioners filled in a ques-
tionnaire relating to the circumstances of death. Subsequently, research assistants gathered information 
Figure 1 Flowdiagram of the Rotterdam study
ECGs were taken at every research round.
Baseline cohort First extended cohort
Rotterdam Study
7983 subjects participating in the first 
research round
6315 subjects participating in the second 
research round
4797 subjects participating in the third 
research round
3550 subjects participating in the fourth 
research round
1049 participants died 
6 were lost to follow-up or 
were not invited 
463 did not participate in the 
third research round
504 participants died 
11 were lost to follow-up or 
were not invited 
1153 did not participate in 
the second research round
765 participants died 
35 were lost to follow-up or 
were not invited
447 did not participate in the 
fourth research round
137 participants died 
144 were lost to follow-up or 
were not invited 
341 did not participate in the 
second research round
3011 subjects participating in the first 
research round
2389 subjects participating in the second 
research round
1990
1993
1993
1995
1997
1999
2000
2001
2002
2004
2004
2005
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regarding these events at the general practitioners’ offices. Two research physicians independently coded 
all reported events. In cases of disagreement, consensus was sought and finally, a cardiologist, whose 
judgment was considered decisive, reviewed all events. Sudden cardiac deaths were defined operation-
ally as: 1) a witnessed natural death attributable to cardiac causes, heralded by abrupt loss of conscious-
ness, within one hour of onset of acute symptoms, or 2) an unwitnessed, unexpected death of someone 
seen in a stable medical condition <24 hours previously with no evidence of a non-cardiac cause.25, 26
Medication. In this study, the exposure of interest included listed cardiovascular QTc-prolonging drugs, 
as specified in lists 1 through 4 from a commonly consulted internet based registry of QTc prolonging 
drugs from R.L.Woosley (www.qtdrugs.org/medical-pros/drug-lists.cfm); and in the list with QTc prolong-
ing drugs from De Ponti et al. 27-30  The lists with QTc prolonging drugs are based on the medical literature 
and on the FDA database for reported adverse events. The QTc prolonging drugs from the internet based 
registry are classified into 4 categories, varying from drugs that are generally accepted by authorities to 
have a risk of causing Torsade de Pointes (list 1) to drugs that, in some reports, have a weak association 
with Torsade de Pointes and are unlikely to increase the risk when used in therapeutic dosages (list 4). 
In addition, De Ponti et al. have published a list of non-anti-arrhythmic drugs with pro-arrhythmogenic 
effects, based on a structured literature search including published (non-) clinical evidence and official 
warnings in the labelling.27, 28 
In our analyses, we included the following listed cardiovascular QTc prolonging drugs: anti-arrhythmics: 
amiodarone, disopyramide, flecainide, quinidine, sotalol; and other cardiovascular drugs: diltiazem, inda-
pamide, isradipine, ketanserin, losartan, nicardipine, triamterene and verapamil.
The index date in the QTc study population was the date of the ECG and in the sudden cardiac death 
study population the date of mortality. Cardiovascular drugs were considered to be currently used if the 
duration of the prescription covered the index date. The duration was the total number of units issued per 
prescription divided by the prescribed daily number of units. 
Covariates. Diabetes mellitus, hypertension, myocardial infarction and heart failure are considered to be 
risk factors for QTc prolongation and presence of these conditions at each index date was included as a 
covariate.31-34 Clinical measures were obtained during the visits at the Rotterdam Study research center. 
In 1990-1993 non-fasting blood samples were obtained, while in 1997-2000 blood samples were obtained 
after overnight fasting. Diabetes mellitus was defined as the use of blood glucose–lowering medication 
and/or a non-fasting serum glucose level of 11.1 mmol/l or higher and/or serum glucose levels  ≥ 7 mmol/l 
(1997-2000).35 Hypertension was defined as a systolic blood pressure ≥ 160 mm Hg and/or diastolic 
blood pressure ≥ 100 mm Hg and/or use of antihypertensive medication, encompassing grade 2 and 
grade 3 hypertension according to World Health Organization (WHO) criteria.36 Myocardial infarction at 
baseline and during follow-up was assessed by hospital discharge diagnosis or in case a patient was not 
hospitalized, when signs and symptoms, analysis of the standard 12-lead electrocardiogram and cardiac 
enzyme data were diagnostic of a myocardial infarction.37, 38 Heart failure at baseline and during follow-up 
were assessed by the presence of suggestive signs and symptoms and by the use of medication for the 
indication heart failure.39, 40 
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Genotyping. All participants were genotyped for the NOS1AP SNP rs10494366 T>G which was previ-
ously shown to be associated with QT interval in 3 independent samples.10 The partially correlated SNP 
rs10918594 C>G, which was associated with QT interval in one of the samples,10 was also genotyped. 
Both were genotyped using Taqman assays C_1777074_10 and C_1777009_10 (Applied Biosystems, 
Foster City, Ca., USA) in 1 ng of genomic DNA extracted from leukocytes, as previously reported.41 Hap-
lotypes were estimated using the estimation-maximization algorithm implemented in PHASE 2.0 (Univer-
sity of Washington, Seattle, WA)42, 43 and only individuals with successful genotyping for both SNPs were 
included in haplotype analyses.
Statistical analysis. Two types of analysis were conducted to assess the association between exposure 
to cardiovascular drug use, NOS1AP and QTc prolongation or sudden cardiac death.
The first analysis examined the association between exposure to cardiovascular drugs and the length 
of the QTc-interval. Since QTc measurements in subsequent ECGs in the same subject are correlated, 
the association was examined by means of linear regression repeated measures analyses implemented 
in PROC MIXED (SAS software, version 8.2). Analyses were adjusted for sex and the following time-
depending covariates: age, diabetes mellitus, hypertension, myocardial infarction, heart failure and use 
of other listed QTc prolonging drugs. 
Genotype frequencies were tested for Hardy-Weinberg equilibrium using a Chi-square test. Allelic geno-
type models were tested for the two polymorphisms rs10494366 T>G and rs10918594 C>G. In a sepa-
rate allelic analysis, non-users with the major alleles were considered the referent, to which users with 
the other alleles were compared individually. For all above-mentioned cardiovascular drugs, we tested 
whether the 2 NOS1AP variant alleles modified the effect on a multiplicative scale.
In a second analysis, the association between exposure to cardiovascular drugs, the NOS1AP variant 
and the risk of sudden cardiac death was examined using Cox proportional hazards models. Non-users 
with the major alleles were considered the referent, to which users with the minor alleles were compared. 
The analyses were adjusted for sex and time-depending age. The analyses were performed using SPSS 
for Windows version 11.0 (Chicago, Illinois, USA).
Results
Study subjects. The baseline characteristics of all participants of the QTc study population after exclu-
sion of left ventricular hypertrophy (538 ECGs), left and right bundle branch block (387 and 665 ECGs), 
use of digoxin (557 ECGs), participants with a pacemaker (53 ECGs) and with missing genotypes (2055 
ECGs) are presented in Table 1. Overall 16,603 ECGs in 7,565 participants, remained for analysis.
The mean age of the study population at the first ECG in the Rotterdam Study and the first extended 
cohort was 67.1 years (Standard Deviation 8.2), women were significantly older than men. At baseline 
574 participants had diabetes mellitus (9.8%), 127 participants had heart failure (2.2%), 1637 participants 
had hypertension (27.9%) and 509 participants have had a myocardial infarction (8.7%). At the time of an 
ECG, 319 participants used anti-arrhytmics and 676 participants used other cardiovascular drugs.
After exclusion of participants with missing genotypes (1685 participants) in the sudden cardiac death 
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study population, 6214 participants remained for analysis (Table 1). Overall, 2503 participants died of all 
causes, of whom 271 participants experienced sudden cardiac death. At baseline, the mean age of the 
study population was 69.4 years (SD 9.1), 646 participants had diabetes mellitus (10.4%), 198 partici-
pants had heart failure (3.2%), 2077 participants had hypertension (33.4%), 727 participants had myo-
cardial infarction (11.7%), 1383 participants currently smoked (22.3%), 2502 participants ever smoked 
(40.3%) and the mean body mass index was 26.3 kg/m2 (SD 3.7). These variables did not significantly 
differ between participants with or without sudden cardiac death. The mean follow-up period was 10.4 
years (SD 3.7).
Genotyping. The G-allele (minor) frequency of rs10494366 T>G was 36.5% and of rs10918594 C>G was 
31.4%. Successful genotype calls were made in 96.3% and 97.3% of subjects, respectively. Both SNPs 
were in Hardy-Weinberg equilibrium (p= 0.53 for rs10494366 and p= 0.78 for rs10918594). The two SNPs 
were in linkage disequilibrium with an r2 of 0.63 and D’ of 0.88 (95%CI 0.87 – 0.90). Upon phasing, we 
observed two common two-SNP haplotypes: TC (61.2%) and GG (29.2%), consisting of the two major 
and two minor alleles, respectively, and two minor haplotypes containing one major and one minor allele 
each: GC (7.2%) and TG (2.3%). Genotype distributions were similar for men and women and there were 
no age differences among genotypes.
Table 2 Cardiovascular drugs and QTc prolongation
Cardiovascular medication Users Prolongation QTc interval (95% CI)a
Anti-arrhytmics
Amiodarone 62 19.1 (13.7 ; 24.4)
Disopyramide 17 31.1 (20.8 ; 41.5)
Flecainide 52 12.7 (6.9 ; 18.4)
Quinidine 7 34.4 (13.0 ; 55.7)
Sotalol 181 16.0 (12.9 ; 19.0)
Other cardiovascular
Diltiazem 295 2.3 (-0.2 ; 4.8)
Indapamide 30 15.5 (7.7 ; 23.4)
Isradipine 44 1.1 (-5.7 ; 7.9)
Ketanserin 14 1.1 (-10.6 ; 12.8)
Losartan 146 4.3 (1.0 ; 7.6)
Nicardipine 6 -17.8 (-34.0 ; -1.7)
Triamterene 28 13.3 (5.3 ; 21.4)
Verapamil 113 6.7 (2.5 ; 10.9)
a Adjusted for age and sex, diabetes mellitus, hypertension, myocardial infarction, heart failure and 
use of other QTc prolonging drugs.   
111
Cardiovascular drugs, NOS1AP and QTc prolongation 
111
Cardiovascular drugs and QTc. The mean QTc interval at study entry was significantly lower in males 
(421.8 msec.) than in females (431.5 msec.). 74.3% had normal QTc durations at baseline and 19.3% had 
a borderline QTc interval, using previously described gender specific cut-off points. 
Overall, 559 participants developed QTc prolongation during follow-up (7.4%), with mean QTc levels of 
473.9 milliseconds. 
Current use of amiodarone (19.1 (95% CI 13.7 ; 24.4)), disopyramide (31.1 (20.8 ; 41.5)), flecainide (12.7 
(6.9 ; 18.4)), quinidine (34.4 (13.0 ; 55.7)), sotalol (16.0 (12.9 ; 19.0)), indapamide (15.5 (7.7 ; 23.4)), 
losartan (4.3 (1.0 ; 7.6)), triamterene (13.3 (5.3 ; 21.4)) and verapamil (6.7 (2.5 ; 10.9)) was associated 
with a significant QTc interval prolongation, after adjustment for age, sex, diabetes mellitus, heart failure, 
hypertension, myocardial infarction and use of other listed QTc prolonging drugs (Table 2).
Cardiovascular drugs, NOS1AP variant alleles and QTc interval. Minor alleles of both NOS1AP SNPs 
in combination with several listed QTc prolonging drugs were associated with a significant increase of the 
QTc interval (Table 3). SNP rs10494366 T>G in combination with current use of triamterene and vera-
pamil was associated with a significant QTc prolongation for the GG genotype compared to users with 
the TT genotype. Furthermore, although confidence intervals overlapped, point estimates indicated that 
a similar effect might exist for amiodarone, sotalol, diltiazem, indapamide, and perhaps isradipine and 
disopyramide. Point estimates suggest an opposite effect for losartan, i.e., less QTc prolongation for minor 
allele carriers. We observed no difference in effect of the SNPs between men and women.
SNP rs10494366 T>G modified the effect on QTc interval on a multiplicative scale in association with the 
following drugs: amiodarone, disopyramide, losartan, triamterene and verapamil. 
Similar effects were observed for the rs10918594 C>G SNP.
Cardiovascular drugs, NOS1AP variant alleles and sudden cardiac death. The NOS1AP polymor-
phisms rs10494366 T>G and rs10918594 C>G were not associated with a significantly increased risk of 
sudden cardiac death. After adjustment for known risk factors, each additional minor allele was associ-
ated with hazard ratio for sudden cardiac death of 1.11 (0.91-1.34) and 1.09 (0.90-1.33), respectively.
The number of SCD cases exposed to QT-prolonging medication at the time of death was too low to make 
a proper assessment of the influence of NOS1AP variants on SCD risk in users of these drugs. However, 
although confidence intervals overlap, point estimates for users of amiodarone (15 exposed SCD cases, 
HR 21.30 vs 5.47) and verapamil (8 exposed cases, HR 3.97 and 2.50 vs 1.81) suggest that NOS1AP mi-
nor variant carriers might be at increased risk of SCD compared to major allele homozygotes (Table 4). 
Discussion
We demonstrated, in this large prospective cohort study of an elderly population that the minor alleles of 
both NOS1AP SNPs significantly potentiated the QTc interval prolonging effect of current use of triam-
terene and verapamil. Furthermore, although confidence intervals overlapped, regression coefficients 
indicated that a similar effect might exist for amiodarone, sotalol, diltiazem, indapamide, and perhaps 
isradipine and disopyramide. Point estimates suggested an opposite effect for losartan. Furthermore, we 
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found indication that the NOS1AP minor alleles are associated with a significantly higher risk of sudden 
cardiac death in users of amiodarone, and verapamil. For some of the listed cardiovascular drugs we 
could not confirm a significant increase in the QTc interval or a higher risk of sudden cardiac death. This 
may have been due to limited power from small sample sizes. In general, the direction of change was as 
expected. The significant QTc interval shortening of nicardipine which we observed in our study popula-
tion, has been described before in mice.44
Recently, one of us found that SNP rs10494366 T>G was associated with a 3.8 msec increase in multivar-
iable-adjusted QTc interval for each additional G-allele, and SNP rs10918594 C>G was associated with a 
3.6 msec increase per additional G-allele.45 In participants with minor alleles of both NOS1AP SNPs the 
effect of the drugs on the QTc interval is reinforced. The effect we found exceeded an additive effect, while 
for several drugs the potentiation was even significant on a multiplicative scale.
Our study has several strengths. First, the fact that we had extensive information on potential confound-
ers as well as 15 years of follow-up to obtain enough cases of sudden cardiac death. Second, the avail-
ability of genetic material, extensive information on potential confounders, and complete coverage of 
drug dispensing records allowed us to study the association between cardiovascular drugs, NOS1AP 
variant alleles and QTc prolongation. Since the Rotterdam Study is a prospective cohort study within a 
circumscribed population with little loss-to-follow-up, selection bias is unlikely. If exposure misclassifica-
tion occurred it is probably non-differential. There is no information bias, since we used pharmacy data, 
which are registered prospectively and irrespective of disease status. One major advantage in our study 
was the availability of data on a large group of participants, including up to four ECGs per subject at 
regular intervals during follow-up, which allowed us to obtain more precise long-term ECG measures for 
each individual. Furthermore, the use of digital ECG recordings all measured using the MEANS system 
likely reduced intra- and interobserver variability in the assessment of the QTc interval. Confounding was 
minimized by adjusting for all known risk factors of QTc prolongation. An advantage of the Rotterdam 
Study is the prospective ascertainment of risk factors and the active surveillance for sudden cardiac death 
events over a relative long period of follow-up. Furthermore, we were able to take advantage of the fact 
that in most cases extensive information of the facts surrounding the event was available including, in 
many cases, the time between start of symptoms and death. This allowed rigorous adjudication of sudden 
cardiac death events.
Our study examined modification of the QTc prolonging effect of certain cardiovascular drugs by genetic 
variation. One might assume that genetic factors play a smaller role in our elderly cohort than in younger 
cohorts where long and short QT syndromes will add to mortality. This study confirms that the QTc interval 
is influenced by NOS1AP polymorphisms measured at a mean age at baseline of 67 years, increasing 
with follow-up. This serves as strong confirmation that genetic factors continue to play a role in an el-
derly population. While rare variants of strong genetic effects, such as are found in congenital Long QT 
Syndromes, are likely to be under negative selection as they reduce survival to reproduction, common 
variants of modest effects are more likely to escape negative selection as they contribute modestly and 
incrementally to a trait.46 Common polymorphisms with a relatively small effect are capable of explaining 
a great degree of the population QTc interval variation. Also, the polymorphisms may modify the risk as-
sociated with QTc prolonging drugs.
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In conclusion, we demonstrated that the minor alleles of both NOS1AP SNPs significantly potentiate the 
QTc prolonging effect of several cardiovascular drugs which were published on a list of QTc prolonging 
drugs, mainly in users of triamterene and verapamil. The fact that he minor alleles of NOS1AP are as-
sociated with a higher risk of sudden cardiac death in users of amiodarone, and verapamil, endorses the 
clinical importance of these gene-drug interactions.
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4.4
Common variation in the NOS1AP gene is associated 
with reduced glucose lowering effect
and with increased mortality in users of sulfonylurea
Abstract
Objective. The single nucleotide polymorphism rs10494366 in the NOS1AP gene is associated with QTc 
prolongation, through an effect on the intracellular Ca2+ levels. As sulfonylurea stimulate insulin secretion 
by an increased influx of Ca2+, we hypothesized that this polymorphism is associated with glucose lower-
ing effect and mortality risk in sulfonylurea users.
Methods. Associations between the NOS1AP polymorphism, prescribed doses and mortality rates in 
sulfonylurea, metformin and insulin users were assessed in the Rotterdam Study, a population based 
cohort study of 7,983 elderly people.
Results. We identified 619 who were prescribed oral antidiabetic drugs during follow-up. In glibenclamide 
users carrying the TG genotype, the prescribed doses were higher compared to users carrying the TT 
genotype (0.38 DDD units, 95% CI 0.14; 0.63). Glibenclamide users with the TG or GG genotype had an 
increased mortality risk compared to glibenclamide users with the TT genotype (HR 2.80, 95% CI 1.09; 
7.22). Tolbutamide users with the TG or GG genotype (HR 0.30, 95% CI 0.14; 0.63) and glimepiride users 
with the TG or GG genotype (HR 0.18, 95% CI 0.04; 0.74) had a decreased mortality risk compared to 
users with the TT genotype. 
Conclusion. In subjects with the TG or GG genotype at rs10494366 in the NOS1AP gene, glibenclamide 
is less effective in reducing glucose levels and mortality rates were higher compared to glibenclamide us-
ers with the TT genotype. In tolbutamide and glimepiride users the TG and GG genotype were associated 
with a reduced mortality rate.
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Introduction
Sulfonylurea drugs have been used extensively for decades in the treatment of type 2 diabetes. Since the 
publication of the University Group Diabetes Program trial in 1970, in which tolbutamide treatment was 
compared with other treatments and placebo, sulfonylurea have been associated with an increased risk of 
cardiovascular mortality.1 However, there was criticism on this study in subsequent publications.2-4 In 1998 
the results of another trial with sulfonylurea were published. In this UK Prospective Diabetes Study trial, 
in which treatment with a sulfonylurea (chlorpropamide, glibenclamide or glipizide) was compared with 
insulin treatment and conventional policy with diet, no detrimental effects of sulfonylurea were seen.5 Ever 
since, controversy remains as to whether sulfonylurea may increase the risk of cardiovascular death.
Sulfonylurea stimulate insulin secretion by the pancreatic β-cells.6-8 The sulfonylurea receptor (SUR) is 
part of the ATP-sensitive K+ (KATP) channel. Binding of the sulfonylurea to SUR causes inhibition of the 
KATP-channel, decreasing the K+ efflux and depolarization of the cell membrane. This triggers the open-
ing of voltage dependent Ca2+ channels, eliciting Ca2+ influx and a rise in intracellular Ca2+. In the pancre-
atic β-cell, this rise stimulates the exocytosis of insulin-containing secretory granules.
Nitric oxide synthases (NOS) are the enzymes responsible for nitric oxide generation. Nitric oxide regulates 
cardiovascular homeostasis.9 Recently, two nearby single nucleotide polymorphism (SNP), rs10494366 
and rs10918594, in the gene encoding Nitric Oxide Synthase 1 Adaptor Protein (NOS1AP) have been 
associated with QTc-interval prolongation in electrocardiograms (ECGs).10-12 NOS1AP is a regulator of 
neuronal NOS (nNOS encoded by NOS1), one of the isoforms of NOS. The nNOS enzyme is believed 
to regulate intracellular calcium levels.9, 13 It is thought that nNOS inhibits the inward Ca2+ current through 
voltage dependent calcium channels, reducing the intracellular calcium concentrations. Thereby it sup-
presses β-adrenoreceptor stimulation of the heart. nNOS has also been associated with insulin release. 
14, 15
There are similarities between the effects of nNOS and sulfonylurea. Both nNOS and sulfonylurea influ-
ence the calcium influx through voltage dependent calcium channels. Moreover nNOS and sulfonylurea 
modulate the release of insulin by pancreatic β-cells. Both might be associated with cardiovascular mor-
tality. In view of these similarities we hypothesized that genetic variation in the NOS1AP gene influences 
the glucose lowering effect of sulfonylurea and mortality risk in patients using sulfonylurea.
Methods
Setting. The data were obtained from the Rotterdam Study, a prospective population based closed cohort 
study in the suburb Ommoord in Rotterdam. All inhabitants who were 55 years of age or older and had 
lived in the district for at least one year, were invited between 1990 and 1993 to participate in the study. 
Of the 10,275 eligible persons, 7,983 participated and were followed since then. At baseline, trained 
interviewers administered a questionnaire during a home interview covering socioeconomic background 
and medical history, among other topics. During subsequent visits to the study center, laboratory assess-
ments and clinical examinations were performed, including recording of ECGs. Follow-up examinations 
were carried out periodically (every 4 to 5 years). All participants of the Rotterdam Study gave written 
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informed consent. Ethical approval was obtained from the Medical Ethical Committee of the Erasmus 
Medical Center. The aim of the study was to investigate determinants of chronic and disabling cardio-
vascular, neurodegenerative, locomotor and ophthalmological diseases. The design of the Rotterdam 
Study has been described before.16, 17 All mortality cases were identified, by obtaining at regular intervals 
the vital status of the participants from the municipal population registry. After notification of death, cause 
and circumstances were established by information from the general practitioner, letters, and in case of 
hospitalization, discharge reports from medical specialists were obtained. Two research physicians coded 
all events independently according to the International Classification of Diseases-10th edition.18 In case of 
disagreement, consensus was sought. The seven pharmacies in Ommoord dispense the prescriptions of 
more than 99% of all participants. Information on all filled prescriptions from January 1st 1991 until January 
1st 2005 was available and included the product name of the drug, the Anatomical Therapeutical Chemical 
(ATC) code, the amount dispensed, the prescribed dosage regimen and the date of dispensing.19
Cohort Definition. All participants of the Rotterdam Study, who received a prescription for an oral an-
tidiabetic drug in the period between January 1st 1991 and January 1st 2005, were included in the study 
population at the time of the first prescription. These subjects were followed until death or end of the study 
period whichever came first. 
Outcomes. Associations between the SNPs rs10494366 and rs10918594 in the NOS1AP gene, and pre-
scribed doses of sulfonylurea, all-cause and cardiovascular mortality and first myocardial infarction were 
assessed. We used two types of study outcome, the change in prescribed dose of oral antidiabetic drugs 
compared to the first prescription and mortality while using antidiabetic drugs.
First, we analyzed differences between genotypes in prescribed doses in incident oral antidiabetic drug 
users. All subjects who received a first prescription for a sulfonylurea drug after July 1st, 1991 were in-
cluded in this analysis and followed until the last prescription of that particular antidiabetic drug. July 1st, 
1991 was chosen to ensure that we would have complete medication histories for at least half a year from 
January 1st, 1991. For every prescription of the oral antidiabetic drug the subject started on, the change in 
prescribed daily dose compared to the first prescription was calculated. As doses are titrated to avoid hy-
poglycemia and diabetes mellitus is a progressive disease, the prescribed doses of oral antidiabetic drugs 
usually increase over time. The prescribed daily dose is given as the number of defined daily dose (DDD) 
units, established by the World Health Organization, to make prescribed doses comparable between dif-
ferent drugs.19 If subjects received more than one oral antidiabetic drug, the number of DDD units of the 
other drugs was added to the drug, which was prescribed first. 
Second, we analyzed differences in all-cause mortality between genotypes within users of the same 
antidiabetic drug. We also analyzed differences in mortality in patients using metformin and insulin. In a 
subsequent analysis, we restricted to events that were coded as cardiovascular mortality. Similarly, we 
analyzed differences in the risk for a first (fatal and non-fatal) myocardial infarction.
Cofactors. The following characteristics were considered as potential determinants for affecting the 
change in prescribed daily dose of sulfonylurea after start: age, sex and calendar time. Determinants 
122
Chapter 4.4
122
potentially affecting the mortality rates were age, sex, QTc-interval at baseline, the cumulative prescribed 
dose of all oral antidiabetic drugs at the index date, the number of days the sulfonylurea of interest was 
prescribed until the index date and whether the subject used insulin at the index date. We also adjusted 
for current dihydropyridine calcium channel blocker use, because we recently found an association be-
tween genetic variation in NOS1AP and mortality in dihydropyridine calcium channel blocker users. The 
time of entrance in the Rotterdam Study was regarded as baseline and the results of physical examina-
tions at the first visit were used in the analysis.
Genotyping. All participants were genotyped for the NOS1AP SNP rs10494366 T>G previously shown 
to be associated with QTc interval in five independent samples.10-12 The correlated SNP rs10918594 
C>G, which is in linkage disequilibrium, was also genotyped. Both were genotyped using Taqman assays 
C_1777074_10 and C1777009_10 (Applied Biosystems, Foster City, Ca., USA) in 1 ng of genomic DNA 
extracted from leukocytes, as previously reported.11, 20
Statistical analysis. A χ2-test was used to test for deviation from Hardy-Weinberg equilibrium. We used 
unbalanced repeated measurements analysis to analyze the difference per genotype in the change in 
prescribed daily dose (in DDD units) in series of all consecutive prescriptions of oral antidiabetic drugs 
for the same subject compared to the prescribed daily dose of the first prescription. For these analyses, 
we used the PROC Mixed module of SAS (version 8.2). Cox proportional hazards analysis was used to 
analyze difference in mortality between genotypes in users of the same antidiabetic drug. For each antidi-
abetic drug, all subjects in the study population who died between July 1st,1991 and January 1st, 2005, 
while using that antidiabetic drug were identified as cases. The mortality date was taken as the index 
date. To each case we matched all persons in the cohort using that antidiabetic drug on the index date of 
the corresponding case. Subjects with missing values were excluded from the analyses. Cox proportional 
hazards analysis was also used for analyzing differences in first myocardial infarction between genotypes. 
These analyses were performed using SPSS software (version 11.0.1; SPSS, Chicago IL).
Results
In the Rotterdam Study, we identified 784 subjects who were prescribed oral antidiabetic drugs. One hun-
dred thirty-four subjects were excluded because a blood sample was not available and 31 subjects were 
excluded because of failure to genotype successfully. Consequently, 619 subjects were available for the 
analysis (Table 1). We analyzed the associations between both SNPs rs10494366 and rs10918594 and 
the study outcomes. Since the associations with the SNP rs10494366 were stronger, only these results 
are presented. The minor allele frequency was 0.38 (G allele) and genotype distribution was in Hardy-
Weinberg equilibrium (χ2=1.94, p=0.38). 
Four hundred fifty-two subjects received a first prescription for sulfonylurea between July 1st 1991 and 
January 1st 2005, and these patients were considered as incident users. There were no significant dif-
ferences in starting dose among the genotypes. The average increase in prescribed daily dose for all 
consecutive prescriptions compared to the first prescriptions is given in Table 2. Among 74 patients using 
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Table 1 Characteristics of the study population by NOS1AP rs10494366 genotype
rs10494366 genotype
Characteristic TT TG GG
Number 247 275 97
Gender, male 103 (41.7%) 118 (42.9%) 44 (45.4%)
Age (SD) 69.7 (8.3) years 69.1 (7.9) years 69.8 (8.5) years
Follow-up time (SD) 11.1 (3.3) years 11.0 (3.7) years 10.5 (4.0) years
Body mass index (SD) 28.0 (3.6) kg/m2 28.2 (3.8) kg/m2 28.6 (4.5) kg/m2
Serum creatinine, μmol/l (SD) 85.0 (16.1) (n=198) 84.9 (17.0) (n=213) 84.3 (17.9) (n=70)
Drug use during follow up
Glibenclamide 87 (35.2%) 109 (39.6%) 37 (38.1%)
Tolbutamide 137 (55.5%) 155 (56.4%) 55 (56.7%)
Gliclazide 43 (17.4%) 41 (14.9%) 10 (10.3%)
Glimepiride 56 (22.7%) 77 (28.0%) 23 (23.7%)
Metformin 141 (57.1%) 165 (60.0%) 55 (56.7%)
Insulin 49 (19.8%) 62 (22.5%) 19 (19.6%)
Figure 1 Change in prescribed daily dose (in DDD units) of glibenclamide plus co-prescribed oral antidi-
abetic drugs in patients starting with glibenclamide compared to the first prescription.
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Table 2 Average change in prescribed dose of oral antidiabetic drugs (in DDD units) in incident sulfo-
nylurea users by rs10494366 genotype.
Drug TT TG GG
N N Change (95% CI) N Change (95% CI)
Glibenclamide 32 Reference 28 0.38 (0.14; 0.63) 14 0.11 (-0.32; 0.55)
Tolbutamide 115 Reference 116 -0.02 (-0.12; 0.08) 50 -0.05 (-0.19; 0.08)
Gliclazide 12 Reference 11 0.05 (-0.45; 0.55) 2 0.37 (-0.65; 1.39)
Glimepiride 24 Reference 41 0.16 (-0.22; 0.53) 7 0.26 (-0.43; 0.95)
Table 3 Association between the polymorphism rs10494366 in the NOS1AP gene and all-cause mor-
tality in sulfonylurea users.
Drug and genotype Casesa Unadjusted HR Adjusted HR (95% CI)b
Glibenclamide
TT Reference Reference
TG 15 2.30 2.95 (1.02; 8.52)
GG 8 2.97 4.42 (1.23; 15.9)
Tolbutamide
TT 21 Reference Reference
TG 13 0.34 0.26 (0.11; 0.59)
GG 6 0.48 0.27 (0.09; 0.87)
Gliclazide
TT 9 Reference Reference
TG 3 0.41 0.32 (0.03; 3.27)
GG 0 -c -c
Glimepiride
TT 9 Reference Reference
TG 7 0.50 0.15 (0.05; 0.75)
GG 2 -c -c
Metformin
TT 10 Reference Reference
TG 12 0.86 0.82 (0.33; 2.06)
GG 7 1.45 1.65 (0.59; 4.55)
Insulin
TT 16 Reference Reference
TG 22 1.03 1.00 (0.48; 2.06)
GG 8 0.90 1.23(0.41; 3.68)
a Since patients can use more than one antidiabetic drug, these numbers do not add up to 142
b Adjusted for: age, sex, QTc time, prescribed doses oral antidiabetic drugs, duration of use, insulin use and dihy-
dropyridine calcium channel blocker use
c Too few cases were available to calculate HR’s
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glibenclamide, patients with the TG genotype received on average a daily-prescribed dose that was 0.38 
DDD higher (95% CI 0.14; 0.63) than in patients with the TT genotype. The difference between patients 
with the GG genotype and the TT genotype was not significantly different (0.11 DDD, 95% CI –0.32; 0.55). 
The change in prescribed daily dose for consecutive prescriptions of glibenclamide is given in Figure 1. 
Patients with the GG genotype starting on glibenclamide were on average prescribed fewer prescriptions 
for glibenclamide than patients with the TG genotype (20.4 versus 27.4, p=0.04). For the other sulfonylu-
rea no differences in prescribed doses were found.
In the cohort of 619 subjects, 156 subjects died during follow-up while using antidiabetic drugs. In 142 of 
the 156 cases we had complete follow-up information, including QTc-interval, and these subjects were 
used for the mortality analyses. In the group of glibenclamide users, both users with the TG genotype 
(Hazard Ratio (HR) 2.95, 95% CI 1.02; 8.52) and GG genotype (HR 4.42, 95% CI 1.23; 15.9) had a higher 
mortality rate than users with the TT genotype (Table 3). For tolbutamide (TG genotype HR 0.26, 95% 
CI 0.11; 0.59 and GG genotype HR 0.27, 95% CI 0.09; 0.27) and glimepiride (TG genotype HR 0.15, 
95% CI 0.05; 0.75) the effects were the opposite. Subjects on these drugs with the TG and GG genotype 
Table 4 Association between the polymorphism rs10494366 in the NOS1AP gene and cardiovascular 
mortality in sulfonylurea users.
All-cause mortality Cardiovascular mortality
Drug and genotype N HR (95% CI)a Nb HR (95% CI)a
Glibenclamide
TT 6 Reference 4 Reference
TG or GG 23 2.80 (1.09; 7.22) 8 1.45 (0.34; 6.19)
Tolbutamide
TT 21 Reference 11 Reference
TG or GG 19 0.30 (0.14; 0.63) 6 0.09 (0.02; 0.40)
Gliclazide
TT 9 Reference 5 Reference
TG or GG 3 0.23 (0.02; 2.34) 0 -c
Glimepiride 3
TT 9 Reference 3 Reference
TG or GG 9 0.18 (0.04; 0.74) -c
Metformin
TT 10 Reference 5 Reference
TG or GG 19 1.12 (0.50; 2.51) 7 1.10 (0.29; 4.23)
Insulin
TT 16 Reference 7 Reference
TG or GG 30 1.03 (0.52; 2.01) 14 1.23 (0.43; 3.50)
a Adjusted for: age, sex, QTc time, prescribed doses oral antidiabetic drugs, duration of use, insulin use and dihy-
dropyridine calcium channel blocker use
b Since patients can use more than one antidiabetic drug, these numbers do not add up to 63
c Too few cases were available to calculate HR’s
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had lower mortality rates, although the numbers for the subjects with the GG genotype using glimepiride 
were too small to calculate hazard rates. In gliclazide users a non-significant protective effect for the TG 
genotype was found (95% CI 0.32, 95% CI 0.03; 3.27). No associations were found between all-cause 
mortality and NOS1AP genotype in metformin or insulin users.
In 63 of the 142 subjects who died during follow-up, the cause of death was categorized as cardiovascu-
lar. In Table 4 the associations between NOS1AP genotype and cardiovascular mortality are given. Since 
the hazard estimates for the all-cause mortality are suggestive of a dominant effect of the G-allele and the 
power is too low for separate analyses, we grouped patients with the TG and GG genotype. In glibencl-
amide users no differences were found in cardiovascular mortality between genotypes (HR 1.45, 95% CI 
0.34; 6.19). With tolbutamide the decreased mortality in users with the TG or GG genotype seemed to be 
caused by a decrease in cardiovascular mortality. (HR 0.09, 95% CI 0.02; 0.40) For metformin and insulin, 
no differences in cardiovascular mortality were found. 
Forty-nine cases of myocardial infarction were identified in subjects using antidiabetic drugs. The number 
of first myocardial infarctions in subjects using glibenclamide was too low to examine. In the group of 
subjects using tolbutamide, gliclazide or glimepiride, the hazard ratio for a myocardial infarction was 0.89 
(95% CI 0.27; 2.97) for users with the TG or GG genotype compared to users with the TT genotype, albeit 
only 12 cases were identified. For subjects using insulin the hazard ratio was 1.34 (95% CI 0.48; 3.73). 
Discussion
In this population based cohort study, the glucose lowering effect of glibenclamide seems to be less effec-
tive in users with the TG or GG genotype, because over time their daily dose is significantly higher than 
in users with the TT genotype. Moreover, for all sulfonylurea differences were found in mortality between 
patients with the TG or GG genotype and patients with the TT genotype. The effects of glibenclamide 
on mortality were opposite to the other sulfonylurea. In subjects using glibenclamide the TG and GG 
genotype were associated with an increased risk of mortality, while in subjects using tolbutamide and 
glimepiride this genotype was associated with a reduced risk of mortality. No differences were found in 
subjects using metformin or insulin.
Subjects with the TG genotype using glibenclamide were prescribed higher doses than subjects with the 
TT genotype. As prescribed doses are titrated according to glucose levels, it is likely that this is caused by 
a difference in glucose lowering effect. Subjects with the GG genotype, starting on glibenclamide, stopped 
sooner with using glibenclamide than subjects with the TG genotype. This may explain why no difference 
in the average prescribed dose was found for users with the GG genotype, although the changes in pre-
scribed dose for users with the TG and GG genotype are similar in Figure 1.
Since the hazard rates for the TG and GG genotype are similar, we suggested a dominant effect of the G 
allele. If the underlying genetic effect operated through a recessive or additive effect, larger differences 
between the TG and GG would be expected. In the analyses of cardiovascular mortality we analyzed 
subjects with the TG or GG genotype as one group, because numbers were too low to analyze them 
separately. Only in subjects with the TG or GG genotype using tolbutamide, a decreased hazard rate for 
cardiovascular mortality was found. 
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The reduced all-cause mortality seen in subjects with the TG or GG genotype using tolbutamide and 
glimepiride may be caused by NOS1AP influencing the pharmacological pathway of sulfonylurea. In met-
formin and insulin users no differences were found, indicating that the differences are related to sulfonylu-
rea use and not to the underlying disease. Also in gliclazide users a reduced mortality was seen, although 
not significant. Both NOS1AP and sulfonylurea regulate the Ca2+ influx by voltage dependent calcium 
channels. Sulfonylurea stimulate Ca2+ influx by blocking the KATP-channels, while the exact mechanism 
of nNOS is not known. In subjects with the TG or GG genotype using tolbutamide a reduced risk of car-
diovascular mortality was seen. In subjects with the TG or GG genotype using gliclazide and glimepiride 
a reduction in cardiovascular mortality was the most likely explanation of the reduced all-cause mortality, 
although the differences were not significant. These effects on cardiovascular mortality in subjects using 
tolbutamide, gliclazide and glimepiride may be caused by the effect sulfonylurea have on the heart. More 
than one isoform of the SUR exist.8, 21-23 The SUR1 isoform is found in the pancreas, the SUR2A isoform in 
the heart and skeletal muscle and the SUR2B isoform in vascular smooth muscles. The glucose lowering 
effect of sulfonylurea is accomplished by binding to the SUR1 receptor on the β-cell. Sulfonylurea also 
bind to other SUR isoforms. It is suggested that the affinity to the SUR2A isoform could be responsible 
for the effects on cardiovascular mortality.21, 24-26 Under normal conditions the KATP-channels in the heart 
are closed. They open in response to metabolic stress such as ischemia, and the increasing total outward 
K+ current shortens the action potential duration, decreases Ca2+ influx and contraction and conserves 
ATP. Binding to the SUR2A isoform by sulfonylurea may block this ATP conserving pathway and possibly 
influences survival of ischemic events. 
The effects seen in subjects using glibenclamide were different from that seen in subjects using other 
sulfonylurea. Glibenclamide has a higher affinity for the SUR2A receptor than the other sulfonylurea.8, 22, 24, 
27-29 This difference in affinity by glibenclamide for the SUR2A receptor cannot explain all the results. Since 
SUR2A is only found on cardiac tissue, no differences would be expected in prescribed doses. 
Glibenclamide is also an inhibitor of other channels than the KATP-channel.30, 31 Studies have shown 
that beside the KATP-channel, other potassium channels are present in the β-cell, such as the Ca2+-de-
pendent K+ channel.32, 33 Blocking one or more of these channels by glibenclamide may be an alternative 
explanation for the results found in this study. A possible explanation for our results may be that there is 
a difference in effect on the Ca2+-dependent K+ channel between glibenclamide and other sulfonylurea. 
This explanation is supported by two observations. First, Ca2+-dependent K+ channel are also found in 
the pancreatic β-cell, influencing the firing of action potentials and possibly insulin release. Second, nitric 
oxide directly activates these Ca2+-dependent K+ channels, which could explain the role of NOS1AP.34 
Since we are not aware of studies assessing the influence of other sulfonylurea than glibenclamide on 
Ca2+-dependent K+ channels, we do not know whether differences in blocking these channels do attribute 
to the differences between glibenclamide and other sulfonylurea found in this study.
Although nNOS has previously been associated with insulin release we do not think that this association 
can explain the differences in prescribed doses and mortality risk in sulfonylurea users. The association 
with insulin release was too weak to explain the results and the associations were not found for metformin 
and insulin, suggesting that the association is related to sulfonylurea. As we adjusted for the QTc interval, 
also the QTc prolongating effect of NOS1AP is less likely to explain the observed results.
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In population based studies, bias may affect the obtained results. We believe that bias in our study is 
minimal. Since diabetes mellitus is a progressive disease, co-prescription of other antidiabetic drugs and 
switching is common. Confounding by indication may have occurred if the risks at the start of a drug were 
different between genotypes, due to differences in the effect of previously prescribed drugs. This is for 
example the case if the genotype influences the rate of switching or co-prescription during previously pre-
scribed drugs. However, if we adjusted for previously prescribed sulfonylurea, the results did not change. 
Therefore we do not think that confounding by indication did influence our results. Information bias is 
unlikely, since information was collected prospectively without prior knowledge of the study hypothesis. It 
is also unlikely that selection bias has occurred since we identified all patients with diabetes mellitus in a 
population based cohort study, and the absence of a blood sample and difficulties with genotyping were 
probably independent of the genotype.
Although there is always the possibility that the results are a chance finding, we think that this is prob-
ably not the case in our study. First, the analyses were not part of a genome wide association study. 
The SNP rs10494366 was associated with QTc prolongation in five independent populations before and 
we were testing whether this SNP affected prescribed doses and all-cause mortality in sulfonylurea us-
ers. Therefore, multiple testing did not bias our results. Second, significant associations with all-cause 
mortality were found for tolbutamide and glimepiride, while no significant associations were found for 
metformin and insulin. The point estimate for gliclazide was similar to the point estimate for tolbutamide 
and glimepiride, although not significant. Probably, this was due to lack of power in this group. For glib-
enclamide, we also found an association with all-cause mortality, although opposite to the effects of the 
other sulfonylurea. Differences in effect between glibenclamide and other sulfonylurea were seen before, 
although the differences were ascribed to differences in the affinity to the SUR2A receptor.
To conclude, the glucose lowering effect of glibenclamide in patients with the TG or GG genotype seems 
to be less effective. Moreover, genetic variation in the NOS1AP gene seems to predict the risk of mortality 
in patients using sulfonylurea. Although the exact mechanism has not been revealed, our results give a 
new insight into the pharmacological association between sulfonylurea use and cardiovascular mortality.
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Effect of ABCB1 and NOS1AP genotypes on cardiac 
function in digoxin users
Abstract
Background. Digoxin is one of the oldest cardiovascular drugs still in use today. It increases contrac-
tile force but delays relaxation of cardiomyocytes which may induce or aggravate diastolic dysfunction. 
Digoxin is a known substrate of ABCB1 gene encoded P-glycoprotein and common ABCB1 SNPs are 
associated with increased digoxin serum concentration. Also, we previously demonstrated that NOS1AP 
variants may interact with digoxin and influence cardiac function. Therefore, we hypothesized that ABCB1 
and NOS1AP SNPs might modify the effects of digoxin on systolic and diastolic cardiac function as as-
sessed by echocardiography.
Methods. Digoxin users were identified in the Rotterdam Study, a prospective population-based cohort 
study of individuals aged 55 years and older. Participants who were not genotyped or with prevalent atrial 
fibrillation or flutter were excluded. Echocardiographic parameters were assessed using two-dimensional, 
M-mode and Doppler echocardiography. ABCB1 and NOS1AP SNPs were assessed on DNA from pe-
ripheral blood lymphocytes using Taqman assays. We studied the association of ABCB1 and NOS1AP 
genotypes and digoxin use with systolic and diastolic cardiac function. Analyses were performed stratified 
on prevalent heart failure or myocardial infarction.
Results. Echocardiograms and genotypes were available for 4827 participants, 59 of which used digoxin. 
We found some support for the hypothesis that common ABCB1 variants potentiate the effects of digoxin 
on cardiac function. NOS1AP minor alleles seem to be associated with increased E/A ratio in digoxin us-
ers, with decreased systolic function in subjects with prevalent heart disease and with increased systolic 
function in those without. However, none of the associations was statistically significant.
Conclusion. The results point at a modulating effect of ABCB1 and NOS1AP SNPs on the cardiac effects 
of digoxin, but the power was too low to reliably demonstrate or exclude any associations.
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Introduction
Digoxin is one of the oldest cardiovascular drugs still in use today. It is widely used for treatment of atrial 
fibrillation and heart failure. Digoxin exerts its action, in part, by increasing intracellular Ca++ concentration 
([Ca++]i), leading to higher contractile force of cardiomyocytes but to delayed relaxation which may induce 
or aggravate diastolic dysfunction.1, 2
Digoxin is a known substrate of P-glycoprotein, a multidrug efflux transporter, which is involved in the up-
take, excretion and distribution of many drugs.3, 4 P-glycoprotein is encoded by the ATP-Binding Cassette 
B1 (ABCB1) also known as the Multidrug Resistance 1 (MDR1) gene, a 200kb gene on chromosome 
7p21. It was first discovered in chemotherapy resistant tumor cells but ABCB1 is also widely expressed in 
normal tissues such as the duodenum, kidneys, liver and the heart.5-10 The influence of ABCB1 SNPs on 
digoxin kinetics has been subject of many studies. However, most studies were small and the results were 
not unequivocal.11 In a recent study, we showed that common variants in ABCB1 were associated with 
increased serum digoxin concentrations and risk of supra-therapeutic concentrations in a group of 195 
chronic digoxin users from the Rotterdam Study.12 These findings imply that ABCB1 polymorphisms lead 
to increased serum digoxin concentrations and may thereby modulate the effects of digoxin on systolic 
and diastolic cardiac function. 
Common variants of the nitric oxide synthase 1 adaptor protein (NOS1AP) gene were recently discov-
ered to be associated with QT-interval prolongation in a genome wide association study.13 We replicated 
this finding in the Rotterdam Study, a large population based cohort of persons 55 years and older.14 So 
far, not much is known about the mechanism by which NOS1AP influences QT duration. NOS1AP acti-
vates neuronal nitric oxide synthase (NOS1). NOS1 knockout cardiomyocytes have increased contractil-
ity through increased [Ca++]i and a slower time to relaxation.
15-19 Furthermore, we recently demonstrated 
that NOS1AP variants and digoxin interact in QT-shortening and risk of sudden cardiac death to digoxin,20 
making a common pathway involving [Ca++]i handling even more likely. Therefore, we hypothesized that 
these variants interact with digoxin possibly resulting in changed cardiac function.
We carried out a prospective cohort study within the Rotterdam Study, in order to analyze the influence 
of common ABCB1 and NOS1AP variants on the effect of digoxin on systolic and diastolic cardiac func-
tion.
Methods
Study population. The study was performed within the framework of the Rotterdam Study, a population-
based cohort study aimed at assessing the occurrence of and risk factors for chronic diseases in the 
elderly.21, 22 Baseline visits of the Rotterdam Study took place in 1990-1993. All inhabitants of a suburb of 
Rotterdam aged 55 years and over were invited and 7983 agreed to participate (response 78%). Follow-
up visits took place approximately every four years. In 2000-2001, the cohort was extended with 3011 
participants from the same suburb (response 67%), also aged 55 years and over. For the present study, 
data collection took place from 2002 to 2005. Within this period, the participants from the original cohort 
completed their fourth center visit (n=3550), and the participants of the extended cohort completed their 
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second center visit (n=2389). Of these, 3052 and 2235, respectively, underwent cardiac echocardiogra-
phy. The large majority of missing echocardiograms was explained by incidental absence of echocardiog-
raphers. 
Participants who were not genotyped for ABCB1 (n=2431, ABCB1 was not genotyped in the inception 
cohort) or NOS1AP (n=330), or those with atrial fibrillation or atrial flutter (n=137) at the time of echocar-
diography were excluded from the analysis. This resulted in a total of 2753 participants available for the 
ABCB1 and 4827 for the NOS1AP analyses. The medical ethics committee of Erasmus Medical Center, 
Rotterdam, approved the study. Participants gave written informed consent and permission to retrieve 
information from treating physicians. The investigation is in accordance with the principles outlined in the 
declaration of Helsinki. 
Assessment of risk factors and prevalent disease. Clinical characteristics including smoking, body 
mass index (BMI), hypertension, diabetes mellitus, heart failure and myocardial infarction were ascer-
tained as previously described.23-28 Active surveillance for incident diabetes mellitus, heart failure and 
myocardial infarction is conducted continuously between follow-up examinations. Presence of atrial fibril-
lation or atrial flutter at the time of echocardiography was assessed with electrocardiography by applying 
the Modular ECG Analysis System (MEANS), which has been extensively evaluated,29, 30 and is charac-
terized by a high sensitivity (96.6%) and a high specificity (99.5%) in coding arrhythmias.31 For a small 
sample of participants, ECGs were not available at the time this report was written because of logistic 
problems and were approximated by using ECGs from the previous examination (year 2000-2001).
Genotyping. All participants from the baseline cohort of the Rotterdam Study for whom DNA was avail-
able were genotyped for the ABCB1 C1236T, G2677T/A and C3435T polymorphisms. Genotyping was 
done using Taqman allelic discrimination assays as previously described.12 Haplotypes were estimated 
using the estimation maximization algorithm and software as described in the statistical analyses sec-
tion.
All participants from both cohorts for whom DNA was available were genotyped for the NOS1AP SNP 
rs10494366 T>G and the correlated SNP rs10918594 C>G, as previously described.14, 32 Because SNP 
rs10494366 showed stronger evidence of association with QTc in the Rotterdam Study we considered it 
primary in the analyses.14
Digoxin exposure. Exposure of study participants to medications is gathered on a continuous basis 
since January 1st, 1991 through computerized pharmacy records from the study area covering >99% of 
prescriptions to the study population. In order to assess exposure to digoxin on the date of the echocar-
diography, we calculated the prescription duration of dispensed digoxin prescriptions as the number of 
units dispensed divided by the number of units to be taken per day. Digoxin dose was expressed as the 
defined daily dose (DDD) as determined by the WHO (1 DDD is 0.25mg of digoxin).
A study participant was considered to be exposed to digoxin if the echocardiography was taken on a date 
that fell within the duration of a dispensed digoxin prescription.
138
Chapter 5
138
Echocardiography. Our primary endpoint was echocardiographic parameters of cardiac function. For 
each participant, an echocardiogram was obtained. The first 2188 echocardiograms were performed with 
a commercially available ultrasonography system (AU3 Partner, Esaote Biomedica, with a 3.5/2.5 MHz 
transducer). The following 3099 echocardiograms were performed with another commercially available 
system (Acuson Cypress, with a 3V2c transducer). A standardized protocol was used, including two-
dimensional scanning in the parasternal long axis view, parasternal short axis view, apical view and sub-
costal view, M-mode scanning in the parasternal long axis view, and pulsed wave Doppler scanning in the 
apical four chamber view.33 Echocardiograms were recorded onto VHS tape and assessed at the reading 
center, which was located at Erasmus Medical Center. 
Several structural parameters were assessed.34 Left ventricular end systolic dimension (LVES) and left 
ventricular end diastolic dimension (LVED), were measured in the parasternal long axis view using M-
mode with two-dimensional guidance. With regard to systolic parameters, left ventricular ejection frac-
tion was calculated as (end-diastolic volume minus end-systolic volume)/end-diastolic volume,34 where 
the end-diastolic volume was LVED3 and end-systolic volume was LVES3, based on the cubed method. 
Fractional shortening at the endocardium was calculated as (LVED-LVES)/LVED*100%.34 Global left ven-
tricular systolic function was qualitatively assessed, without quantitative measurement, from the two-
dimensional echocardiogram and classified as normal, fair, moderate or poor. Furthermore, diastolic pa-
rameters were measured.35 Pulsed Doppler recordings of transmitral filling velocity were performed in 
the apical 4-chamber view, with the sample volume placed in the mitral valve orifice near the tips of the 
leaflets. Doppler peak E and peak A velocities were averaged over 3 cycles.  E/A ratio was computed by 
dividing Doppler peak E velocity by Doppler peak A velocity. Early mitral valve velocity deceleration time 
was measured as the time between the peak E wave and the upper deceleration slope extrapolated to 
the zero baseline.
Echocardiograms were made and read by 4 trained echocardiographers blinded to the research ques-
tion and exposure. To assess intra-reader and inter-reader agreement, 32 participants were examined in 
duplicate. For continuous variables, overall median percent intra-reader and inter-reader measurement 
variabilities were calculated as the absolute measurement difference divided by the average of the two 
measurements, multiplied by 100. Overall median intra-reader and inter-reader variabilities for left ven-
tricular end-diastolic dimension were 3% and 4%, respectively. For left ventricular end-systolic dimension 
both variabilities were 6%, and for fractional shortening both were 8%. Overall median intra-reader and 
inter-reader variabilities for E/A ratio were 15% and 18%, respectively, and for deceleration time both were 
16%. Finally, the percentage agreement for categorization of left ventricular systolic function as normal or 
other than normal was 82% within readers and 86% between readers.
Statistical analysis. We calculated means, medians and proportions of cardiovascular risk factors and 
echocardiographic characteristics in men and women. We categorized E/A ratio and deceleration time 
according to cut points used in previous reports. Normal diastolic function was defined as E/A ratio be-
tween 0.75 and 1.50 and deceleration time between 150 ms and 240 ms. Impaired relaxation was defined 
as E/A ratio < 0.75 and deceleration time > 240 ms. Restrictive diastolic dysfunction was defined as E/A 
ratio > 1.50 and deceleration time < 150 ms.36, 37  Participants were required to have both Doppler criteria 
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consistent with impaired relaxation or restrictive dysfunction in order to be classified. Participants with one 
abnormal criterion were classified as indeterminate rather than as normal.
Exact Hardy Weinberg equilibrium p-values were computed for bi-allelic SNPs and a simulated p-value 
for the tri-allelic SNP were computed for both the total population and digoxin users, using the Genetics 
1.2.1 (G.Warns and F. Leisch) package for R 2.5.0 software. Genetic linkage, as expressed by D’ was 
calculated using the ldmax command from GOLD software.38 Expectation maximization for the haplotypes 
was performed with the HaploStats 1.3.0 package for R 2.5.0, using haplo.em.39, 40 Inferred haplotypes 
with a posterior probability < 0.95 were excluded from further analyses.
Linear regression was used to test the association of genotypes or haplotypes and digoxin use with 
systolic parameters (ejection fraction, fractional shortening) and diastolic parameters (mitral valve inflow 
peak E velocity, mitral valve inflow peak A velocity, E/A ratio and mitral valve inflow deceleration time) as 
dependent variables. To test for the effect of ABCB1 and NOS1AP genotypes on digoxin induced changes 
in echocardiographic parameters, we created an interaction dummy variable with six levels for the three 
genotypes with and without digoxin use in which non-digoxin users homozygous for the major allele were 
considered as referent. Furthermore, to minimize the influence of differences in underlying cardiovascu-
lar disease -as present between digoxin users and non-digoxin users (confounding by indication)-, we 
performed the analyses stratified on prevalent heart failure or myocardial infarction. For the E/A ratio, the 
distribution of the residuals was skewed. After log-transformation the residuals were normally distributed 
with a constant variance. We adjusted for age, sex and type of ultrasonography system used. The low 
number of digoxin exposed subjects did not allow adjustment for additional risk factors or use of other 
drugs. All analyses were performed using SPSS 11.0 (Chicago, Illinois, USA).
Results
Study population and genotyping. Distribution of cardiovascular risk factors and drug use in ABCB1 
and NOS1AP study populations and in digoxin users is shown in Table 1. Echocardiographic characteris-
tics for these groups are shown in Table 2. 
Successful genotype calls for ABCB1 C1236T, G2677T/A and C3435T were made in 97.1%, 95.5% and 
95.5% respectively and for NOS1AP rs10494366 and rs10918594 in 96.9% and 97.8% respectively. Al-
lele frequencies were: 1236T 44.2%, 2677T 43.9%, 2677A 2.2%, 3435T 54.0%, rs10494366 G 36.7% 
and rs10918594 G 31.5%. Hardy-Weinberg equilibrium p-values were: C1236T p= 0.39, G2677T/A p= 
0.002, C3435T p= 0.21, rs10494366 p= 0.93 and rs10918594 p= 0.75; the finding that G2677T/A is out 
of Hardy-Weinberg equilibrium is explained by a relative excess of homozygotes for the rare A-allele and 
is probably a chance finding. We excluded ABCB1 2677A allele carriers from further analyses because 
this allele was too rare to gain reliable results. The three ABCB1 SNPs are in strong linkage disequilib-
rium, as previously reported.3, 41 D’ was 0.94 between C1236T and G2677T/A, 0.84 between G2677T/A 
and C3435T, and 0.80 between C1236T and C3435T. D’ between the two NOS1AP SNPs was 0.88. 
Expectation maximization resulted in two major haplotype alleles, the 1236-2677-3435 C-G-C and T-T-T 
haplotypes, both at an allele frequency of 40%, a C-G-T haplotype with a frequency of 12% and a number 
of rare haplotypes. After exclusion of subjects with <0.95 posterior probability haplotype pairs, the mean 
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posterior probability was 0.99. Genotype distributions did not statistically significantly differ between the 
general population and digoxin users. Genotype and haplotype frequencies were consistent with other 
European populations.13, 41-45 
Digoxin. The effects of digoxin use on systolic and diastolic parameters is shown in Table 3. Digoxin was 
associated with a slightly increased E/A ratio and decreased systolic function. Also, mitral valve inflow 
deceleration time was increased in participants with prevalent heart failure or myocardial infarction but 
decreased in those without. However, none of these digoxin effects was statistically significant.
ABCB1 and digoxin. Although the number of digoxin was to low to obtain statistically robust estimates, 
the point estimates suggest a subtle effect of ABCB1 TTT haplotype on cardiac function in digoxin us-
ers (Table 4). In the stratum of participants without prevalent heart disease, digoxin users carrying the 
TTT haplotype (heterozygotes plus 1 homozygous TTT) showed improved ejection fraction and fractional 
shortening compared to those not carrying this haplotype. However, the effect of TTT haplotype alleles in 
combination with digoxin seemed opposite in the prevalent heart disease stratum. Also, TTT-haplotype 
appeared to drive digoxin users more towards diastolic dysfunction. E/A ratio in digoxin users was lower 
(Table 3), and E/A ratio was lower in digoxin users with the TTT-haplotype in presence or absence of 
Table 1 Population characteristics
Characteristic NOS1AP
genotyped
ABCB1
genotyped
Digoxin users
Number 4827 2753 59
Women, % 57.0 58.2 55.9
Age at echo, years 72.1 (7.5) 75.4 (6.1) 80.3 (6.1)
Body mass index, kg/m2 27.6 (4.1) 27.4 (4.1) 26.0 (4.4)
Systolic blood pressure, mmHg 149.7 (21.2.) 152.9 (21.6) 145.6 (20.4)
Diastolic blood pressure, mmHg 79.8 (10.9) 79.4 (11.2) 70.9 (11.5)
Total cholesterol, mmol/l 5.6 (1.0) 5.6 (1.0) 5.3 (0.9)
HDL-cholesterol, mmol/l 1.5 (0.4) 1.4 (0.4) 1.3 (0.4)
Prevalent diabetes mellitus, % 14.0 15.2 28.8
Prevalent heart failure, % 5.2 7.0 52.5
Prevalent myocardial infarction, % 10.5 14.2 33.9
Smoking
Never, % 29.7 29.7 33.9
Former, % 54.9 56.5 45.8
Current, % 15.4 13.9 20.3
Use of digoxin, % 1.2 1.8 100
The group of NOS1AP genotyped consists of all genotyped subjects from both the baseline and the extension co-
hort, the ABCB1 group comprises only genotyped participants from the baseline cohort, the digoxin group consists 
of all genotyped digoxin users from both cohorts. Mean (SD) is shown for continuous variables and for proportions, 
percentages are shown.
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Table 2 Echocardiographic characteristics
Echocardiographic parameter NOS1AP
genotyped
ABCB1
genotyped
Digoxin users
Number 4827 2753 59
Structural parameters
Left ventricular end systolic dimension, 
mm (median (IQR))
31.0 (28.0-35.0) 32.0 (28.0-35.0) 34.0 (28.0-43.0)
Left ventricular end diastolic dimension, 
mm (mean (SD))
51.2 (5.6) 50.6 (5.9) 53.1 (8.5)
Systolic parameters
Ejection fraction, % (median (IQR)) 78.0 (71.3-82.1) 73.7 (68.6-80.6) 71.1 (61.3-78.9)
Fractional shortening, % (mean (SD)) 38.5 (7.1) 36.9 (7.5) 33.2 (10.1)
Left ventricular function, %a
Normal 56.1 44.8 25.9
Fair 38.1 47.9 43.1
Moderate 4.1 5.1 19.0
Poor 1.7 2.3 12.1
Diastolic parameters
Mitral valve inflow peak E, m/s 
(mean (SD))
0.65 (0.16) 0.64 (0.17) 0.68 (0.23)
Mitral valve inflow peak A, m/s 
(mean (SD))
0.77 (0.18) 0.78 (0.18) 0.75 (0.20)
E/A ratio (median (IQR)) 0.83 (0.71-1.00) 0.80 (0.67-1.00) 0.75 ( (0.65-
1.00)
Mitral valve inflow deceleration time, 
msec (mean (SD))
215.3 (47.9) 219.3 (51.3) 223.5 (66.7)
Diastolic function, %b
Normal 51.3 45.0 35.4
Impaired relaxation 12.2 15.1 14.6
Restrictive 0.5 0.5 2.1
Indeterminate 36.0 39.4 47.9
The group of NOS1AP genotyped consists of all genotyped subjects from both the baseline and the extension cohort, 
the ABCB1 group comprises only genotyped participants from the baseline cohort, the digoxin group consists of all 
genotyped digoxin users from both cohorts. For normally distributed variables, mean (SD) is displayed. If a variable 
was not normally distributed, median (inter quartile range (IQR)) is shown.
a Qualitative assessment of ventricular systolic function
b Normal diastolic function: E/A ratio between 0.75 and 1.50 and deceleration time between 150 ms and 240 ms, 
impaired relaxation: E/A ratio < 0.75 and deceleration time > 240 ms, restrictive diastolic dysfunction: E/A ratio > 1.50 
and deceleration time < 150 ms.
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prevalent heart disease (Table 4). Results were less equivocal for mitral valve inflow deceleration time, 
but digoxin users homozygous for the TTT haplotype seemed to have increased deceleration time, also 
driving towards impaired relaxation. For the individual SNPs we found similar effects (results not shown). 
In table 6, the results for an allelic model are displayed stratified on digoxin use and prevalent heart dis-
ease.
NOS1AP and digoxin. The NOS1AP cohort was larger, with extra participants from the second inception 
cohort. Since this cohort was younger at the time of echocardiography, the extension resulted in only few 
extra digoxin users. Also, the NOS1AP variants were less frequent, resulting in little or no extra power 
compared to the ABCB1 study population. Therefore, still no robust effect estimates could be obtained. 
Similar to our observations for the ABCB1 TTT-haplotype, in the stratum of participants without prevalent 
heart disease, digoxin users carrying the rs10494366 minor allele haplotype showed improved ejection 
fraction and fractional shortening compared to those not carrying this haplotype. Again, the effect of the 
minor allele seemed opposite in the prevalent heart disease stratum (Table 5). In diastole, digoxin users 
carrying the minor allele seemed to have an increased E/A ratio. Deceleration time seemed increased in 
digoxin using minor allele carriers in the prevalent heart disease stratum, but the results might be opposite 
for the non-heart disease stratum. Similar results were observed for rs10918594 minor allele carriers.
We observed no effect of NOS1AP genotype on systolic or diastolic function in non-users of digoxin. 
In table 6, the results for an allelic model are displayed (where applicable) stratified on digoxin use and 
prevalent heart disease, but none of the results showed a significant association.
Table 3 Association between digoxin use and systolic or diastolic properties on echocardiography
B (95% CI)
Variable No prevalent heart failure 
or myocardial infarction
(22 users of digoxin)
Prevalent heart failure or 
myocardial infarction
(37 users of digoxin)
Systolic function
Ejection fraction (%) -1.5 (-4.8;1.7) -3.7 (-7.9;0.4)
Fractional shortening (%) -0.2 (-2.8;2.5) -2.7 (-5.6;0.3)
Diastolic function
Mitral valve inflow peak E (m/s) 0.00 (-0.06;0.06) 0.06 (-0.01;0.13)
Mitral valve inflow peak A (m/s) -0.10 (-0.17;-0.02) -0.03 (-0.10;0.04)
Ln E/A ratioa 0.08 (-0.03;0.20) 0.06 (-0.06;0.18)
Mitral valve inflow deceleration time -17.6 (-37.7;2.6) 11.6 (-10.0;33.3)
All NOS1AP genotyped subjects, adjusted for age, sex and ultrasonography system.
a Log-transformed because E/A ratio and residuals were not normally distributed, after log-transformation residuals 
were normally distributed.
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Table 4 Effect of digoxin use and ABCB1 TTT haplotype on systolic and diastolic function
Echocardiographic
variable
No prevalent heart failure or 
myocardial infarction
Prevalent heart failure or
myocardial infarction
N B (95% CI) N B (95% CI)
Ejection fraction (%)
0 TTT no digoxin 652 Reference 129 Reference
1 TTT no digoxin 895 0.06 (-0.91;0.78) 194 -0.60 (-3.27;2.07)
2 TTT no digoxin 318 0.96 (-0.17;2.08) 68 -3.59 (-7.12;-0.06)
0 TTT digoxin 5 -11.70 (-19.08;-4.33) 15 -4.16 (-10.58;2.26)
1 TTT digoxin 9 3.13 (-2.38;8.63) 7 -2.95 (-12.1;6.20)
2 TTT digoxin 1 15.63 (not calculated)b 5 -11.62 (-22.31;-0.92)
Fractional shortening (%)
0 TTT no digoxin 652 Reference 129 Reference
1 TTT no digoxin 895 -0.01 (-0.70;0.68) 194 -0.48 (-2.38;1.43)
2 TTT no digoxin 318 0.82 (-0.09;1.74) 68 -2.59 (-5.10;-0.08)
0 TTT digoxin 5 -6.40 (-12.39;-0.40) 15 -3.28 (-7.85;1.29)
1 TTT digoxin 9 2.39 (-2.09;6.86) 7 -2.63 (-9.14;3.88)
2 TTT digoxin 1 16.06 (not calculated)b 5 -7.58 (-15.19;0.03)
Ln E/A ratioa
0 TTT no digoxin 676 Reference 137 Reference
1 TTT no digoxin 928 -0.01 (-0.03;0.02) 200 -0.04 (-0.11;0.04)
2 TTT no digoxin 325 -0.01 (-0.05;0.02) 76 0.01 (-0.09;0.10)
0 TTT digoxin 5 0.19 (-0.04;0.42) 14 -0.02 (-0.21;0.16)
1 TTT digoxin 6 0.21 (0.01;0.42) 8 0.19 (-0.05;0.43)
2 TTT digoxin 1 0.02 (not calculated)b 4 -0.37 (-0.70;-0.04)
Mitral valve inflow decelera-
tion time
0 TTT no digoxin 666 Reference 135 Reference
1 TTT no digoxin 914 -0.7 (-5.4;4.1) 202 3.8 (-9.8;17.4)
2 TTT no digoxin 318 6.1 (-0.2;12.3) 76 6.0 (-11.6;23.5)
0 TTT digoxin 5 -11.8 (-53.4;29.8) 15 2.9 (-30.4;36.1)
1 TTT digoxin 7 -41.2 (-76.3;-6.1) 7 -7.7 (-55.4;39.9)
2 TTT digoxin 1 7.9 (not calculated)b 4 39.0 (-22.8;100.9)
Numbers may differ between genotype and digoxin use groups due to missings in echography measures. All ad-
justed for age, sex and ultrasonography system.
a Log-transformed because E/A ratio and residuals were not normally distributed, after log-transformation residu-
als were normally distributed
b No confidence interval was calculated since n=1
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Table 5 Effect of digoxin use and NOS1AP genotype on systolic and diastolic function
Echocardiographic
variable
No prevalent heart failure or 
myocardial infarction
Prevalent heart failure or
myocardial infarction
N B (95% CI) N B (95% CI)
Ejection fraction (%)
TT no digoxin 1518 Reference 218 Reference
TG no digoxin 1753 -0.02 (-0.49;0.52) 266 0.78 (-1.30;2.87)
GG no digoxin 521 0.07 (-0.66;0.80) 78 0.34 (-2.65;3.33)
TT digoxin 14 -4.55 (-8.49;-0.62) 16 -1.69 (-7.56;4.38)
TG digoxin 7 4.50 (-1.03;10.04) 16 -3.46 (-9.48;2.56)
GG digoxin 0 NA 2 -14.82 (-31.37;1.74)
Fractional shortening (%)
TT no digoxin 1518 Reference 218 Reference
TG no digoxin 1753 -0.02 (-0.44;0.39) 266 0.39 (-1.11;1.89)
GG no digoxin 521 0.02 (-0.58;0.62) 78 0.30 (-1.85;2.44)
TT digoxin 14 -2.12 (-5.36;1.12) 16 1.50 (-5.86;2.86)
TG digoxin 7 3.71 (-0.86;8.27) 16 -2.45 (-6.77;1.88)
GG digoxin 0 NA 2 -9.76 (-21.66;2.13)
Ln E/A ratioa
TT no digoxin 1543 Reference 225 Reference
TG no digoxin 1785 -0.01 (-0.03;0.01) 269 0.01 (-0.05;0.06)
GG no digoxin 532 -0.02 (-0.04;0.01) 80 0.00 (-0.08;0.09)
TT digoxin 14 -0.06 (-0.19;0.07) 11 -0.07 (-0.27;0.13)
TG digoxin 4 0.56 (0.33;0.81) 18 0.11 (-0.05;0.27)
GG digoxin 0 NA 2 0.37 (-0.09;0.83)
Mitral valve inflow decelera-
tion time
TT no digoxin 1539 Reference 224 Reference
TG no digoxin 1765 0.01 (-3.0;3.0) 274 -4.9 (-15.2;5.4)
GG no digoxin 524 3.4 (-1.0;7.7) 81 -2.1 (16.8;12.7)
TT digoxin 14 -9.5 (-33.0;14.0) 12 -10.2 (-44.7;24.3)
TG digoxin 5 -38.3 (-77.4;0.9) 18 -2.1 (-30.6;26.5)
GG digoxin 0 NA 2 221.5 (138.8;304.2)
NOS1AP results are shown for rs10494366, results for rs10918594 were similar.Numbers may differ between geno-
type and digoxin use groups due to missings in echography measures. All adjusted for age, sex and ultrasonogra-
phy system. NA = not applicable
a Log-transformed because E/A ratio and residuals were not normally distributed, after log-transformation residu-
als were normally distributed
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Discussion
Digoxin is known to improve systolic function and to increase the risk of diastolic dysfunction.1, 2 It is also 
a known substrate for ABCB1 encoded P-glycoprotein3, 4 and we previously found evidence for interac-
tion with NOS1AP variants.20 In the present study, we found some indication that common variants in the 
ABCB1 gene were associated with increased systolic function in digoxin users without prevalent heart 
disease, but wit decreased function in those with prevalent heart failure or myocardial infarction. Similar 
results were seen for NOS1AP minor allele carriers. Also, the ABCB1 variants seemed to be associated 
with decreased diastolic function in digoxin users, driving their echocardiographic parameters towards 
impaired relaxation. In contrast with ABCB1 variants, digoxin users with NOS1AP variants showed in-
creased E/A ratios, but, similar to the observed effect in ABCB1 1236-2677-3435 TTT-allele carriers, 
increased deceleration time in subjects with prevalent heart disease and decreased deceleration time in 
those without. This might suggest a protective effect of the NOS1AP minor allele against impaired relax-
ation. However, the number of digoxin users with an echocardiogram was too low draw to solid conclu-
sions and to reach statistical significance.
The suggested increased risk of diastolic failure through impaired relaxation in digoxin users with the 
ABCB1 TTT-haplotype allele is in concordance with our previous finding that ABCB1 TTT haplotype carri-
ers have increased digoxin serum concentration.12 Also, in another previous study using the population of 
the Rotterdam Study, we were able to demonstrate that ABCB1 genotype was associated with increased 
QT-interval shortening to digoxin, further enforcing the potential of ABCB1 TTT-haplotypes to potentiate 
digoxin effects.46 The allele dose-effect of ABCB1 TTT-haplotype on increased ejection fraction to digoxin 
in those without prevalent heart disease is also in line with these findings. These effects are expected as 
increased digoxin effects. The fact that we observed an opposite effect in those with prevalent myocardial 
infarction or heart failure is not, but might be partly explained by confounding by severity as it is likely that 
in those with prevalent heart failure, the more severe cases are treated with digoxin. This hypothesis is 
supported by the finding that digoxin use in the overall analyses in the group with prevalent heart disease 
was associated with decreased systolic function (Table 3). Furthermore, our results for participants with 
prevalent heart disease not using digoxin could suggest that ABCB1 TTT-haplotype is associated with 
decreased systolic function in this group. If true, that might explain the observed discrepancy.
Since digoxin increases [Ca++]i 
1, 2 and NOS1AP minor alleles may do the same,15-19 an increased systolic 
function, as observed in digoxin users without prevalent heart disease, and decreased diastolic function 
were expected. However, we observed decreased systolic function in minor allele carriers with prevalent 
heart disease using digoxin. Furthermore, E/A ratio was increased in digoxin with and without prevalent 
heart disease and the results for deceleration time were unequivocal. Too little is known about normal 
NOS1AP function to explain these findings. Also, numbers are too small to draw solid conclusions, in-
creasing the possibility of a spurious association.
The main strength of the study lies in the population based prospective approach. Both echocardiogra-
phy and medication prescription is blinded to genotype. Therefore, no selection bias is to be expected. 
Although confounding by indication, through the potential of an association between genotype and heart 
disease, cannot fully be excluded, the stratification on prevalent heart failure or myocardial infarction 
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should limit its influence. However, even such a stratification can not exclude confounding by severity of 
heart failure in those who receive digoxin. Moreover, the number of subjects who were exposed to digoxin 
at the time of the echocardiogram was very low, resulting in little power to detect an effect of genotype 
on the association of digoxin and systolic and diastolic function. The small sample size also increases 
the risk of finding a spurious association, since it limited the possibilities of adjusting for possible other 
cardiovascular risk factors. The fact that most findings for ABCB1 genotypes are in line with our previous 
findings12, 46 and with known mechanisms does, however, endorse the possibility of an effect of ABCB1 
SNPs on cardiac function in digoxin users.
In conclusion, in line with previous studies on ABCB1 genotype and digoxin in the Rotterdam Study,12, 
46 we found some support that common ABCB1 variants increase the effects of digoxin on systolic  (in-
creased) and diastolic (decreased) cardiac function. NOS1AP minor alleles seem to be associated with 
increased E/A ratio in digoxin users, with decreased systolic function in subjects with prevalent heart dis-
ease and with increased systolic function in those without. However, power was too low to reliably dem-
onstrate or exclude any associations. Larger studies of echocardiograms -or other imaging techniques of 
the heart- in digoxin users will be needed to further clarify the exact role of these genes in the effects of 
digoxin on cardiac function.
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Despite all research efforts on safety and efficacy preceding marketing authorization of drugs, not every 
drug is safe and beneficial for every patient. Different people do not always react in the same way to 
the same drugs at the same dose. Pharmacogenetic and pharmacogenomic research helps to identify 
genetic factors that may predict the chance of success and the risk of adverse outcomes of drug therapy. 
The objective of this thesis was to explore the effect of interaction of common variants in the ABCB1 and 
NOS1AP genes with drugs on drug response and adverse effects. Most studies were conducted within 
the Rotterdam Study, a population-based cohort study among men and women aged 55 years and over.1, 
2 In this chapter, the main findings and methodological considerations are discussed. Furthermore, poten-
tial clinical implications and future directions for future research will be discussed.
Main findings
Risk of digoxin intoxication. One of the oldest drugs still in use today is the cardiac glycoside digoxin. 
It has been successfully used in the treatment of heart disease for more than 200 years. The use of an 
extract of Digitalis purpurea, commonly known in English as the Foxglove, containing cardiac glycosides 
for the treatment of heart conditions was first described by William Withering in 1785,3 which is considered 
the beginning of modern therapeutics. However, since its first introduction digoxin has been associated 
with toxicity. Studies on toxicity over the period 1969 to 1983 showed a frequency in digitalis users of as 
high as 11 – 30%.4-6 Digitalis intoxication was associated with high mortality and frequent occurrence of 
life-threatening arrhythmias.6, 7 Improvements in therapy management and monitoring have resulted in a 
major reduction of the incidence of digoxin intoxication and an improved prognosis over the last decades. 
More recent studies showed digoxin intoxication in 4.8-0.9% of digoxin users.8-12 However, the latest stud-
ies date from the late 1980s and no recent incidence figures of digoxin intoxication are available. Further-
more, recent literature suggests that women are at an increased risk of digoxin toxicity.11, 13
Using a national computerized hospital discharge registry and extrapolated drug figures, we performed a 
nationwide cohort-study of all hospital admissions in the years 2001-2004. In this study, we show that the 
relative number of digoxin intoxication requiring hospitalization is rather low in The Netherlands (around 
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2 per 1000 person years of use). Although there may have been some underrecognition of cases, these 
findings seem to confirm that current management of digoxin treatment has reduced the risk of digoxin 
toxicity dramatically. Furthermore, we found that women have a 40% higher risk of intoxication than men 
(95%CI: 30-60%)(Chapter 2). Our observations of a decreased incidence of digoxin intoxication and 
increased risk of intoxication for women were confirmed in a recent German study covering the same 
years.14
ABCB1 variants and drug effects. Digoxin serum concentration is an important factor in digoxin toxicity 
within one individual. However, toxic concentrations may occur at therapeutic doses and concentrations 
differ between persons receiving the same dose. Moreover, toxic effects of digoxin can appear within 
the accepted therapeutic serum concentration range.15 Digoxin is a known substrate of P-glycoprotein, 
a multi-drug efflux transporter encoded by the ATP-Binding Cassette B1 (ABCB1). ABCB1 is widely ex-
pressed in normal tissues such as the duodenum, kidneys, liver and the blood-brain barrier where it plays 
a role in the uptake and clearance of many drugs.16-22 ABCB1 is a large and polymorphic gene23 and one 
of the first single nucleotide polymorphisms (SNPs) identified in the gene was found to be associated 
with digoxin concentration.24 Since then, many studies on of ABCB1 SNPs and digoxin kinetics have 
been performed, some showed an effect of ABCB1 on digoxin kinetics,24-29 whereas others did not.30-33 
However, most studies were small and they were performed in groups with different ethnic backgrounds, 
which may explain some of the differences by variation in SNP and haplotype allele frequencies between 
ethnic groups. For instance, the 2677A variant is more frequent in certain Asian populations but very rare 
in Caucasians.34, 35
In digoxin users from the Rotterdam Study with digoxin serum concentrations available, we found that 
the common ABCB1 C1236T, G2677T and C3435T variants and the associated 1236-2677-3435 TTT-
haplotype were associated with higher digoxin serum concentrations (Chapter 3.1). Moreover, we found 
that ABCB1 variants explain an important part of the variability in digoxin concentrations in a model also 
containing age, sex, digoxin dose, lean body mass and renal clearance (up to 11.5% by the TTT haplotype 
as determined by the r2). The increase in serum concentration in ABCB1 TTT-haplotype allele carriers 
equaled the effect of a 0.25 DDD (1DDD= 0.25mg) dose increase. The majority of previous studies in 
Caucasians showed similar effects of ABCB1 variants on digoxin kinetics, but a meta-analysis could not 
confirm an effect for the C3435T SNP.36 The main difference with our study is that most studies comprised 
only single dose kinetics and were underpowered to demonstrate small effects. Only one study was per-
formed in actual digoxin using patients.33 and did not show an association of ABCB1 variants with digoxin 
kinetics. However, the dose was almost twice that of the average daily dose in our study. At these higher 
dosages, the maximum efflux capacity of ABCB1 might be saturated and other transport mechanisms 
may become more important.
In a study using all genotyped digoxin users and non-users of digoxin, we found a more than two fold 
increased risk of sudden cardiac death (SCD) in digoxin users homozygous for ABCB1 variant alleles 
(Chapter 3.2). No increase of SCD risk was found in non-users of digoxin with ABCB1 variant alleles. 
This is the first study to show an association between ABCB1 variants and the risk of toxic effects of 
digoxin. The interaction of ABCB1 and digoxin was further confirmed by its influence on the QTc short-
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ening properties of digoxin on ECG. Apart from the influence on QTc-shortening to digoxin, we found 
echocardiographic indications that the ABCB1 TTT-haplotype allele was associated with decreased dia-
stolic function in digoxin users, driving their echocardiographic parameters towards impaired relaxation. 
The TTT-haplotype allele was also associated with an increased systolic function in digoxin users without 
prevalent heart disease, but with a decreased function in those with prevalent heart failure or myocardial 
infarction (Chapter 5). Although the latter associations were not statistically significant, probably due to 
low numbers, these observations (apart from the decreased systolic function in those with prevalent heart 
disease) are in line with the findings of increased digoxin concentrations in TTT-haplotype allele carriers 
and the known effects of digoxin on cardiac function.37, 38 Unfortunately, the number of digoxin users with 
eligible echocardiograms available was too low to draw solid conclusions from this study.
The quinolone derivative mefloquine is widely used in the treatment and prophylaxis of malaria in trav-
ellers to areas with chloroquine resistant falciparum malaria but its use is associated with, sometimes 
severe, neuropsychiatric adverse effects.39-41 Risk factors for adverse effects of mefloquine identified so 
far include history of seizures or psychiatric disorders, female gender and low body mass index (BMI).42, 
43 It has been suggested that the distribution volume or blood concentration of mefloquine plays a role, 
although no clear association between mefloquine blood level and neuropsychiatric adverse effects could 
be demonstrated.43, 44 Mefloquine is able to cross the blood brain barrier45 and ABCB1 is not only ex-
pressed in the intestine and in the liver, where it may influence the uptake in the blood and excretion in the 
bile of mefloquine, but also in the blood-brain barrier.22 Therefore, even at similar serum concentrations, 
ABCB1 function may influence the risk of neuropsychiatric adverse effects by affecting the brain tissue 
concentration.
We studied a cohort of mefloquine users followed during the three weeks preceding their travel, as was 
previously studied for neuropsychiatric effects of mefloquine (Chapter 3.3).40, 42 We found that ABCB1 
C1236T, G2677T and C3435T variants and the associated 1236-2677-3435 TTT haplotype were associ-
ated with an increased risk of neuropsychiatric adverse effects during the study period (relative risk (RR) 
for homozygous TTT subjects versus all other haplotype carriers 2.5, 95%CI 1.3-4.6). The effect was 
stronger in women (RR 3.2, 95%CI 2.0-5.2) in whom the frequency of adverse effects was much higher. 
In men, the effect was smaller and no longer statistically significant (RR 1.7, 95%CI 0.4-6.5). We found no 
association between ABCB1 SNPs or haplotypes and serum concentration of mefloquine. Furthermore, 
consistent with literature,43, 44 we found no association of mefloquine serum concentration and the oc-
currence of neuropsychiatric adverse effects. This suggests that the association of ABCB1 variants with 
neuropsychiatric adverse effects of mefloquine is driven by differences in brain tissue concentration rather 
than in serum concentration. A lower expression of ABCB1 will result in lower mefloquine efflux from the 
brain, thus exposing it to higher tissue concentrations. Similar effects of ABCB1 polymorphisms have 
recently been shown for other drugs.46, 47
NOS1AP variants and drug effects. Recently, common genetic variants of NOS1AP were discovered 
to be associated with QT-interval prolongation in a genome wide association study.48 The NOS1AP gene, 
encoding the Nitric Oxide Synthase 1 Adaptor protein, was not previously known to be involved in myo-
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cardial repolarization. Both syndromal49 and non-syndromal50-53 long- and short54 QT-interval increase the 
risk of SCD, making QT-interval and QT-altering factors important to study. Many drugs are known to pro-
long QT-interval duration,55, 56 and medication-induced prolonged QT interval and ventricular arrhythmias, 
which may result in SCD, have led to the withdrawal of many non-cardiac medications.57, 58
Since the impact of NOS1AP variants on QT interval duration in older populations, in whom non-genetic 
factors might play a stronger role than heritable factors, is unknown, we sought to replicate this finding 
in the Rotterdam Study, comprising participants of 55 years and older (Chapter 4.1). We also tested for 
association of NOS1AP variants with SCD. In the Rotterdam Study, we strongly confirmed the association 
of NOS1AP variants with a 3.8 (95%CI 3.0-4.6) msec increase in QT interval duration per additional minor 
variant allele. With the limited number of SCD cases in our cohort, it was not possible to demonstrate that 
this association translates into an influence on risk of SCD although the point estimates suggest that such 
a risk increase may truly exist. Additional larger studies will be required to determine whether NOS1AP 
genotype is associated with SCD.
Since QT-altering drugs may interact with genetic variants in QT-duration associated genes,49, 59, 60 this 
makes NOS1AP an interesting candidate for pharmacogenetic studies with QT-altering drugs. One of 
these QT-altering drugs is digoxin. Digoxin exerts its action, in part, by increasing intracellular Ca++ con-
centration ([Ca++]i) through an increase of intracellular Na
+ by inhibition of the Na/K ATPase.61, 62 This leads 
to higher contractile force and to QT-shortening.38 Therefore, we hypothesized that subjects carrying the 
minor variants of two NOS1AP SNPs known to prolong the QT interval might be less sensitive to the QT 
shortening effects and pro-arrhythmogenic effects of digoxin.54, 63, 64 In contrast with our expectations, in 
the Rotterdam Study, comprising both digoxin users and non-users of digoxin, we found that NOS1AP 
minor allele carriers had a significantly increased QT shortening on digoxin compared to major allele 
homozygotes, in contrast to the effect observed in non-digoxin users (Chapter 4.2). Participants homozy-
gous for the NOS1AP major allele using digoxin had a 11.4 (95%CI 7.5;15.3) msec shorter QTc interval 
than major allele homozygotes not using digoxin (reference group), whereas digoxin users homozygous 
for the minor allele showed 23.0 (95%CI 14.4;31.5) msec QTc shortening compared to the reference 
group. Apparently, the QTc-shortening effect of digoxin is significantly worsened in those with a variant al-
lele. Furthermore, minor alleles were associated with an increased risk of SCD to digoxin up to three-fold. 
Although the mechanism by which NOS1AP influences QT interval duration and interacts with digoxin is 
not known, it may involve calcium handling in the cardiomyocyte.65-68 NOS1AP has been found to activate 
NOS1.69 NOS1 knockout cardiomyocytes have increased contractility through increased [Ca++]i and a 
slower decay of the [Ca++]i transient.
65-68, 70 This slower decay of the [Ca++]i transient is at contrast with 
normal [Ca++]i kinetics,
38 but does explain the QT-prolonging effects of NOS1AP gene variants if these 
variants result in less activation of NOS1. Furthermore, NOS1 is able to interact with the L-type Ca++ 
channel,71 which is known to be associated with both Short- and Long QT Syndrome and SCD.72, 73 This 
suggests a model in which both digoxin and NOS1AP minor alleles lead to increased [Ca++]i, resulting 
in excess [Ca++]i. Cardiac calcium overload could in turn increase risk of ventricular arrhythmias.
61 This 
would explain the increased risk of SCD in digoxin users with the minor NOS1AP alleles. If either digoxin 
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or the excess [Ca++]i counteracted the unexpected slower decay of the [Ca
++]i transient as found in NOS1 
knockout mice (and, as suggested by their QT-prolonging effect, in NOS1AP minor allele carriers), the 
excess [Ca++]i would also result in faster [Ca
++]i decline38 explaining the increased QTc-shortening in us-
ers of digoxin carrying NOS1AP variants. In turn, short QT in itself, both as a congenital syndrome and in 
the general population, is a risk factor of SCD.54, 63, 64, 72, 74
In Chapter 5, we studied the effects of interaction of NOS1AP variants and digoxin on cardiac systolic and 
diastolic function. We found some indication that common variants in the NOS1AP gene are associated 
with an increased systolic function in digoxin users without prevalent heart disease, but with a decreased 
function in those with prevalent heart failure or myocardial infarction. Digoxin users with NOS1AP variants 
showed increased E/A ratios, but increased deceleration time in subjects with prevalent heart disease and 
decreased deceleration time in those without. This might suggest a protective effect of the NOS1AP minor 
allele against impaired relaxation. However, the number of digoxin users with an echocardiogram was too 
low to draw solid conclusions and to reach statistical significance.
Many cardiovascular drugs are known to prolong QT-interval duration.55, 56 Since common NOS1AP vari-
ants are associated with QT-interval prolongation,48, 75, 76 these QT-prolonging genetic variants and drugs 
might interact,49, 59, 60 resulting in even further increased QT-prolongation and increased risk of SCD. In 
the Rotterdam Study, we studied QTc-interval duration of both users of QT-prolonging cardiovascular 
drugs and of non-users, to compare effects of QT-prolonging drugs in different NOS1AP genotype groups. 
Although numbers of drug-users per genotype group were low, we found that users of triamterene or 
verapamil homozygous for the minor variant showed statistically significantly more QTc prolongation than 
major allele homozygotes (Chapter 4.3). Furthermore, although confidence intervals overlapped, regres-
sion coefficients indicated that a similar effect might exist for amiodarone, sotalol, diltiazem, indapamide, 
and perhaps isradipine and disopyramide. The number of SCD cases exposed to QT-prolonging medica-
tion at the time of death was too low to make a proper assessment of the influence of NOS1AP variants 
on SCD risk in users of these drugs. However, point estimates for amiodarone (15 exposed SCD cases) 
and verapamil (8 exposed cases) suggest that NOS1AP minor variant carriers might be at increased risk 
of SCD in users of these drugs.
NOS1AP variants might also interfere with other drugs. NOS1 is not only expressed in the heart where it 
may interact with the voltage dependent L-type Ca++ channel,71 it also plays a role in insulin secretion.77-79 
The antidiabetic class of sulfonylureas stimulate insulin secretion by an increased influx of Ca++.80-82 As 
previously mentioned, NOS1AP variants may also influence Ca++ levels.65-68, 70 Furthermore, sulfonylurea 
have since long been associated with increased risk of cardiovascular mortality, although there remains 
controversy on this matter.83-87 Since both NOS1 and sulfonylurea influence insulin secretion and both 
may be associated with increased cardiovascular mortality, we hypothesized that genetic variation in the 
NOS1AP gene influences the glucose lowering effect of sulfonylurea and mortality risk in patients using 
sulfonylurea. In the Rotterdam Study, we found that the glucose lowering effect of glibenclamide was less 
effective in patients carrying the NOS1AP minor allele (Chapter 4.4). Moreover, carriers of NOS1AP mi-
nor alleles using glibenclamide were at increased risk of mortality, whereas these genotypes were associ-
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ated with reduced mortality in patients using tolbutamide, gliclazide or glimepiride. The reduced mortality 
risk for tolbutamide, gliclazide and glimepiride seemed to be explained by a reduction in cardiovascular 
mortality. The increased risk of death in glibenclamide users with the minor allele opposite to users of 
other sulfonylurea might be explained by a higher affinity of glibenclamide for the SUR2A receptor (sul-
fonylurea 2A),82, 88-92 which is thought to be responsible for the effects of sulfonylurea on cardiovascular 
mortality.89, 93-95
Methodological considerations
The main limitation of genetic association studies, to which pharmacogenetics is no exception, is lack 
of replication. Many promising associations published later on appeared to be false positive findings. 
This is especially an issue for the two genes chosen in this thesis. Digoxin is known to be a substrate 
for ABCB1, but results of previous studies on ABCB1 SNPs and digoxin kinetics were contradictory. The 
main problem may reside in the fact that most studies were very small.36 Another problem is the fact that 
most studies were performed in a setting with little clinical relevance. They comprised healthy volunteers 
receiving a single dose of digoxin. Only two studies were performed in a more steady state population,26, 
33 only one of which was performed in patients using the drug under everyday circumstances.33 No studies 
on clinical effects of ABCB1 SNPs in digoxin users have been performed so far. NOS1AP is such a new 
candidate that no studies on pharmacogenetic associations have been performed. Biological plausibility 
and clinical relevance of our findings have been discussed in the previous paragraphs. In the following 
sections we will discuss some methodological considerations that apply to the internal and external valid-
ity of the studies described in this thesis.
Setting. All studies described in this thesis were performed using population-based data sources. For the 
study on the incidence of digoxin intoxication in the Netherlands, we used the National Morbidity Regis-
tration (LMR, Landelijke Medische Registratie), a nationwide computer database containing all hospital 
discharge records using International Classification of Disease (ICD) coding. The major strength of this 
database is its nationwide coverage and the fact that coding of discharge diagnosis is in no way related 
to reimbursement of hospital or specialist. Its main limitation is its lack of linkage to medication data and 
other clinical information. This was in part solved using data on digoxin prescriptions from the Foundation 
for Pharmaceutical Statistics (SFK) pharmacy database, which extrapolates drug figures for the Nether-
lands from dispensed prescriptions from 90% of all community pharmacies.
For the study on the influence of ABCB1 SNPs and haplotypes on the risk of adverse effects to meflo-
quine, we used a cohort of mefloquine users in the three weeks previous to their journey. Its main limita-
tions reside in the relative small number of subjects and the relative short follow-up. The main strength is 
the fact that this design eliminates effects related to travelling itself.
All other studies were performed using data from the Rotterdam Study,1, 2 a large population of older adults 
included in a follow-up program. Its strengths reside in the relatively long follow-up and extensive infor-
mation available on various clinical characteristics of all participants gathered at every follow-up round. 
In addition, through linkage with general practitioner and municipal mortality records, the total cohort is 
159
General discussion
159
continuously monitored for major morbidity and mortality. Furthermore, clinical laboratory assessments 
were available (for a part of the period) from 3 hospital laboratories and 1 general practitioner’s labora-
tory serving the area of the Rotterdam Study. Finally, virtually all participants fill their prescriptions in 
automated pharmacies linked to one computer network. Since January 1, 1991, data on all dispensed 
drugs, including the prescribed daily dose, are available in computerized format on a day-to-day basis. 
All information is gathered before, and irrespective of, the outcome under study. This limits the chance of 
selection bias and information bias.
Design. Although all studies described in this thesis were designed as prospective population-based 
cohort studies, they each have there specific problems. For the study on incidence of digoxin intoxication, 
we used two separate sources for the outcome (intoxication) and the exposure (digoxin use). Data from 
these two sources could only be studied in an ecological design, correlating group- (age-group and sex) 
and period (year) level. Also, no information of clinical relevant risk factors for digoxin intoxication was 
available. Therefore, only very crude incidence measures of intoxications per number of prescriptions 
could be obtained. The cohort of mefloquine users used in Chapter 3.3 was not only limited by the relative 
small number of participants with genotype information available, the fact that it only included users of the 
drug did not allow assessment of the effect of ABCB1 SNPs on the risk of neuropsychiatric complaints 
without the use of mefloquine. These problems did not occur in the Rotterdam Study, which contains 
individual drug exposure and a wide range of clinical characteristics for a large number of participants. 
However, the number of users of one specific drug, especially at the time of assessment of a specific clini-
cal characteristic may still be small. Also, studies on associations of a drug with characteristics assessed 
at follow-up rounds (ECGs and echocardiograms) were assessed in a cross-sectional manner, assessing 
both exposure to the drug and outcome at that specific date. The most important shortcoming is the un-
certainty of a temporal relationship. Since multiple ECGs per subject were available, some subjects both 
had ECG-measures available at moments that they used and moments that they did not use the drug. 
Although numbers for these analyses were very small, this allowed us to assess the effect of a drug within 
these persons, making a causal relationship more likely.
Availability of information on all dispensed drugs, including the number of dispensed units and prescribed 
daily dose in computerized format, since January 1, 1991 allowed us to calculate the duration of use per 
drug for each participant at each point in time. This results in a high level of information about medication 
use and fewer misclassification of exposure. In order to adjust for changing risks over time due to changes 
in medication use, we chose a time-dependent Cox-proportional hazards model in our analyses of drug 
use and mortality in the Rotterdam Study. Although compiling a data set with time-dependent exposure is 
laborious and may require much computing time in the analyses on standard PCs, it has several advan-
tages.96 This allowed us to assess the exposure status and to adjust for dosing regimen of both cases and 
the remainder of the cohort at each index date.
Bias and confounding. In observational studies, selection bias, information bias and/or confounding 
may jeopardize the validity. The population-based design of the studies probably limited the chances of 
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selection bias. However, the cohort of mefloquine users consists of travellers, who are probable healthier 
than the general population. On the other hand, this is no major jeopardy to external validity since this is 
also the target population for the drug. In the Rotterdam Study, there is a chance that non-participants to 
the study or to (part of) the examinations at the research center are sicker. However, the fact that geno-
types of study populations from these two cohorts were in Hardy-Weinberg equilibrium make selection 
bias less likely.
Because all information in the Rotterdam Study is gathered prospectively, without knowledge of drug-use 
or genotype, the chance of information bias is unlikely. The same is true for the cohort of mefloquine us-
ers. Although misclassification of neuropsychiatric effects is not unlikely due to the self-reporting and the 
broad definition of the outcome, assessment of the outcome was performed before genotyping, making 
misclassification most likely random. In the digoxin intoxication incidence study, no drug use could be 
linked to the discharge diagnosis at patient level. Nevertheless, misclassification of digoxin intoxication 
is probably limited since intoxication has its own ICD code and can only occur in digoxin-users. It is, 
however, possible that we missed cases who did not require hospitalization or died before reaching the 
hospital. Also, in the case of severe co-morbidity digoxin intoxication might not be coded as one of the 
reasons of hospitalization whereas patients with elevated digoxin serum levels at hospitalization without 
clinical symptoms of digoxin intoxication may be coded as cases. Therefore, we might have slightly under-
estimated, or -less likely- overestimated, the true incidence of digoxin intoxication. It is, however, unlikely 
that this resulted in differential misclassification of potential cases for men and women.
Confounding is not very likely in our studies on ABCB1 SNPs and digoxin, since there is no association 
between polymorphisms of this gene and use of digoxin. An association of ABCB1 polymorphisms with 
neuropsychiatric complaints in persons not using mefloquine cannot be excluded since our study only 
comprised mefloquine users. Since NOS1AP SNPs are associated with QT-prolongation, they may also 
be associated with SCD or other cardiovascular conditions. Therefore, confounding by indication might be 
a problem in our studies on NOS1AP SNPs, drugs and risk of (cardiovascular or SCD) mortality if those 
with a certain genotype would more readily receive digoxin. In the study on the interaction of digoxin and 
NOS1AP we were able to exclude this by stratifying on digoxin use and sub-analyses limited to digoxin 
users without previous heart disease or to participants with heart disease not using digoxin. In the study 
on cardiovascular QT-prolonging drugs, however, numbers were too small for such analyses or even 
proper adjustment for known risk factors of SCD. The influence of confounding could not be assessed 
beyond age and sex in the study using LMR data because clinical information on co-variates was not 
available.
Clinical implications
The studies presented in this thesis clearly show the potential of pharmacogenetic studies. We were able 
to identify genetic high risk groups for unfavorable outcomes of drug therapy. Genotyping for ABCB1 and 
subsequent dose adjustment of digoxin and perhaps also mefloquine might reduce the number of neu-
ropsychiatric adverse effects to mefloquine and the number of digoxin intoxications and digoxin related 
SCD. Genotyping for NOS1AP might also reduce SCD to digoxin and potentially to other QT-prolonging 
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cardiovascular drugs. NOS1AP genotyping might also improve safety and efficacy of sulfonylurea treat-
ment in diabetes mellitus.
Genotype information is already being used to improve drug safety, incorporating information on geno-
typic risk groups in the product information.97 The benefits for all parties involved in drug therapy are 
obvious. The patient is not needlessly exposed to a drug or drug-dose that puts him/her at risk of serious 
adverse effects. The doctor knows which drug or dose should be avoided in a certain situation. The drug 
company avoids putting its drug at risk of being taken from the market because of serious adverse effects. 
However, there are also downsides to this. If a company and doctors know that a drug will not work for 
a certain (potentially large) group of patients, the drug can no longer be sold to all patients, making the 
market smaller and less economically profitable. Whether this would jeopardize drug development in the 
future, however, remains to be seen as most industries will probably be creative enough to overcome this 
hurdle. Another drawback would be that genotype information may not only inform on risk of adverse drug 
effects, but also on risk of future disease. This may raise ethical problems, especially if adequate therapy 
for that disease is not at hand.
Future directions
Currently, only a limited number of SNPs have been genotyped in the Rotterdam Study in the ABCB1 and 
NOS1AP genes. Since there is still debate on the functionality of the three genotyped ABCB1 SNPs and 
no evidence is at hand for a mechanism involved in the NOS1AP variants, there is enough interesting 
future work left.
In vitro and animal research may give more insight into the physiological role of NOS1AP. Studying this 
gene and protein in cultured myocardial cells or knockout mice could provide valuable clues to its role in 
both normal repolarization and the mechanisms involved in interaction with various drugs.
Also, the effects of both NOS1AP and ABCB1 variants require further fine-mapping and potential identifi-
cation of a causal SNP or haplotype. The availability of genotype information from the GWA arrays in the 
Rotterdam Study may allow this in the near future.
We realize that a number of studies in this thesis show results based on a very limited number of exposed 
individuals. This is especially the case for the (non-digoxin) cardiovascular drugs and sulfonylurea stud-
ies. These studies may therefore have to be replicated in other populations. As we were the first to report 
a number of gene variant-drug interactions (mefloquine with ABCB1, all drugs with NOS1AP), replication 
of these findings is needed in order to confirm them. One of the ways larger numbers for the various 
drugs could be obtained is by using genotype data from randomized clinical trials. Although these are 
considered the gold standard, they are very laborious and expensive. Alternatively, the phenomenon of 
‘Mendelian randomization’ could be used to study these variants. One could think of a population-based 
cohort design with prospective follow-up of patients receiving a certain drug without interfering in normal 
therapy. The treating doctor will remain blinded to genotype to avoid bias. Since genotypes are distributed 
random in the population and genotype information is not related to receiving treatment, this will allow 
studying the outcome of patients receiving the drug in relation to their genotype. The idea of Mendelian 
randomization does, however, rely on a number of assumptions and therefore has its limitations.98, 99 One 
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of the main problems is that the genotypes are not always randomly distributed over the study population. 
A certain genetic variant may, for instance, be related to the (severity of the) disease for which the drug is 
indicated and also to the outcome of interest. This might be the case for NOS1AP (which plays a role in 
cardiac function) and cardiovascular drugs in relation to SCD. These limitations of Mendelian randomiza-
tion can often –but not always- be surmounted by restricting the analyses to incident users but should 
nevertheless be carefully considered in such studies.
Finally, the previously mentioned Genome Wide Association studies hold promising opportunities for 
pharmacogenomic and –genetic research. Allowing to search for new candidate variants which influence 
drug response and risk of adverse drug reactions.100, 101 This could be done by taking advantage of the 
precise drug exposure data in the Rotterdam Study. If the number of users of the drug of interest is large 
enough within the Rotterdam Study, one could test for the association of genotypes with the outcome of 
drug therapy. Alternatively, the genotyping and drug use information from the Rotterdam Study can be 
used as a reference population against which one could test a series of cases with the outcome of inter-
est. This might greatly increase the number of drug-exposed cases and therefore statistical power. Cases 
of (rare) adverse drug effects can be gathered through general practitioners or other databases. Subse-
quently, genotypes of these cases can be compared to those of ‘normal’ drug users or from the general 
population as available from the Rotterdam Study.
Main conclusions
Drug therapy has become safer over the last three to four decades. Nevertheless, almost 1300 hospital 
admissions because of digoxin intoxication in four years are still considerable. Identification of specific risk 
groups may even further improve the safe use of digoxin and other drugs.
The studies of ABCB1 SNPs or haplotypes and both digoxin and mefloquine show that genotyping for 
ABCB1 SNPs may contribute to safer use of these drugs. By prescribing lower doses to ABCB1 TTT-
haplotype allele carriers, the number of digoxin intoxications and SCD to digoxin, and, possibly, the num-
ber of neuropsychiatric adverse effects to mefloquine might be reduced. Given that many drugs are a 
substrate for ABCB1-derived P-glycoprotein,22, 102 these findings might have implications for the safe use 
of many more drugs.
The studies on NOS1AP variants show that new pharmacogenomic techniques may not only be directly 
applied to research on susceptibility to (adverse) drug effects. Genome wide association studies looking 
for genetic variation that influences variation in physiological traits also yields new and unexpected candi-
dates for ‘classical’ pharmacogenetic studies beyond known drug targets or drug-metabolizing enzymes. 
Our study of digoxin and NOS1AP variants is the first49 to show interaction of a QT-altering drug with 
a QT-altering genetic variant in an epidemiological study comprising users of the drug. Not only do we 
demonstrate interaction at the level of QT-interval duration. We were also able to identify subjects with in-
creased risk of SCD to digoxin. Apart from digoxin, we found indication for interaction of NOS1AP variants 
with a number of QT-prolonging cardiovascular drugs. Finally, NOS1AP is also an interesting candidate 
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for non-cardiovascular pharmacogenetics. In Chapter 4.4 we show an association of NOS1AP variants 
with efficacy and risk of death to sulfonylurea. This endorses the chance that the findings considering the 
NOS1AP gene are of a physiologically fundamental character.
164
Chapter 6
164
References
Hofman A, Grobbee DE, de Jong PT, et al. Determinants of disease and disability in the elderly: the Rotterdam 1. 
Elderly Study. Eur J Epidemiol 1991;7(4):403-22.
Hofman A, Breteler MM, van Duijn CM, et al. The Rotterdam Study: objectives and design update. Eur J Epidemiol 2. 
2007.
Withering W. An account of the foxglove and some of its medical uses with practical remarks on dropsy and other 3. 
diseases. In: Willins FA, Keyes TE, eds. Classics of Cardiology. New York: Henry Schuman; 1941:231-52.
Boman K. Digitalis intoxication in geriatric in-patients. A prospective clinical study of the value of serum digitalis 4. 
concentration measurement. Acta Med Scand 1983;214(5):345-51.
Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. Br Med J 1969;1(643):531-6.5. 
Beller GA, Smith TW, Abelmann WH, et al. Digitalis intoxication. A prospective clinical study with serum level cor-6. 
relations. N Engl J Med 1971;284(18):989-97.
Lehmann HU, Witt E, Temmen L, et al. [Life-threatening digitalis intoxication with and without additional diuretic 7. 
treatment (author’s transl)] Lebensbedrohliche Digitalisintoxikationen mit und ohne saluretische Zusatztherapie. 
Dtsch Med Wochenschr 1978;103(40):1566-71.
Mahdyoon H, Battilana G, Rosman H, et al. The evolving pattern of digoxin intoxication: observations at a large 8. 
urban hospital from 1980 to 1988. Am Heart J 1990;120(5):1189-94.
Steiner JF, Robbins LJ, Hammermeister KE, et al. Incidence of digoxin toxicity in outpatients. West J Med 9. 
1994;161(5):474-8.
The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N 10. 
Engl J Med 1997;336(8):525-33.
Warren JL, McBean AM, Hass SL, et al. Hospitalizations with adverse events caused by digitalis therapy among 11. 
elderly Medicare beneficiaries. Arch Intern Med 1994;154(13):1482-7.
Kernan WN, Castellsague J, Perlman GD, et al. Incidence of hospitalization for digitalis toxicity among elderly 12. 
Americans. Am J Med 1994;96(5):426-31.
Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. 13. 
N Engl J Med 2002;347(18):1403-11.
Schmiedl S, Szymanski J, Rottenkolber M, et al. [Analysis of hospital admissions associated with digitalis gly-14. 
cosides] Fingerhut--ein alter Hut?: Eine Analyse stationarer Aufnahmen durch digitalisassoziierte unerwunschte 
Arzneimittelwirkungen. Med Klin (Munich) 2007;102(8):603-11.
Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with 15. 
heart failure. Jama 2003;289(7):871-8.
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. 16. 
Biochim Biophys Acta 1976;455(1):152-62.
Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full-length cDNA for the human “MDR1” gene confers 17. 
resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987;84(9):3004-8.
Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein 18. 
in normal human tissues. Proc Natl Acad Sci U S A 1987;84(21):7735-8.
Cordon-Cardo C, O’Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothe-19. 
lial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86(2):695-8.
Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant 20. 
gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988;48(7):1926-9.
Klimecki WT, Futscher BW, Grogan TM, et al. P-glycoprotein expression and function in circulating blood cells from 21. 
normal volunteers. Blood 1994;83(9):2451-8.
Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical 22. 
relevance. Clin Pharmacol Ther 2004;75(1):13-33.
http://www.ncbi.nlm.nih.gov/SNP/snp. NCBI. (Accessed Juli 11, 2007, at http://www.ncbi.nlm.nih.gov/SNP/snp_ref.23. 
cgi?locusId=5243&chooseRs=het.)
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: 24. 
165
General discussion
165
multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc 
Natl Acad Sci U S A 2000;97(7):3473-8.
Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of 25. 
digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72(2):209-19.
Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein 26. 
MDR1 gene. Clin Pharmacol Ther 2002;72(5):584-94.
Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J 27. 
Clin Pharmacol 2003;58(12):809-12. Epub 2003 Mar 1.
Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and 28. 
more rapid virologic response in HIV-1 infected children. Aids 2005;19(4):371-80.
Comets E, Verstuyft C, Lavielle M, et al. Modelling the influence of MDR1 polymorphism on digoxin pharmacoki-29. 
netic parameters. Eur J Clin Pharmacol 2007;63(5):437-49.
Morita Y, Sakaeda T, Horinouchi M, et al. MDR1 genotype-related duodenal absorption rate of digoxin in healthy 30. 
Japanese subjects. Pharm Res 2003;20(4):552-6.
Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 31. 
transport activities. Biochem Pharmacol 2003;65(11):1843-52.
Gerloff T, Schaefer M, Johne A, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 32. 
mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54(6):610-6.
Kurzawski M, Bartnicka L, Florczak M, et al. Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein 33. 
inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol Rep 2007;59(1):107-11.
Horinouchi M, Sakaeda T, Nakamura T, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 34. 
and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002;19(10):1581-5.
Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 35. 
(MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13(8):481-94.
Chowbay B, Li H, David M, et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin phar-36. 
macokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005;60(2):159-71.
Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988;318(6):358-65.37. 
Bers DM, Berlin JR. Kinetics of [Ca]i decline in cardiac myocytes depend on peak [Ca]i. Am J Physiol 1995;268(1 38. 
Pt 1):C271-7.
van Riemsdijk MM, van der Klauw MM, Pepplinkhuizen L, et al. Spontaneous reports of psychiatric adverse effects 39. 
to mefloquine in the Netherlands. Br J Clin Pharmacol 1997;44(1):105-6.
van Riemsdijk MM, Ditters JM, Sturkenboom MC, et al. Neuropsychiatric events during prophylactic use of meflo-40. 
quine before travelling. Eur J Clin Pharmacol 2002;58(6):441-5. Epub 2002 Jul 27.
Barrett PJ, Emmins PD, Clarke PD, et al. Comparison of adverse events associated with use of mefloquine and 41. 
combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. 
Bmj 1996;313(7056):525-8.
van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Low body mass index is associated with an increased risk 42. 
of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 
2004;57(4):506-12.
Schwartz E, Potasman I, Rotenberg M, et al. Serious adverse events of mefloquine in relation to blood level and 43. 
gender. Am J Trop Med Hyg 2001;65(3):189-92.
Schlagenhauf P, Steffen R, Lobel H, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event 44. 
assessments, stereochemistry and compliance. Trop Med Int Health 1996;1(4):485-94.
Baudry S, Pham YT, Baune B, et al. Stereoselective passage of mefloquine through the blood-brain barrier in the 45. 
rat. J Pharm Pharmacol 1997;49(11):1086-90.
Babaoglu MO, Bayar B, Aynacioglu AS, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic 46. 
efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 2005;78(6):619-26.
Skarke C, Jarrar M, Schmidt H, et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on dispo-47. 
sition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003;13(11):651-60.
Arking DE, Pfeufer A, Post W, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac 48. 
166
Chapter 6
166
repolarization. Nat Genet 2006;38(6):644-51.
Newton-Cheh C, Shah R. Genetic determinants of QT interval variation and sudden cardiac death. Curr Opin 49. 
Genet Dev 2007;17(3):213-21.
Schouten EG, Dekker JM, Meppelink P, et al. QT interval prolongation predicts cardiovascular mortality in an ap-50. 
parently healthy population. Circulation 1991;84(4):1516-23.
Siscovick DS, Raghunathan TE, Rautaharju P, et al. Clinically silent electrocardiographic abnormalities and risk of 51. 
primary cardiac arrest among hypertensive patients. Circulation 1996;94(6):1329-33.
Karjalainen J, Reunanen A, Ristola P, et al. QT interval as a cardiac risk factor in a middle aged population. Heart 52. 
1997;77(6):543-8.
Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of 53. 
older adults. J Am Coll Cardiol 2006;47(2):362-7.
Algra A, Tijssen JG, Roelandt JR, et al. QT interval variables from 24 hour electrocardiography and the two year 54. 
risk of sudden death. Br Heart J 1993;70(1):43-8.
Drugs that Prolong the QT Interval and/or Induce Torsades de Pointes Ventricular Arrhythmia. In: The University of 55. 
Arizona Center for Education and Research on Therapeutics, Arizona Health Sciences Center, Tucson, Arizona.
De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce 56. 
torsade de pointes: an overview. Drug Saf 2002;25(4):263-86.
Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89(11):1363-72.57. 
Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-22.58. 
Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. 59. 
Proc Natl Acad Sci U S A 2000;97(19):10613-8.
Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades 60. 
de pointes. Circulation 2002;105(16):1943-8.
Hauptman PJ, Kelly RA. Digitalis. Circulation 1999;99(9):1265-70.61. 
Santana LF, Gomez AM, Lederer WJ. Ca2+ flux through promiscuous cardiac Na+ channels: slip-mode conduc-62. 
tance. Science 1998;279(5353):1027-33.
Brugada R, Hong K, Cordeiro JM, et al. Short QT syndrome. Cmaj 2005;173(11):1349-54.63. 
Viswanathan MN, Page RL. Short QT: when does it matter? Circulation 2007;116(7):686-8.64. 
Massion PB, Pelat M, Belge C, et al. Regulation of the mammalian heart function by nitric oxide. Comp Biochem 65. 
Physiol A Mol Integr Physiol 2005;142(2):144-50.
Ashley EA, Sears CE, Bryant SM, et al. Cardiac nitric oxide synthase 1 regulates basal and beta-adrenergic con-66. 
tractility in murine ventricular myocytes. Circulation 2002;105(25):3011-6.
Barouch LA, Harrison RW, Skaf MW, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide 67. 
synthase isoforms. Nature 2002;416(6878):337-9.
Sears CE, Bryant SM, Ashley EA, et al. Cardiac neuronal nitric oxide synthase isoform regulates myocardial con-68. 
traction and calcium handling. Circ Res 2003;92(5):e52-9.
Jaffrey SR, Snowman AM, Eliasson MJ, et al. CAPON: a protein associated with neuronal nitric oxide synthase that 69. 
regulates its interactions with PSD95. Neuron 1998;20(1):115-24.
Bai CX, Namekata I, Kurokawa J, et al. Role of nitric oxide in Ca2+ sensitivity of the slowly activating delayed recti-70. 
fier K+ current in cardiac myocytes. Circ Res 2005;96(1):64-72.
Burkard N, Rokita AG, Kaufmann SG, et al. Conditional neuronal nitric oxide synthase overexpression impairs 71. 
myocardial contractility. Circ Res 2007;100(3):e32-44.
Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel un-72. 
derlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. 
Circulation 2007;115(4):442-9.
Splawski I, Timothy KW, Decher N, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel 73. 
mutations. Proc Natl Acad Sci U S A 2005;102(23):8089-96; discussion 6-8.
Cerrone M, Noujaim S, Jalife J. The short QT syndrome as a paradigm to understand the role of potassium chan-74. 
nels in ventricular fibrillation. J Intern Med 2006;259(1):24-38.
Aarnoudse AJ, Newton-Cheh C, de Bakker PI, et al. Common NOS1AP variants are associated with a prolonged 75. 
167
General discussion
167
QTc interval in the Rotterdam Study. Circulation 2007;116(1):10-6.
Post W, Shen H, Damcott C, et al. Associations between genetic variants in the NOS1AP (CAPON) gene and 76. 
cardiac repolarization in the old order Amish. Hum Hered 2007;64(4):214-9.
Lajoix AD, Reggio H, Chardes T, et al. A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-77. 
cells controls insulin secretion. Diabetes 2001;50(6):1311-23.
Kingwell BA, Formosa M, Muhlmann M, et al. Nitric oxide synthase inhibition reduces glucose uptake during exer-78. 
cise in individuals with type 2 diabetes more than in control subjects. Diabetes 2002;51(8):2572-80.
Gunawardana SC, Rocheleau JV, Head WS, et al. Mechanisms of time-dependent potentiation of insulin release: 79. 
involvement of nitric oxide synthase. Diabetes 2006;55(4):1029-33.
Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 1989;54(2):87-143.80. 
Boyd AE, 3rd, Aguilar-Bryan L, Nelson DA. Molecular mechanisms of action of glyburide on the beta cell. Am J Med 81. 
1990;89(2A):3S-10S; discussion 51S-3S.
Proks P, Reimann F, Green N, et al. Sulfonylurea stimulation of insulin secretion. Diabetes 2002;51 Suppl 3:S368-82. 
76.
Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications 83. 
in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:Suppl:789-830.
Schor S. The University Group Diabetes Program. A statistician looks at the mortality results. Jama 84. 
1971;217(12):1671-5.
Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program 85. 
(UGDP). Diabetes 1972;21(9):976-9.
Cornfield J. The University Group Diabetes Program. A further statistical analysis of the mortality findings. Jama 86. 
1971;217(12):1676-87.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk 87. 
of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. 
Lancet 1998;352(9131):837-53.
Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J 88. 
Pharmacol 2001;133(1):193-9.
Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. 89. 
J Diabetes Complications 2000;14(4):192-6.
Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 90. 
2003;88(2):531-7.
Legtenberg RJ, Houston RJ, Oeseburg B, et al. Effects of sulfonylurea derivatives on ischemia-induced loss of 91. 
function in the isolated rat heart. Eur J Pharmacol 2001;419(1):85-92.
Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protec-92. 
tion afforded by either ischemic preconditioning or diazoxide. Circulation 2001;103(25):3111-6.
Yokoshiki H, Sunagawa M, Seki T, et al. ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth 93. 
muscle cells. Am J Physiol 1998;274(1 Pt 1):C25-37.
Venkatesh N, Lamp ST, Weiss JN. Sulfonylureas, ATP-sensitive K+ channels, and cellular K+ loss during hypoxia, 94. 
ischemia, and metabolic inhibition in mammalian ventricle. Circ Res 1991;69(3):623-37.
Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular dis-95. 
ease. Time for reconsideration. Circulation 1996;94(9):2297-301.
Clayton DHM. Time-varying explanatory variables. In: Statistical models in epidemiology: Oxford University Press; 96. 
1993:307-18.
Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharma-97. 
cogenomic tests. Clin Pharmacol Ther 2005;78(6):559-81.
Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 98. 
2004;33(1):30-42.
Nitsch D, Molokhia M, Smeeth L, et al. Limits to causal inference based on Mendelian randomization: a comparison 99. 
with randomized controlled trials. Am J Epidemiol 2006;163(5):397-403.
Christensen K, Murray JC. What genome-wide association studies can do for medicine. N Engl J Med 100. 
168
Chapter 6
168
2007;356(11):1094-7.
Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev 101. 
Genet 2005;6(2):95-108.
Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234(1):4-102. 
33.
169
General discussion
169
170
171
171
7
Summary
172
173
173
Despite all research efforts on safety and efficacy preceding marketing authorization of drugs, not every 
drug is safe and beneficial for every patient. Different people do not always react in the same way to the 
same drugs at the same dose. Differences in efficacy and adverse effects do not occur at random. It is 
estimated that genetic variation can account for 20-95% of variability in drug response. 
One of the products of classical research on pharmacogenetics is the discovery of the ATB-binding cas-
sette family B member 1 (ABCB1) gene. It plays a role in the uptake, distribution and clearance of many 
drugs. Despite the many studies on ABCB1 genotype and drug kinetics that have already been per-
formed, the influence of common genetic variants of this gene on drug effects are still unclear. In addition, 
common genetic variants in the nitric oxide synthase 1 adaptor protein (NOS1AP) gene were recently 
discovered to be associated with QT-interval prolongation. QT-interval duration is associated with the risk 
of sudden cardiac death (SCD), making this gene an interesting candidate to study in relation to the risk 
of SCD and to its interaction with QT-altering drugs.
In this thesis we explore the effect of interaction of common variants in the ABCB1 and NOS1AP genes 
with drugs on drug response and adverse effects of drugs in a number of epidemiological studies. We 
mainly focus on digoxin and on other cardiovascular drugs as drugs of interest because these drugs are 
widely used and are a common cause of adverse reactions. Most studies were conducted within the Rot-
terdam Study, a population-based cohort study. Additionally, we used the ‘Landelijke Medische Registratie 
(LMR), a database with discharge information from all hospitalizations in the Netherlands, and a cohort of 
mefloquine users who were followed in the three weeks preceding their travel.
In Chapter 2, we studied the incidence of hospitalization for digoxin intoxication in the general popula-
tion in the Netherlands. We showed that, although the safety of digoxin therapy has increased during the 
last few decades, the number of digoxin intoxication related hospitalizations is still considerable and that 
women are at 40% higher risk of digoxin intoxication than men.
In Chapter 3 we studied the interaction of common genetic ABCB1 variants with digoxin and mefloquine. 
In Chapter 3.1, we showed that among 195 users of digoxin in the Rotterdam Study, the ABCB1 1236-
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2677-3435 TTT-haplotype allele is associated with higher digoxin serum concentrations and explains up 
to 11.5% of the variability in digoxin concentrations in a model also containing age, sex, digoxin dose, lean 
body mass and renal clearance. In Chapter 3.2, we studied the effect of the same ABCB1 variants on 
digoxin induced SCD and QT-shortening. We found that the TTT-haplotype allele was associated with a 
two-fold increased risk of SCD in digoxin users. No effect of this haplotype on SCD was observed in non-
users of digoxin. The increased QTc shortening to digoxin on ECG in TTT-haplotype allele carriers further 
confirmed the interaction of ABCB1 and digoxin. The effect of ABCB1 variants is not limited to digoxin. 
Mefloquine is widely used in the treatment and prophylaxis of malaria, but is notorious for its, sometimes 
severe, neuropsychiatric adverse effects. In Chapter 3.3 we studied the effect of ABCB1 genotypes and 
haplotypes on neuropsychiatric adverse effects of mefloquine. We found that the ABCB1 1236-2677-3435 
TTT-haplotype allele increases the risk of these adverse events by 2.5 times. The effect was stronger in 
women (RR 3.2) than in men (RR 1.7) and, consistent with literature, seemed not to be mediated by the 
serum concentration of mefloquine, suggesting an effect at the level of brain-tissue concentration.
In Chapter 4 we studied the effects of common genetic variants of the NOS1AP gene, both in the general 
population and in users of specific drugs. In Chapter 4.1, we replicated the finding from an earlier genome 
wide association study, that common variants in the NOS1AP gene are associated with a 3.5 msec in-
crease in QTc interval per additional minor allele. We also found some indication that these variants might 
be associated with a slightly increased risk of SCD. Although the effect was in the expected direction, 
numbers were too low to statistically significantly demonstrate this association. In Chapter 4.2, we stud-
ied whether the QT-prolonging NOS1AP variants would counteract the QT-shortening effects of digoxin, 
and perhaps also its pro-arrhythmogenic effects. In contrast with our expectations, we found that digoxin 
users carrying the NOS1AP minor allele showed increased QT-shortening to digoxin. Furthermore, digox-
in users carrying the minor allele showed increased risk of SCD with a HR of 1.8 per additional minor 
allele, resulting in a more than three fold increased risk of SCD in digoxin users homozygous for the minor 
allele compared to those homozygous for the major allele. Since QT-prolonging genetic variants might 
increase the risk of SCD to QT-prolonging drugs, we studied in Chapter 4.3 whether NOS1AP variants 
interact with cardiovascular QT-prolonging drugs,. Although numbers of users of each specific drug per 
genotype group were low, we found that users of triamterene or verapamil homozygous for the NOS1AP 
minor variant showed statistically significantly more QTc prolongation than major allele homozygotes. 
Furthermore, regression coefficients indicated that a similar effect might exist for amiodarone, sotalol, 
diltiazem, indapamide, and perhaps isradipine and disopyramide. The number of drug exposed cases 
was too low to assess whether this increased QT-prolongation translates into an increased SCD risk. In 
Chapter 4.4 we studied whether these NOS1AP variants affect the efficacy of the antidiabetic class of 
sulfonylureas, or the cardiovascular mortality to these drugs. Sulfonylureas stimulate insulin secretion by 
an increased influx of calcium. NOS1, which is activated by NOS1AP, may also influence cytoplasmatic 
calcium handling and also plays a role in insulin secretion. Furthermore, like NOS1, sulfonylureas are 
associated with cardiovascular mortality. We found that the glucose lowering effect of glibenclamide was 
less effective in patients carrying the NOS1AP minor allele. Moreover, carriers of NOS1AP minor alleles 
using glibenclamide were at increased risk of mortality, whereas these genotypes were associated with 
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reduced mortality in patients using tolbutamide, gliclazide or glimepiride. These differences may be ex-
plained by differences in affinity to the sulfonylurea 2A receptor.
In Chapter 5, we studied whether the observed interactions of ABCB1 and NOS1AP genotypes with 
digoxin were also associated with differences in digoxin effect on cardiac systolic and diastolic function. In 
line with our previous findings in combination with the known effects of digoxin, we found that the ABCB1 
TTT-haplotype allele seemed to be associated with worsened diastolic function in digoxin users, driving 
their echocardiographic parameters towards impaired relaxation. The TTT-haplotype allele was also as-
sociated with an increased systolic function in digoxin users without prevalent heart disease, but with a 
decreased function in those with prevalent heart failure or myocardial infarction. Similar to our findings for 
ABCB1, we found some indication that common variants in the NOS1AP gene were associated with an 
increased systolic function in digoxin users without prevalent heart disease, but with a decreased function 
in those with prevalent heart failure or myocardial infarction. Results for NOS1AP and diastolic function 
were less clear. However, the number of digoxin users with an echocardiogram was too low to draw solid 
conclusions and to reach statistical significance.
In Chapter 6, the general discussion, the main findings form this thesis are placed in a broader perspec-
tive and methodological considerations with regard to these studies are described. Furthermore, the 
clinical implications of our findings with regard to improving drug safety by potential genetic testing are 
discussed. Finally, recommendations for future research on ABCB1, NOS1AP and pharmacogenetics and 
–genomics in general are discussed.
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Ondanks alle onderzoeken op het gebied van veiligheid en werkzaamheid voorafgaand aan het toelaten 
van geneesmiddelen op de markt, is niet ieder geneesmiddel veilig en werkzaam bij iedere patiënt. Ver-
schillende mensen reageren niet altijd op dezelfde manier op hetzelfde geneesmiddel bij gelijke dosering. 
Verschillen in werkzaamheid en het optreden van bijwerkingen treden niet willekeurig op. Genetische 
variatie kan naar schatting 20-95% van de verschillen in reactie op geneesmiddelen verklaren.
Een van de resultaten van klassiek farmacogenetisch onderzoek is de ontdekking van het ATP-bindende 
casette familie B1 (ABCB1) gen. Dit gen speelt een rol in de opname, distributie en uitscheiding van vele 
geneesmiddelen. Ondanks het grote aantal studies naar ABCB1 genotype en farmacokinetiek, is de inv-
loed van veelvoorkomende genetische varianten binnen dit gen op geneesmiddeleneffecten nog steeds 
niet duidelijk. Daarnaast werd recent ontdekt dat veelvoorkomende genetische varianten van het stikstof-
oxide synthase 1 adapter eiwit (NOS1AP) gen geassocieerd zijn met verlenging van het QT-interval op 
het ECG. QT-interval duur is geassocieerd met een verhoogde kans op plotse hartdood. Dat maakt dit 
gen een interessante kandidaat om te bestuderen in relatie tot de kans op plotse hartdood en als effect 
modulator op QT-duur beïnvloedende geneesmiddelen.
In dit proefschrift onderzoeken we in een aantal epidemiologische studies hoe de interactie van veel-
voorkomende varianten van de ABCB1 en NOS1AP genen met geneesmiddelen de werkzaamheid en 
bijwerkingen van die geneesmiddelen beïnvloedt. We concentreren ons voornamelijk op het geneesmid-
del digoxine en op andere cardiovasculaire geneesmiddelen, omdat deze geneesmiddelen veel worden 
gebruikt en vaak bijwerkingen veroorzaken. De meeste studies werden uitgevoerd binnen het Erasmus 
Rotterdam Gezondheids Onderzoek (ERGO), ook wel bekend als de Rotterdam Studie, een cohort dat 
een afspiegeling is van de algemene bevolking. Daarnaast gebruikten we de Landelijke Medische Reg-
istratie (LMR), een database met ontslaginformatie van alle ziekenhuisopnamen in Nederland, en een 
cohort van mefloquinegebuikers, die werden gevolgd in de drie weken voorafgaand aan hun reis.
In Hoofdstuk 2 onderzochten we de incidentie van ziekenhuisopname vanwege digoxine intoxicatie in de 
algemene bevolking van Nederland. We toonden aan dat, hoewel het gebruik van digoxine veiliger is ge-
worden gedurende de laatste decennia, het aantal ziekenhuisopnames vanwege digoxine intoxicatie nog 
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steeds aanzienlijk is en dat vrouwen een 40% hoger risico op digoxine intoxicatie hebben dan mannen.
In Hoofdstuk 3 onderzochten we de interactie tussen veelvoorkomende varianten van het ABCB1 gen 
met digoxine en mefloquine. In Hoofdstuk 3.1 toonden we, onder 195 digoxine gebruikers uit de Rot-
terdam Studie aan, dat het ABCB1 1236-2677-3435 TTT-haplotype allel geassocieerd is met hogere 
digoxine spiegels in het bloed en tot 11.5% van de variatie in digoxine concentratie kan verklaren in een 
model dat ook leeftijd, geslacht, digoxine dosis, ‘lean body mass’ en nierfunctie bevat. In Hoofdstuk 3.2 
bestudeerden we het effect van dezelfde ABCB1 varianten op digoxine gerelateerde plotse hartdood en 
QT-verkorting. We vonden dat het TTT-haplotype allel was geassocieerd met een twee maal zo hoge 
kans op plotse hartdood binnen digoxine gebruikers. Er werd geen effect van dit haplotype op plotse 
hartdood gezien bij mensen die geen digoxine gebruikten. Het toegenomen QT-verkortend effect van 
digoxine in TTT-haplotype allel dragers bevestigde de interactie tussen ABCB1 varianten en digoxine. 
Het effect van ABCB1 varianten is niet beperkt tot digoxine. Mefloquine wordt veel gebruikt in de behan-
deling- en ter voorkoming van malaria, maar is berucht vanwege, soms ernstige, neuropsychiatrische 
bijwerkingen. In Hoofdstuk 3.3 onderzochten we het effect van ABCB1 genotypes en haplotypes op het 
optreden van neuropsychiatrische bijwerkingern van mefloquine. We vonden dat het ABCB1 1236-2677-
3435 TTT-haplotype allel het risico op dit soort bijwerkingen 2.5 maal verhoogde. Het effect was sterker 
in vrouwen (3.2 maal) dan in mannen (1.7 maal) en leek, in overeenstemming met de literatuur, niet 
gemedieerd te worden door de mefloquine serumconcentratie, hetgeen een effect op de concentratie in 
het hersenweefsel suggereert.
In Hoofdstuk 4 onderzochten we de effecten van veelvoorkomende genetische varianten van het 
NOS1AP gen, zowel in de algemene bevolking als binnen gebruikers van bepaalde geneesmiddelen. 
In Hoofdstuk 4.1 repliceerden we de bevinding uit een eerdere ‘genome wide association study’ dat 
veelvoorkomende varianten van het NOS1AP gen geassocieerd zijn met een QTc-interval verlenging van 
3.5 msec per extra variant (‘minor’) allel. We vonden ook aanwijzingen dat deze varianten geassocieerd 
zijn met een licht verhoogde kans op plotse hartdood. Hoewel het effect in de verwachte richting was, 
waren de aantallen te klein om een associatie statistisch significant aan te tonen. In Hoofdstuk 4.2 onder-
zochten we of QT-verlengende NOS1AP varianten het QT-verkortend effect van digoxine en mogelijk ook 
het pro-aritmogene effect ervan zouden tegengaan. In tegenstelling tot wat we verwachtten vonden we 
dat digoxine gebruikers met het variant NOS1AP allel een versterkte QT-verkorting hadden. Daarnaast 
hadden digoxine gebruikers met het variant NOS1AP allel een verhoogde kans op plotse hartdood van 
1.8 maal per variant allel hadden, hetgeen resulteert in een meer dan drie keer verhoogde kans op plotse 
hartdood in digoxine gebruikers met twee variant allelen vergeleken met digoxine gebruikers met twee 
niet-variant (‘major’) allelen. Omdat QT-verlengende genetische varianten het risico op plotse hartdood 
door QT-verlengende geneesmiddelen zouden kunnen verhogen, onderzochten we in Hoofdstuk 4.3 
of NOS1AP varianten interactie vertonen met cardiovasculaire geneesmiddelen die het QT-interval ver-
lengen. Hoewel de aantallen gebruikers per afzonderlijk geneesmiddel per genotype groep laag waren, 
vonden we dat gebruikers van triamtereen of verapamil met twee variant NOS1AP allelen statistisch 
significant meer QTc-verlenging vertoonden dan gebruikers met twee niet-variant allelen. Daarnaast sug-
179
Samenvatting
179
gereerden de regressie coëfficienten dat er een vergelijkbaar effect zou kunnen bestaan voor amio-
darone, sotalol, diltiazem, indapamide en mogelijk ook voor isradipine en disopyramide. Het aantal plotse 
hartdoden ten tijde van medicatie gebruik was te klein om vast te kunnen stellen of deze versterkte QT-
verlenging ook resulteerde in een verhoogde kans op plotse hartdood. In Hoofdstuk 4.4 onderzochten 
we of de NOS1AP varianten de effectiviteit van de antidiabetica uit de sulfonylurea geneesmiddelengroep 
de kans op cardiovasculaire mortaliteit bij gebruik van deze geneesmiddelen beïnvloedt. Sulfonylurea 
stimuleren insuline secretie door het verhogen van de calcium influx. NOS1, dat geactiveerd wordt door 
NOS1AP, zou ook de cytoplasmatische calcium huishouding kunnen beïnvloeden en speelt daarnaast 
een rol bij insuline secretie. Verder zijn sulfonylurea, net als NOS1, geassocieerd met cardiovasculaire 
mortaliteit. We vonden dat het glucose verlagende effect van glibenclamide minder sterk was in patiënten 
met het variant NOS1AP allel. Verder vertoonden de glibenclamide gebruikers die drager zijn van het 
variant NOS1AP allel een verhoogd sterfterisico, terwijl deze genotypes juist geassocieerd waren met 
verminderde sterfte in gebruikers van tolbutamide, gliclazide of glimepiride. Deze verschillen worden 
mogelijk verklaard door een verschil in affiniteit voor de sulfonylurea 2A receptor.
In Hoofdstuk 5 onderzochten we of het ABCB1 en NOS1AP genotype is geassocieerd met verschillen 
in digoxine-effect op cardiale systolische en diastolische functie. In overeenstemming met onze eerdere 
bevindingen en met de bekende effecten van digoxine, vonden we dat het ABCB1 TTT-haplotype geas-
socieerd leek met een verslechterde diastolische functie in digoxine gebruikers, waarbij de echocar-
diografische parameters in de richting van verminderde relaxatie gedreven werden. Het TTT-haplotype 
allel was ook geassocieerd met een verbeterde systolische functie in digoxine gebruikers zonder preva-
lent hartfalen of myocard infarct, maar met een verslechterde systolische functie onder gebruikers met 
prevalent hartfalen of myocard infarct. Vergelijkbaar met onze bevindingen voor ABCB1, vonden we 
aanwijzingen dat veelvoorkomende varianten van het NOS1AP gen geassocieerd waren met verbeterde 
systolische functie bij digoxine gebruikers zonder prevalente hartziekte, maar met een verslechterde 
functie in gebruikers met een prevalente hartziekte. De resultaten voor NOS1AP en diastolische functie 
waren minder duidelijk. De aantallen digoxine gebruikers met een echocardiogram waren echter te laag 
om een duidelijke conclusie te trekken of om statistische significantie te bereiken.
In Hoofdstuk 6, de algemene discussie, worden de belangrijkste bevindingen uit dit proefschrift in een 
breder perspectief geplaatst en worden methodologische overwegingen met betrekking tot de verschil-
lende studies beschreven. Daarnaast worden de klinische implicaties van onze bevindingen, met betrek-
king tot verbetering van de medicatieveiligheid door genetische testen, besproken. Ten slotte worden 
aanbevelingen gedaan voor verder onderzoek op het gebied van ABCB1, NOS1AP en farmacogenetica 
in het algemeen.
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Dankwoord
Een proefschrift schrijf je niet alleen. Daarom wil ik op deze plaats iedereen bedanken die een rol heeft 
gespeelt bij het tot stand komen van dit proefschrift. Allereerst de mensen die hebben deelgenomen aan 
het ERGO-onderzoek en aan het mefloquine onderzoek. Zonder hun trouwe deelname en medewerking 
was dit onderzoek niet mogelijk geweest. Dat geldt ook voor alle huisartsen en apothekers die de data 
beschikbaar hebben gesteld.
Een aantal mensen wil ik ook persoonlijk bedanken voor hun bijdrage. Allereerst mijn promotoren, Prof.dr. 
Bruno H.Ch. Stricker en Prof.dr. Albert Hofman, en mijn co-promotor Jeanne P. Dieleman. Beste Bruno, 
bedankt dat ik mijn promotie-onderzoek bij jouw pharmacoëpidemiologie groep heb mogen doen, ook al 
had ik voor die tijd zelfs nog nooit gehoord van iets als pharmacoëpidemiologie. Je laagdrempeligheid, 
betrokkenheid bij het onderzoek en uitgebreide kennis maakten je tot een prettige begeleider. Ik heb 
de gelegenheid om eigen ideeën en zijlijntjes uit te pluizen ook erg gewaardeerd. Het stimuleren van 
nieuwsgierigheid staat tenslotte aan de basis van het opleiden van wetenschappers. Beste Bert, hartelijk 
dank dat ik mijn onderzoek binnen jouw afdeling mocht doen. Jouw visie bij het oprichten van het ERGO-
onderzoek bood een unieke mogelijkheid voor een zeer breed scala aan epidemiologisch onderzoek, 
waaronder het grootste deel van de onderzoeken in dit proefschrift. Beste Jeanne, zonder jou waren mijn 
manuscripten niet geweest wat ze geworden zijn. Jouw kritische blik maakte die altijd een stuk compacter 
en leesbaarder en tabellen werden plotseling kleiner en begrijpelijk. Zeker in het begin heb ik daarnaast 
veelvuldig gebruik mogen maken van je ervaring om analyse- en syntaxproblemen op te lossen. 
Prof.dr. André G. Uitterlinden, prof.dr. J.C.M. Witteman en prof.dr. L.J.L.M. Jordaens wil ik bedanken voor 
hun bereidheid zitting te nemen in de kleine commissie en voor de inhoudelijke beoordeling van dit proef-
schrift. Beste André, ik wil je daarnaast bedanken voor de leerzame overlegmomenten over manuscripten 
en binnen het ‘pharmacogenetica-overleg’, en voor de genotyperingen in je genetisch lab. De discussies 
en praktische aanbevelingen voor analyses hebben me geholpen om de genetische component van het 
pharmacogenetisch-epidemiologisch onderzoek beter in de vingers te krijgen en in het juiste perspectief 
te plaatsen. Prof.dr. Witteman wil ik ook bedanken voor de kritische blik op diverse manuscripten uit dit 
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proefschrift. Verder speciale dank aan de leden van de grote commissie.
Alle co-auteurs van mijn manuscripten wil ik hartelijk bedanken voor hun bijdragen en waardevolle com-
mentaar op de diverse manuscripten. Allereerst bijzondere dank aan Matthijs Becker en Charlotte van 
Noord die met hun artikelen een belangrijke bijdrage aan dit proefschrift hebben geleverd. Daarnaast wil 
ik dr. Ron van Schaik bedanken voor zijn bijdrage aan de artikelen over, en voor het organiseren van de 
genotyperingen van de ABCB1 SNPs. Dr. Melanie van Riemsdijk, wij hebben elkaar nooit persoonlijk 
ontmoet, maar ik heb dankbaar gebruik gemaakt van de data uit het mefloquine cohort die jij verzameld 
hebt. 
Chris Newton-Cheh special thanks for the privilige to work together on the NOS1AP papers. Your enthou-
siasm, QT knowledge and your quick and elaborate comments to the various manuscript are very much 
appreciated. I learned a lot from this project and hope that further cooperation will be as fruitfull. 
I would also like to thank Mariam Molokhia for her valuable comments. Good luck with the continuation 
of the EUDRAGENE project.
Ilse van der Heiden, Pascal Arp en Rowena Utberg wil ik bedanken voor het uitvoeren van de diverse 
genotyperingen.
Een promotie onderzoek is meer dan het alleen maar schrijven van ‘stukjes’. Daarom dank aan mijn 
kamergenoten. Sabine, Cornelis, en Claire, jullie zorgden voor de eerste gezelligheid en opvang. Sabine 
bedankt voor je altijd positieve blik op promotie-onderzoek en je opvoedkundige tips. Uiteindelijk is je ent-
housiasme over QT-duur en plotse hartdood toch nog blijven hangen in deze kamer. Cornelis, jij was niet 
alleen een belangrijk koffie-maatje, maar ook mochten we samen de inspectieperikelen delen, je bleek tot 
nog toe niet te vervangen. Claire, nog excuus dat ik je altijd zo ergerde met mijn rotzooi. Jij was een beetje 
sneller klaar met promoveren, maar straks gaan we weer een stukje samen op in de kliniek. Ook mijn 
andere kamergenoten Mariëtte, Ronald, Laura (tevens IGZ collega) en Yannick, de overige pharmaco-
epi collega’s Ana, Annemiek, Betty, Bert, Charlotte (nog iemand die ook Haagse beslommeringen kent), 
Dika, Eva, Fatma, Gianlucca, Georgio, Hedi, Katia, Marissa, Martina, Matthijs, Mendel, Miriam, Monique, 
Nathalie, Patty, Roelof, Seppe en de epidemiologie collega’s Abbas, Arlette, Arfan, Christiane, Fernando, 
Frank-Jan, Germaine, Isabella, Julia, Kamran, Lintje, Lonneke, Mark Sie, Marieke O, Marieke D, Marielle, 
Meike, Michiel (speciaal voor de Indesign tips), Monika, Miranda, Quirijn, Sharmila, Simone, Sjoerd, Su-
zette en alle anderen, allemaal bedankt voor de gezelligheid, discussies en adviezen.
Dank ook aan alle medewerkers van de biostatistiek die altijd even tijd hadden als ik er weer niet helemaal 
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